

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

Coxib and traditional NSAID Trialists' (CNT) Collaboration

The Lancet, Volume 382, Issue 9894, 769 - 779

Contents

Webtable 1 - Details of trials involving a randomised comparison of a coxib (X) versus placebo (Y)	2
Webtable 2 - Details of trials involving a randomised comparison of a coxib (X) versus a tNSAID (Y)	7
Webtable 3 - Details of trials involving a randomised comparison of a tNSAID (X) versus placebo (Y)	10
Webtable 4 - Details of trials involving a randomised comparison of naproxen, ibuprofen or diclofenac (X) versus: a) each other; or b) another tNSAID regimen (Y)	13
Webtable 5 - Details of trials involving a randomised comparison of one coxib regimen (X) versus another coxib regimen (Y)	17
Webtable 6 - Details of trials involving a randomised comparison of two doses of the same coxib (high [X] vs low [Y])	19
Publications of trials shown in supplementary tables 1-6	21
Publications of other trials (not already listed) that involved two or more NSAIDs	29

Webtable 1 - Details of trials involving a randomised comparison of a coxib (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years		
								X	Y	X	Y	
<i>Celecoxib versus placebo 800 mg daily</i>												
Kvale 2006	w1	HIV	T	P	Unknown	Open	C 800	13	14	3	3	
Pfizer Dirix 2008	w2	Breast cancer	T	P	Unknown	Double	C 800	55	56	76	77	
APC	w3	Colorectal polyps	I	P	Other	Double	C 800	671	679	1544	1557	
Cudkowitz 2006	w4	Amylotrophic lateral sclerosis	I	P	Pharmacy	Double	C 800	201	99	168	84	
Falandry 2008	w5	Breast cancer	I	P	Closed list	Double	C 800	74	83	94	104	
Pfizer IQ4-96-02-001	w6	Familial adenomatous polyposis	I	P	Unknown	Double	C 800	32	17	15	8	
Pfizer N49-96-02-012	w7	Rheumatoid arthritis	I	P	Unknown	Double	C 800	82	85	6	5	
Pfizer N49-96-02-022	w8	Rheumatoid arthritis	I	P	Other	Double	C 800	218	231	37	31	
Pfizer N49-96-02-023	-	Rheumatoid arthritis	I	P	Unknown	Double	C 800	217	221	36	25	
Pfizer N49-96-02-047	-	Osteoarthritis	I	P	Unknown	Double	C 800	99	101	7	6	
Pfizer NQ5-98-02-005 03T-459	-	Alzheimer's disease	I	P	Unknown	Unknown	C 800	11	5	1	0	
Antonarakis 2009	w9	Prostate cancer	T	P	Other	Double	C 800	32	32	4	4	
NCI-02-C-0194	-	Colorectal polyps	T	P	Other	Double	C 800	4	4	2	2	
Kim 2010	w10	Cancer prevention	T	C	Pharmacy	Double	C 800	103	101	26	25	
Pfizer COXAON-0509-125	w11	Prostate cancer	T	C	Other	Double	C 800	38	40	17	18	
Pfizer Jhee 2004	w12	Alzheimer's disease	T	P	Unknown	Double	C 800	5	5	0.4	0.4	
98-C-0087	-	Colorectal polyps	U	P	Unknown	Double	C 800	13	14	13	14	
Pfizer 0509-092	w13	Lung cancer	U	P	Unknown	Double	C 800	21	20	42	40	
<i>Celecoxib versus placebo 400 mg daily</i>												
ADAPT	w14	Alzheimer's disease	I	P	Onsite computer	Double	C 400	726	1083	2102	3099	
APC	w3	Colorectal polyps	I	P	Other	Double	C 400	685	679	1581	1557	
Brese 2006	w15	Schizophrenia	I	P	Pharmacy	Double	C 400	20	17	4	2	
CDME	w16	Macular oedema	I	P	Unknown	Unknown	C 400	39	47	45	56	
COREA-TAXUS	w17	Coronary angioplasty	I	P	Closed list	Open	C 400	130	137	64	67	
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	C 400	132	132	16	14	
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	C 400	379	379	84	79	
MK 065	w18	Osteoarthritis	I	P	Other	Double	C 400	107	111	25	25	
MK 905	w19	Healthy volunteer	I	P	Unknown	Double	C 400	17	16	2	2	
Novartis 114	-	Rheumatoid arthritis	I	P	Unknown	Unknown	C 400	302	309	64	59	
Pfizer A3191174	w20	Back pain	I	P	Unknown	Unknown	C 400	411	412	54	54	
Pfizer COXA-0508-269	-	Back pain	I	P	Unknown	Double	C 400	264	264	48	44	
Pfizer EQ5-98-02-002	-	Alzheimer's disease	I	P	Other	Double	C 400	23	13	24	12	
Pfizer IQ5-97-02-001	w21	Alzheimer's disease	I	P	Other	Double	C 400	285	140	248	120	
Pfizer N49-01-02-193	w22	Ankylosing spondylitis	I	P	Unknown	Double	C 400	161	156	30	21	
Pfizer N49-01-02-202	w23	Psoriatic arthritis	I	P	Other	Double	C 400	201	194	39	31	
Pfizer N49-96-02-012	w7	Rheumatoid arthritis	I	P	Unknown	Double	C 400	82	85	6	5	
Pfizer N49-96-02-020	w24	Osteoarthritis	I	P	Other	Double	C 400	222	220	39	30	
Pfizer N49-96-02-021	w25	Osteoarthritis	I	P	Unknown	Double	C 400	237	247	43	36	
Pfizer N49-96-02-022	w8	Rheumatoid arthritis	I	P	Other	Double	C 400	235	231	43	31	
Pfizer N49-96-02-023	-	Rheumatoid arthritis	I	P	Unknown	Double	C 400	219	221	36	25	
Pfizer N49-96-02-054	w26	Osteoarthritis	I	P	Other	Double	C 400	213	218	34	26	
Pfizer NQ5-98-02-005	-	Alzheimer's disease	I	P	Unknown	Unknown	C 400	5	5	0	0	
preSAP	w27	Colorectal polyps	I	P	IVRS	Double	C 400	933	628	2329	1570	
Farley 2006	w28	Cervical intraepithelial neoplasia	T	P	Onsite computer	Double	C 400	12	13	6	6	
Muller 2002	w29	Schizophrenia	T	P	Sealed envelopes	Double	C 400	25	25	2	2	
Muller 2006	w30	Major depression	T	P	Sealed envelopes	Double	C 400	20	20	2	2	
NCI-P01-0190	-	Basal cell carcinoma	T	P	Unknown	Double	C 400	30	30	60	60	
NO1-CN-25140	-	Cancer prevention	T	P	Other	Double	C 400	10	12	5	6	
NO1-CN-85183-Step 2	-	Cancer prevention	T	P	Unknown	Double	C 400	122	118	91	88	
NO1-CN-85186	-	Cancer prevention	T	P	Unknown	Double	C 400	76	70	76	70	
NO1-RC-91019	w31	Cancer prevention	T	F	Other	Double	C 400	180	180	148	148	
Palmer 2003	w32	Hypertension	T	P	Unknown	Double	C 400	97	96	7	7	
U19-CA-81888-UV	-	Cancer prevention	T	P	Unknown	Double	C 400	10	10	3	3	
Adeqbehingbe 2008	w33	Osteoarthritis	T	P	Onsite computer	Double	C 400	21	21	2	2	
Akhondzadeh 2007	w34	Schizophrenia	T	P	Unknown	Double	C 400	30	30	5	5	
Feng 2008	w35	Gastrointestinal dysplasia	T	P	Onsite computer	Double	C 400	511	513	1019	1022	
Nery 2008	w36	Bipolar disorder	T	P	Pharmacy	Double	C 400	17	15	2	2	
Pfizer A3191105	w37	Schizophrenia	T	P	Unknown	Double	C 400	138	132	29	28	
Pfizer Jhee 2004	w12	Alzheimer's disease	T	P	Unknown	Double	C 400	5	5	0.4	0.4	
Pfizer N49-01-02-200	w38	Osteopenia	T	F	Unknown	Double	C 400	31	27	7	6	
Pfizer NQ4-00-02-011	w39	Oral premalignant lesion	T	P	Other	Double	C 400	15	18	3	4	
Pfizer NQ4-99-02-007	w40	Barrett's oesophagus	T	P	Onsite computer	Double	C 400	49	51	45	47	
Pfizer White 2002	w41	Hypertension	T	P	Unknown	Double	C 400	91	87	7	7	
Reid 2005	w42	Cocaine dependence	T	P	Unknown	Single	C 400	10	13	2	2	
98-C-0087	-	Colorectal polyps	U	P	Unknown	Double	C 400	12	14	12	14	
<i>Celecoxib versus placebo 200 mg daily</i>												
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	C 200	111	107	14	13	
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	C 200	190	189	43	42	
Kohne 2008	w44	Metastatic cancer	I	F	Other	Double	C 200	42	43	32	31	
MK 076	w45	Osteoarthritis	I	B	Unknown	Double	C 200	241	127	50	24	
MK 077	w45	Osteoarthritis	I	B	Other	Double	C 200	247	117	53	20	
MK 112	w46	Osteoarthritis	I	P	Unknown	Double	C 200	456	150	64	18	
MK 116	w46	Osteoarthritis	I	P	Unknown	Double	C 200	460	151	66	18	
MK 219	w47	Osteoarthritis	I	P	Other	Double	C 200	157	78	17	8	
MK 220	w48	Osteoarthritis	I	P	Unknown	Double	C 200	169	85	24	11	
Novartis 109	w49	Osteoarthritis	I	P	Unknown	Double	C 200	444	231	96	46	
Novartis 112E	w50	Osteoarthritis	I	B	Unknown	Double	C 200	481	243	122	55	
Novartis 2367	w51	Osteoarthritis	I	P	Other	Double	C 200	419	416	127	119	
Novartis 360E	w52	Osteoarthritis	I	B	Other	Double	C 200	393	382	86	73	
Novartis 361E	w53	Osteoarthritis	I	B	Other	Double	C 200	420	424	111	96	
Pfizer 635-IFL-0508-003	w54	Osteoarthritis	I	P	Other	Double	C 200	189	98	19	8	
Pfizer A3191051	w55	Osteoarthritis	I	P	Unknown	Double	C 200	126	67	13	6	
Pfizer A3191052	-	Osteoarthritis	I	P	Unknown	Double	C 200	145	76	14	8	
Pfizer A3191053	w56	Osteoarthritis	I	P	Unknown	Double	C 200	126	62	12	6	
Pfizer A3191062	w57	Osteoarthritis	I	P	Unknown	Double	C 200	153	79	16	7	
Pfizer A3191063	-	Osteoarthritis	I	P	Unknown	Double	C 200	163	73	16	7	
Pfizer A3191069	w58	Osteoarthritis	I	P	Unknown	Double	C 200	188	189	19	17	
Pfizer A3191075 (PACES-a)	w59	Osteoarthritis	I	B	Other	Double	C 200	181	172	20	17	
Pfizer A3191075 (PACES-a)	w59	Osteoarthritis	I	E	Other	Double	C 200	86	43	9	5	
Pfizer A3191082	w60	Osteoarthritis	I	P	Unknown	Double	C 200	195	191	20	18	
Pfizer A3191101 (PACES-b)	w59	Osteoarthritis	I	B	Other	Double	C 200	189	182	19	15	
Pfizer A3191101 (PACES-b)	w59	Osteoarthritis	I	E	Other	Double	C 200	96	41	10	4	
Pfizer COXA-0508-244	-	Back pain	I	P	Unknown	Double	C 200	183	177	37	32	
Pfizer COXA-0508-245	-	Back pain	I	P	Unknown	Double	C 200	183	191	33	32	
Pfizer COXA-0508-269	-	Back pain	I	P	Unknown	Double	C 200	262	264	47	44	

Webtable 1 - Details of trials involving a randomised comparison of a coxib (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years	
								X	Y	X	Y
Pfizer F49-98-02-137	w61	Ankylosing spondylitis	I	P	Unknown	Double	C 200	80	76	7	6
Pfizer IQ4-96-02-001	w6	Familial adenomatous polyposis	I	P	Unknown	Double	C 200	34	17	16	8
Pfizer J49-01-02-216	-	Osteoarthritis	I	P	Unknown	Double	C 200	382	192	27	14
Pfizer N49-01-02-193	w22	Ankylosing spondylitis	I	P	Unknown	Double	C 200	137	156	26	21
Pfizer N49-01-02-202	w23	Psoriatic arthritis	I	P	Other	Double	C 200	214	194	41	31
Pfizer N49-96-02-020	w24	Osteoarthritis	I	P	Other	Double	C 200	217	220	35	30
Pfizer N49-96-02-021	w25	Osteoarthritis	I	P	Unknown	Double	C 200	240	247	44	36
Pfizer N49-96-02-022	w8	Rheumatoid arthritis	I	P	Other	Double	C 200	240	231	42	31
Pfizer N49-96-02-023	-	Rheumatoid arthritis	I	P	Unknown	Double	C 200	228	221	35	25
Pfizer N49-96-02-047	-	Osteoarthritis	I	P	Unknown	Double	C 200	101	101	7	6
Pfizer N49-96-02-054	w26	Osteoarthritis	I	P	Other	Double	C 200	207	218	33	26
Pfizer N49-96-02-060	w62	Osteoarthritis	I	P	Unknown	Double	C 200	454	232	47	20
Pfizer N49-98-02-087	w63	Osteoarthritis	I	P	Unknown	Double	C 200	474	244	47	21
Pfizer N49-98-02-118	w64	Osteoarthritis	I	P	Unknown	Double	C 200	201	200	20	17
Pfizer N49-99-02-152	w65	Osteoarthritis	I	P	Other	Double	C 200	63	60	6	6
GAIT	w66	Osteoarthritis	T	P	Other	Double	C 200	318	313	146	144
Gonzalez-Ortiz 2005	w67	Obesity	T	P	Sealed envelopes	Double	C 200	6	6	0.5	0.5
Yen 2008	w68	Chronic periodontitis	T	P	Pharmacy	Double	C 200	66	65	33	32
Donley 2007	w69	Plantar fasciitis	T	P	Unknown	Double	C 200	12	17	1	1
Lionberger 2005	w70	Osteoarthritis	T	P	Pharmacy	Double	C 200	24	25	3	3
Pfizer A3191068	w71	Osteoarthritis	T	P	Unknown	Double	C 200	17	6	34	12
Pfizer A3191225	w72	Knee arthroplasty	T	P	Other	Double	C 200	11	11	2	2
Pfizer NQ4-00-02-011	w39	Oral premalignant lesion	T	P	Other	Double	C 200	17	18	4	4
Small 2008	w73	Age related memory loss	T	P	Pharmacy	Double	C 200	36	36	54	54
Ta 2004	w74	Temporomandibular joint pain	T	P	Pharmacy	Double	C 200	24	22	3	3
BO2.CT3.021.TRA.P03	-	Osteoarthritis	U	P	Unknown	Double	C 200	-	-	-	-
MK 2007_636	-	OA/RA	U	P	Unknown	Double	C 200	-	-	-	-
Pfizer A9011030	-	Osteoarthritis	U	P	Unknown	Double	C 200	-	-	-	-
Sinsakul 2007	w75	Diabetic kidney disease	U	C	Unknown	Double	C 200	12	12	1	1
<i>Celecoxib versus placebo</i>											
<i>100 mg daily</i>											
Pfizer N49-96-02-020	w24	Osteoarthritis	I	P	Other	Double	C 100	218	220	35	30
Pfizer N49-96-02-021	w25	Osteoarthritis	I	P	Unknown	Double	C 100	258	247	46	36
Pfizer N49-96-02-054	w26	Osteoarthritis	I	P	Other	Double	C 100	216	218	33	26
Pfizer NQ5-98-02-005	-	Alzheimer's disease	I	P	Unknown	Unknown	C 100	5	5	0	0
Falahatkar 2008	w76	Benign prostatic hyperplasia	T	P	Other	Double	C 100	40	40	3	3
Pfizer Jhee 2004	w12	Alzheimer's disease	T	P	Unknown	Double	C 100	5	5	0.4	0.4
Rother 2007	w77	Osteoarthritis	T	P	Pharmacy	Double	C 100	132	127	15	15
<i>Celecoxib versus placebo</i>											
<i>80 mg daily</i>											
Pfizer N49-96-02-012	w7	Rheumatoid arthritis	I	P	Unknown	Double	C 80	81	85	5	5
<i>Celecoxib versus placebo</i>											
<i>50 mg daily</i>											
Pfizer N49-96-02-047	-	Osteoarthritis	I	P	Unknown	Double	C 50	101	101	7	6
<i>Celecoxib (unknown dose) versus placebo</i>											
PN 400-307	-	Osteoarthritis	U	P	Unknown	Double	Unknown dose	-	-	-	-
PN 400-309	-	Osteoarthritis	U	P	Unknown	Double	Unknown dose	-	-	-	-
SWOG-S0300	-	Breast cancer	U	P	Unknown	Double	Unknown dose	-	-	-	-
<i>Etoricoxib versus placebo</i>											
<i>120 mg daily</i>											
MK 010	w78	Rheumatoid arthritis	I	B	Unknown	Double	E 120	119	123	18	21
MK 026	w79	OA/RA	I	P	Pharmacy	Double	E 120	251	247	60	60
MK 027	w79	Healthy volunteer	I	P	Pharmacy	Double	E 120	23	21	3	2
MK 029 Etor	w80	Osteoarthritis	I	P	Unknown	Double	E 120	221	233	54	58
MK 032	w81	Ankylosing spondylitis	I	B	Onsite computer	Double	E 120	92	93	10	8
<i>Etoricoxib versus placebo</i>											
<i>90 mg daily</i>											
MK 007	w82	Osteoarthritis	I	B	Pharmacy	Double	E 90	112	60	14	7
MK 010	w78	Rheumatoid arthritis	I	B	Unknown	Double	E 90	134	123	21	21
MK 024	w83	Rheumatoid arthritis	I	B	Unknown	Double	E 90	323	323	63	45
MK 025	w84	Rheumatoid arthritis	I	B	Other	Double	E 90	353	357	75	66
MK 032	w81	Ankylosing spondylitis	I	B	Onsite computer	Double	E 90	103	93	11	8
MK 036	w85	Haemophilic arthropathy	I	B	Other	Double	E 90	46	45	5	4
MK 041	w86	Back pain	I	P	Onsite computer	Double	E 90	106	110	26	25
MK 042	w87	Back pain	I	P	Other	Double	E 90	107	109	24	24
MK 065	w18	Osteoarthritis	I	P	Other	Double	E 90	108	111	26	25
MK 086	-	Rheumatoid arthritis	I	B	Unknown	Double	E 90	155	161	27	20
Ghosh 2007	w88	Osteoarthritis	T	P	Unknown	Double	E 90	195	195	15	15
<i>Etoricoxib versus placebo</i>											
<i>60 mg daily</i>											
MK 007	w82	Osteoarthritis	I	B	Pharmacy	Double	E 60	112	60	13	7
MK 010	w78	Rheumatoid arthritis	I	B	Unknown	Double	E 60	126	123	22	21
MK 018	w89	Osteoarthritis	I	B	Other	Double	E 60	222	56	49	11
MK 019	w90	Osteoarthritis	I	B	Other	Double	E 60	224	56	51	12
MK 041	w86	Back pain	I	P	Onsite computer	Double	E 60	109	110	26	25
MK 042	w87	Back pain	I	P	Other	Double	E 60	103	109	24	24
MK 086	-	Rheumatoid arthritis	I	B	Unknown	Double	E 60	140	161	21	20
El Miedany 2006	w91	Inflammatory bowel disease	T	P	Pharmacy	Double	E 60	82	77	19	18
<i>Etoricoxib versus placebo</i>											
<i>30 mg daily</i>											
MK 007	w82	Osteoarthritis	I	B	Pharmacy	Double	E 30	102	60	12	7
MK 071	w92	Osteoarthritis	I	P	Pharmacy	Double	E 30	214	104	54	21
MK 073	w93	Osteoarthritis	I	P	Other	Double	E 30	224	111	55	25
MK 076	w45	Osteoarthritis	I	B	Unknown	Double	E 30	231	127	50	24
MK 077	w45	Osteoarthritis	I	B	Other	Double	E 30	244	117	53	20
MK 086	-	Rheumatoid arthritis	I	B	Unknown	Double	E 30	151	161	23	20
<i>Etoricoxib versus placebo</i>											
<i>10 mg daily</i>											
MK 007	w82	Osteoarthritis	I	B	Pharmacy	Double	E 10	114	60	14	7
MK 010	w78	Rheumatoid arthritis	I	B	Unknown	Double	E 10	78	123	14	21
MK 086	-	Rheumatoid arthritis	I	B	Unknown	Double	E 10	154	161	22	20
<i>Etoricoxib versus placebo</i>											
<i>5 mg daily</i>											

Webtable 1 - Details of trials involving a randomised comparison of a coxib (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years	
								X	Y	X	Y
MK 007	w82	Osteoarthritis	I	B	Pharmacy	Double	E 5	117	60	14	7
<i>Lumiracoxib versus placebo</i>											
<i>400 mg daily</i>											
Novartis 104	w94	Osteoarthritis	I	P	Unknown	Double	L 400	198	97	15	7
Novartis 105	w95	Rheumatoid arthritis	I	P	Unknown	Double	L 400	181	99	13	7
Novartis 109	w49	Osteoarthritis	I	P	Unknown	Double	L 400	463	231	101	46
Novartis 111	w96	Rheumatoid arthritis	I	P	Unknown	Double	L 400	281	284	109	96
Novartis 112E	w50	Osteoarthritis	I	B	Unknown	Double	L 400	491	243	125	55
Novartis 114	-	Rheumatoid arthritis	I	P	Unknown	Unknown	L 400	313	309	63	59
Novartis 128	w97	Osteoarthritis	I	P	Unknown	Double	L 400	205	204	45	41
Novartis 2319	w98	Osteoarthritis	I	P	Unknown	Double	L 400	193	196	15	15
<i>Lumiracoxib versus placebo</i>											
<i>200 mg daily</i>											
Novartis 104	w94	Osteoarthritis	I	P	Unknown	Double	L 200	96	97	7	7
Novartis 105	w95	Rheumatoid arthritis	I	P	Unknown	Double	L 200	97	99	7	7
Novartis 109	w49	Osteoarthritis	I	P	Unknown	Double	L 200	462	231	100	46
Novartis 111	w96	Rheumatoid arthritis	I	P	Unknown	Double	L 200	280	284	111	96
Novartis 112E	w50	Osteoarthritis	I	B	Unknown	Double	L 200	487	243	125	55
Novartis 114	-	Rheumatoid arthritis	I	P	Unknown	Unknown	L 200	315	309	63	59
Novartis 2319	w98	Osteoarthritis	I	P	Unknown	Double	L 200	205	196	16	15
Novartis 335E	w99	Rheumatoid arthritis	I	B	Unknown	Double	L 200	458	465	103	80
<i>Lumiracoxib versus placebo</i>											
<i>100 mg daily</i>											
Novartis 104	w94	Osteoarthritis	I	P	Unknown	Double	L 100	98	97	7	7
Novartis 105	w95	Rheumatoid arthritis	I	P	Unknown	Double	L 100	102	99	7	7
Novartis 2316	w100	Osteoarthritis	I	P	Unknown	Double	L 100	122	122	9	9
Novartis 2367	w51	Osteoarthritis	I	P	Other	Double	L 100	427	416	129	119
Novartis 360E	w52	Osteoarthritis	I	B	Other	Double	L 100	776	382	185	73
Novartis 361E	w53	Osteoarthritis	I	B	Other	Double	L 100	840	424	227	96
Novartis A2475	-	Osteoarthritis	U	P	Unknown	Double	L 100	-	-	-	-
<i>Rofecoxib versus placebo</i>											
<i>175 mg daily</i>											
MK 017	-	Rheumatoid arthritis	I	B	Unknown	Unknown	R 175	28	68	4	7
<i>Rofecoxib versus placebo</i>											
<i>125 mg daily</i>											
MK 010	w101	Osteoarthritis	I	P	Other	Double	R 125	74	72	10	8
MK 017	-	Rheumatoid arthritis	I	B	Unknown	Unknown	R 125	41	68	5	7
<i>Rofecoxib versus placebo</i>											
<i>100 mg daily</i>											
Treiber 2006	w102	Hepatocellular cancer	U	P	Unknown	Open	R 100	32	39	16	19
MK 905	w19	Healthy volunteer	I	P	Unknown	Double	R 100	17	16	2	2
<i>Rofecoxib versus placebo</i>											
<i>50 mg daily</i>											
Kvale 2006	w1	HIV	T	P	Unknown	Open	R 50	12	14	3	3
MK 029 Rof	w103	Osteoarthritis	I	B	Unknown	Double	R 50	97	145	11	16
MK 044	w104	Osteoarthritis	I	P	Sealed envelopes	Double	R 50	186	177	74	52
MK 045	w105	Osteoarthritis	I	P	Unknown	Double	R 50	193	194	76	61
MK 050	w106	Healthy volunteer	I	P	Other	Double	R 50	19	17	2	2
MK 068	w107	Rheumatoid arthritis	I	B	Other	Double	R 50	161	168	23	24
MK 097	w108	Rheumatoid arthritis	I	B	Other	Double	R 50	297	299	63	59
MK 098	w109	Rheumatoid arthritis	I	P	Other	Double	R 50	45	48	11	12
MK 103	w109	Rheumatoid arthritis	I	P	Unknown	Double	R 50	174	173	43	44
MK 118	w110	Prostatitis	I	P	Onsite computer	Double	R 50	49	59	7	9
MK 120	w111	Back pain	I	P	Pharmacy	Double	R 50	126	128	14	14
MK 121	w111	Back pain	I	P	Pharmacy	Double	R 50	103	100	12	11
Tikiz 2005	w112	Coronary artery disease (IHD)	U	P	Unknown	Single	R 50	12	10	1	1
<i>Rofecoxib versus placebo</i>											
<i>42 mg daily</i>											
MK 2007_636	-	OA/RA	U	P	Unknown	Double	R 42	-	-	-	-
<i>Rofecoxib versus placebo</i>											
<i>25 mg daily</i>											
Di Silverio 2005	w113	Benign prostatic hyperplasia	T	P	Unknown	Open	R 25	23	23	11	11
Aisen 2003	w114	Alzheimer's disease	I	P	Other	Double	R 25	122	111	129	118
MK 010	w101	Osteoarthritis	I	P	Other	Double	R 25	73	72	11	8
MK 029 Rof	w103	Osteoarthritis	I	B	Unknown	Double	R 25	137	145	16	16
MK 033	w115	Osteoarthritis	I	P	Other	Double	R 25	227	69	33	9
MK 040	w116	Osteoarthritis	I	P	Other	Double	R 25	242	74	35	10
MK 044	w104	Osteoarthritis	I	P	Sealed envelopes	Double	R 25	195	177	79	52
MK 045	w105	Osteoarthritis	I	P	Unknown	Double	R 25	195	194	80	61
MK 050	w106	Healthy volunteer	I	P	Other	Double	R 25	18	17	2	2
MK 058	w117	Osteoarthritis	I	B	Other	Double	R 25	56	52	7	6
MK 068	w107	Rheumatoid arthritis	I	B	Other	Double	R 25	171	168	26	24
MK 078	w118	Alzheimer's disease	I	P	Onsite computer	Double	R 25	725	732	1399	1581
MK 083	w119	Osteoarthritis	I	B	Unknown	Double	R 25	98	100	21	21
MK 091	w120	Alzheimer's disease	I	B	Other	Double	R 25	346	346	286	301
MK 091	w120	Alzheimer's disease	I	E	Other	Double	R 25	25	206	7	55
MK 096	w121	Rheumatoid arthritis	I	B	Unknown	Double	R 25	311	301	64	56
MK 097	w108	Rheumatoid arthritis	I	B	Other	Double	R 25	315	299	68	59
MK 112	w46	Osteoarthritis	I	P	Unknown	Double	R 25	459	150	66	18
MK 116	w46	Osteoarthritis	I	P	Unknown	Double	R 25	471	151	68	18
MK 118	w110	Prostatitis	I	P	Onsite computer	Double	R 25	53	59	8	9
MK 120	w111	Back pain	I	P	Pharmacy	Double	R 25	126	128	14	14
MK 121	w111	Back pain	I	P	Pharmacy	Double	R 25	107	100	12	11
MK 122 (APPROVe)	w122	Colorectal polyps	I	P	Other	Double	R 25	1287	1300	4572	4623
MK 125	w123	Migraine	I	P	Other	Double	R 25	91	84	22	20
MK 126	w124	Alzheimer's disease	I	B	Unknown	Double	R 25	382	376	194	197
MK 129	-	Familial adenomatous polyposis	I	P	Unknown	Double	R 25	8	9	3	4
MK 136 (ASA)	w125	Osteoarthritis	I	P	Other	Double	R 25	399	406	94	100
MK 201 (VIP)	w126	Prostate cancer	I	P	Other	Unknown	R 25	2369	2372	1224	1224
Novartis 128	w97	Osteoarthritis	I	P	Unknown	Double	R 25	102	204	23	41
Pfizer 635-IFL-0508-003	w54	Osteoarthritis	I	P	Other	Double	R 25	190	98	20	8
Pfizer N49-99-02-152	w65	Osteoarthritis	I	P	Other	Double	R 25	59	60	6	6
VICTOR	w127	Colorectal cancer	I	P	Telephone	Double	R 25	1217	1217	2948	2930
MK 054	-	Hypertension	T	P	Unknown	Unknown	R 25	38	38	3	3

Webtable 1 - Details of trials involving a randomised comparison of a coxib (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years	
								X	Y	X	Y
Banovac 2004	w128	Spinal cord injury	T	P	Unknown	Double	R 25	37	39	3	3
Bogaty 2004	w129	Coronary artery disease (IHD)	T	P	Unknown	Double	R 25	18	17	9	8
Cobellis 2004	w130	Endometriosis	T	P	Unknown	Double	R 25	16	12	8	6
Hefler 2008	w131	Cervical intraepithelial neoplasia	T	P	Closed list	Double	R 25	8	8	4	4
Higuchi 2003	w132	Familial adenomatous polyposis	T	P	Unknown	Double	R 25	12	9	9	7
Karlsson 2009	w133	OA/RA	T	P	Other	Double	R 25	115	80	13	9
Leung 2006	w134	Gastrointestinal dysplasia	T	P	Sealed envelopes	Double	R 25	107	106	213	211
MK 301-0 X1	w135	Osteoarthritis	T	B	Unknown	Double	R 25	97	95	11	11
Monakier 2004	w136	Acute coronary syndrome	T	P	Pharmacy	Double	R 25	18	16	4	4
Pfizer 872-IFL-0513-004	w137	OA/RA	T	P	Unknown	Double	R 25	225	113	26	13
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	R 25	104	107	12	12
Title 2003	w139	Coronary artery disease (IHD)	T	P	Sealed envelopes	Double	R 25	30	30	5	5
Tikiz 2005	w112	Coronary artery disease (IHD)	U	P	Unknown	Single	R 25	12	10	1	1
<i>Rofecoxib versus placebo</i>											
<i>21 mg daily</i>											
MK 2007_636	-	OA/RA	U	P	Unknown	Double	R 21	-	-	-	-
<i>Rofecoxib versus placebo</i>											
<i>12.5 mg daily</i>											
Kuklinska 2005	w140	Acute coronary syndrome	U	P	Unknown	Unknown	R 12.5	15	14	1	1
MK 029 Rof	w103	Osteoarthritis	I	B	Unknown	Double	R 12.5	144	145	17	16
MK 033	w115	Osteoarthritis	I	P	Other	Double	R 12.5	219	69	32	9
MK 040	w116	Osteoarthritis	I	P	Other	Double	R 12.5	244	74	36	10
MK 058	w117	Osteoarthritis	I	B	Other	Double	R 12.5	118	52	14	6
MK 085	w141	Osteoarthritis	I	P	Other	Double	R 12.5	424	208	60	27
MK 090	w142	Osteoarthritis	I	P	Other	Double	R 12.5	390	196	55	26
MK 096	w121	Rheumatoid arthritis	I	B	Unknown	Double	R 12.5	148	301	29	56
MK 112	w46	Osteoarthritis	I	P	Unknown	Double	R 12.5	456	150	65	18
MK 219	w47	Osteoarthritis	I	P	Other	Double	R 12.5	160	78	17	8
MK 220	w48	Osteoarthritis	I	P	Unknown	Double	R 12.5	159	85	23	11
MK 301-0 X1	w135	Osteoarthritis	T	B	Unknown	Double	R 12.5	90	95	10	11
<i>Rofecoxib versus placebo</i>											
<i>5 mg daily</i>											
MK 029 Rof	w103	Osteoarthritis	I	B	Unknown	Double	R 5	149	145	17	16
MK 068	w107	Rheumatoid arthritis	I	B	Other	Double	R 5	158	168	23	24
<i>Tiracoxib versus placebo</i>											
<i>200 mg daily</i>											
Iwama 2006	w143	Familial adenomatous polyposis	T	P	Sealed envelopes	Double	T 200	19	21	9	10
<i>Tiracoxib versus placebo</i>											
<i>150 mg daily</i>											
Iwama 2006	w143	Familial adenomatous polyposis	T	P	Sealed envelopes	Double	T 150	21	21	10	10
<i>Valdecoxib versus placebo</i>											
<i>80 mg daily</i>											
Pfizer N91-00-02-040	w144	Cancer pain	T	P	Unknown	Double	V 80	118	119	27	27
<i>Valdecoxib versus placebo</i>											
<i>40 mg daily</i>											
Pfizer N91-00-02-079	w145	Cancer pain	T	P	Unknown	Double	V 40	60	61	7	7
Pfizer N91-01-02-097	w146	Back pain	T	P	Unknown	Double	V 40	125	131	10	10
Pfizer N91-01-02-108	w147	Back pain	T	P	Other	Double	V 40	148	145	11	11
Pfizer N91-01-02-132	w148	Back pain	T	P	Unknown	Double	V 40	153	154	35	35
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	V 40	221	222	51	51
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	V 40	209	220	48	51
<i>Valdecoxib versus placebo</i>											
<i>20 mg daily</i>											
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 20	82	87	9	10
Pfizer 872-IFL-0513-004	w137	OA/RA	T	P	Unknown	Double	V 20	228	113	26	13
Pfizer A3471090	w152	Osteoarthritis	T	P	Unknown	Double	V 20	106	104	12	12
Pfizer N91-01-02-132	w148	Back pain	T	P	Unknown	Double	V 20	154	154	35	35
Pfizer N91-01-02-133	w153	Back pain	T	P	Unknown	Double	V 20	158	163	36	37
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 20	79	82	9	9
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	V 20	219	210	50	48
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 20	202	205	46	47
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	V 20	212	222	49	51
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	V 20	219	220	50	51
<i>Valdecoxib versus placebo</i>											
<i>10 mg daily</i>											
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 10	166	87	19	10
Pfizer A3471018	w157	Rheumatoid arthritis	T	P	Unknown	Double	V 10	170	171	39	39
Pfizer A3471090	w152	Osteoarthritis	T	P	Unknown	Double	V 10	101	104	12	12
Pfizer N91-01-02-133	w153	Back pain	T	P	Unknown	Double	V 10	164	163	38	37
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 10	165	82	19	9
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	V 10	204	210	47	48
Pfizer N91-99-02-049	w158	Osteoarthritis	T	P	Unknown	Double	V 10	111	118	26	27
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 10	206	205	47	47
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	V 10	209	222	48	51
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	V 10	226	220	52	51
<i>Valdecoxib versus placebo</i>											
<i>5 mg daily</i>											
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 5	83	87	10	10
Pfizer A3471090	w152	Osteoarthritis	T	P	Unknown	Double	V 5	105	104	12	12
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 5	83	82	10	9
Pfizer N91-99-02-049	w158	Osteoarthritis	T	P	Unknown	Double	V 5	120	118	28	27
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 5	201	205	46	47
<i>Valdecoxib versus placebo</i>											
<i>2.5 mg daily</i>											
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 2.5	84	87	10	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 2.5	81	82	9	9
<i>Valdecoxib versus placebo</i>											
<i>1 mg daily</i>											
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 1	89	87	10	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 1	77	82	9	9

Webtable 1 - Details of trials involving a randomised comparison of a coxib (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years	
								X	Y	X	Y
<i>GW403681 versus placebo</i>											
<i>50 mg daily</i>											
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	G 50	109	107	14	13
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	G 50	137	132	17	14
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 50	190	189	43	42
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	G 50	379	379	81	79
<i>GW403681 versus placebo</i>											
<i>35 mg daily</i>											
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	G 35	110	107	14	13
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	G 35	139	132	17	14
<i>GW403681 versus placebo</i>											
<i>25 mg daily</i>											
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 25	190	189	43	42
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	G 25	380	379	83	79
<i>GW403681 versus placebo</i>											
<i>20 mg daily</i>											
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	G 20	105	107	13	13
<i>GW403681 versus placebo</i>											
<i>10 mg daily</i>											
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	G 10	107	107	13	13
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	G 10	133	132	16	14
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 10	192	189	42	42
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	G 10	379	379	85	79
<i>GW403681 versus placebo</i>											
<i>5 mg daily</i>											
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 5	191	189	41	42
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	G 5	379	379	85	79
<i>GW403681 versus placebo</i>											
<i>1 mg daily</i>											
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 1	189	189	42	42

OA/RA=Osteoarthritis or rheumatoid arthritis.

Data type (I=Individual patient data; T=Tabular data; U=Unavailable in either tabular or IPD form).

Design (B='Base' phase of a trial with more than one randomisation; C=Cross-over trial (first treatment period only); E='Extension' phase of a trial with a second randomisation (note: a single trial can have several extension phases, each contributing to a different randomised comparison); F=Factorial design; P=Parallel trial with a single randomisation).

Allocation concealment (IVRS = Interactive Voice Response System; Telephone = Telephone central office; Pharmacy = Pharmacy coded containers administered sequentially; Onsite computer = Onsite computer accessible only after entering patients details; Sealed envelopes = Sealed envelopes, sequentially numbered and opaque; Closed list = Closed list of random numbers; Other = Other acceptable method).

Regimens: C=Celecoxib; E=Etoricoxib; L=Lumiracoxib; R=Rofecoxib; T=Tiracoxib; V=Valdecoxib; G=GW403681.

Webtable 2 - Details of trials involving a randomised comparison of a coxib (X) versus a tNSAID (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
								X	Y	X	Y
<i>Celecoxib vs naproxen</i>											
Pfizer N49-96-02-022	w8	Rheumatoid arthritis	I	P	Other	Double	C 800 vs Nap 1000	218	225	37	38
Pfizer N49-96-02-023	-	Rheumatoid arthritis	I	P	Unknown	Double	C 800 vs Nap 1000	217	218	36	37
MK 905	w19	Healthy volunteer	I	P	Unknown	Double	C 400 vs Nap 1000	17	17	2	2
Pfizer I49-98-02-096 (SUCCESS - North America)	w159	Osteoarthritis	I	P	IVRS	Double	C 400 vs Nap 1000	922	914	174	163
Pfizer N49-01-02-193	w22	Ankylosing spondylitis	I	P	Unknown	Double	C 400 vs Nap 1000	161	157	30	30
Pfizer N49-96-02-020	w24	Osteoarthritis	I	P	Other	Double	C 400 vs Nap 1000	222	216	39	37
Pfizer N49-96-02-021	w25	Osteoarthritis	I	P	Unknown	Double	C 400 vs Nap 1000	237	233	43	42
Pfizer N49-96-02-022	w8	Rheumatoid arthritis	I	P	Other	Double	C 400 vs Nap 1000	235	225	43	38
Pfizer N49-96-02-023	-	Rheumatoid arthritis	I	P	Unknown	Double	C 400 vs Nap 1000	219	218	36	37
Pfizer N49-96-02-054	w26	Osteoarthritis	I	P	Other	Double	C 400 vs Nap 1000	213	207	34	33
Pfizer N49-97-02-062	w160	OA/RA	I	P	Other	Double	C 400 vs Nap 1000	270	267	54	44
Adegbingbe 2008	w33	Osteoarthritis	T	P	Onsite computer	Double	C 400 vs Nap 1000	21	21	2	2
ADAPT	w14	Alzheimer's disease	I	P	Onsite computer	Double	C 400 vs Nap 440	726	719	2102	2074
Pfizer 635-IFL-0508-002	w161	Osteoarthritis	I	P	Onsite computer	Double	C 200 vs Nap 1000	136	130	28	26
Pfizer A3191051	w55	Osteoarthritis	I	P	Unknown	Double	C 200 vs Nap 1000	126	126	13	13
Pfizer A3191052	-	Osteoarthritis	I	P	Unknown	Double	C 200 vs Nap 1000	145	144	14	13
Pfizer A3191053	w56	Osteoarthritis	I	P	Unknown	Double	C 200 vs Nap 1000	126	129	12	12
Pfizer A3191152	w162	Osteoarthritis	I	P	Unknown	Double	C 200 vs Nap 1000	296	293	114	106
Pfizer I49-98-02-096 (SUCCESS - North America)	w159	Osteoarthritis	I	P	IVRS	Double	C 200 vs Nap 1000	920	914	174	163
Pfizer N49-01-02-193	w22	Ankylosing spondylitis	I	P	Unknown	Double	C 200 vs Nap 1000	137	157	26	30
Pfizer N49-96-02-020	w24	Osteoarthritis	I	P	Other	Double	C 200 vs Nap 1000	217	216	35	37
Pfizer N49-96-02-021	w25	Osteoarthritis	I	P	Unknown	Double	C 200 vs Nap 1000	240	233	44	42
Pfizer N49-96-02-022	w8	Rheumatoid arthritis	I	P	Other	Double	C 200 vs Nap 1000	240	225	42	38
Pfizer N49-96-02-023	-	Rheumatoid arthritis	I	P	Unknown	Double	C 200 vs Nap 1000	228	218	35	37
Pfizer N49-96-02-054	w26	Osteoarthritis	I	P	Other	Double	C 200 vs Nap 1000	207	207	33	33
Ta 2004	w74	Temporomandibular joint pain	T	P	Pharmacy	Double	C 200 vs Nap 1000	24	22	3	3
Pfizer N49-96-02-020	w24	Osteoarthritis	I	P	Other	Double	C 100 vs Nap 1000	218	216	35	37
Pfizer N49-96-02-021	w25	Osteoarthritis	I	P	Unknown	Double	C 100 vs Nap 1000	258	233	46	42
Pfizer N49-96-02-054	w26	Osteoarthritis	I	P	Other	Double	C 100 vs Nap 1000	216	207	33	33
<i>Celecoxib vs diclofenac</i>											
Pfizer N49-98-02-102 (CLASS)	w163	OA/RA	I	P	Other	Double	C 800 vs Dic 150	2019	2016	1131	1075
Pfizer COXA-0508-243	w164	Ankylosing spondylitis	I	P	Unknown	Double	C 400 vs Dic 150	150	155	30	32
Pfizer COXA-0508-247	w165	Ankylosing spondylitis	I	P	Unknown	Double	C 400 vs Dic 150	108	115	22	23
Pfizer I49-96-02-041	w166	Rheumatoid arthritis	I	P	Pharmacy	Double	C 400 vs Dic 150	326	329	132	124
Pfizer N49-97-02-071	-	OA/RA	I	P	Unknown	Double	C 400 vs Dic 150	366	387	71	73
Pfizer I49-98-02-096 (SUCCESS - Other countries)	w159	Osteoarthritis	I	P	IVRS	Double	C 400 vs Dic 100	3507	3510	726	736
Pfizer COXA-0508-243	w164	Ankylosing spondylitis	I	P	Unknown	Double	C 200 vs Dic 150	153	155	31	32
Pfizer COXA-0508-247	w165	Ankylosing spondylitis	I	P	Unknown	Double	C 200 vs Dic 150	107	115	22	23
Pfizer COXA-0508-261	w167	Osteoarthritis	I	P	Other	Double	C 200 vs Dic 150	126	123	21	22
Pfizer N49-98-02-118	w64	Osteoarthritis	I	P	Unknown	Double	C 200 vs Dic 150	201	199	20	20
Izhar 2004	w168	Osteoarthritis	T	P	Unknown	Unknown	C 200 vs Dic 150	14	14	1	1
Pfizer A3191006 (CAESAR)	w169	Osteoarthritis	I	P	Other	Double	C 200 vs Dic 100	458	458	413	430
Pfizer A3191025	w170	Osteoarthritis	I	P	Unknown	Double	C 200 vs Dic 100	32	28	17	16
Pfizer I49-96-02-042	w171	Osteoarthritis	I	P	Unknown	Double	C 200 vs Dic 100	347	341	38	37
Pfizer I49-98-02-096 (SUCCESS - Other countries)	w159	Osteoarthritis	I	P	IVRS	Double	C 200 vs Dic 100	3501	3510	726	736
Pfizer I49-98-02-105	-	OA/RA	I	P	Unknown	Double	C 200 vs Dic 100	331	334	73	80
Pfizer I49-98-02-107	-	OA/RA	I	P	Unknown	Double	C 200 vs Dic 100	45	44	10	9
Tascioglu 2004	w172	OA/RA	U	P	Unknown	Unknown	C 200 vs Dic 75	35	25	4	3
Pfizer I49-98-02-106	-	OA/RA	I	P	Unknown	Double	C 100 vs Dic 50	63	62	14	12
<i>Celecoxib vs ibuprofen</i>											
Pfizer N49-98-02-035 (CLASS)	w163	OA/RA	I	P	Other	Double	C 800 vs Ibu 2400	2011	2007	1179	1117
MK 065	w18	Osteoarthritis	I	P	Other	Double	C 400 vs Ibu 2400	107	107	25	25
Novartis 110	w173	Rheumatoid arthritis	I	P	Unknown	Double	C 400 vs Ibu 2400	223	216	51	44
Pfizer N49-97-02-071	-	OA/RA	I	P	Unknown	Double	C 400 vs Ibu 2400	366	346	71	61
Palmer 2003	w32	Hypertension	T	P	Unknown	Double	C 400 vs Ibu 2400	97	100	7	8
Novartis 126	w174	Osteoarthritis	I	P	Sealed envelopes	Double	C 200 vs Ibu 2400	258	260	59	56
Pfizer A3191062	w57	Osteoarthritis	I	P	Unknown	Double	C 200 vs Ibu 2400	153	156	16	15
Pfizer A3191063	-	Osteoarthritis	I	P	Unknown	Double	C 200 vs Ibu 2400	163	154	16	16
<i>Celecoxib vs other tNSAID</i>											
Jajic 2005	w175	Rheumatoid arthritis	T	P	Closed list	Double	C 400 vs Amlometin 1200	117	118	54	54
Pfizer A3191174	w20	Back pain	I	P	Unknown	Double	C 400 vs Loxoprofen 180	411	411	54	54
Palmer 2003	w32	Hypertension	T	P	Unknown	Double	C 400 vs Nabumetone 2000	97	96	7	7
Pfizer 635-IFL-0508-007	w176	Osteoarthritis	I	P	Unknown	Open	C 200 vs Aceclofenac 200	106	106	8	7
Pfizer F49-98-02-137	w61	Ankylosing spondylitis	I	P	Unknown	Double	C 200 vs Ketoprofen 200	80	90	7	9
Pfizer J49-01-02-216	-	Osteoarthritis	I	P	Unknown	Double	C 200 vs Loxoprofen 180	382	385	27	27
Pfizer J49-01-02-217	-	Back pain	I	P	Unknown	Double	C 200 vs Loxoprofen 180	441	440	32	31
Orgocmen 2005	w177	Osteoarthritis	T	P	Sealed envelopes	Single	C 200 vs Tenoxicam 20	11	12	1	1
<i>Etoricoxib vs naproxen</i>											
MK 024	w178	Rheumatoid arthritis	I	E	Other	Double	E 120 vs Nap 1000	144	152	191	180
MK 025	w84	Rheumatoid arthritis	I	E	Unknown	Double	E 120 vs Nap 1000	167	169	273	263
MK 026	w79	OA/RA	I	P	Pharmacy	Double	E 120 vs Nap 1000	251	244	60	55
MK 032	w81	Ankylosing spondylitis	I	B	Onsite computer	Double	E 120 vs Nap 1000	92	99	10	10
MK 032	w81	Ankylosing spondylitis	I	E	Onsite computer	Double	E 120 vs Nap 1000	32	28	26	23
MK 032	w81	Ankylosing spondylitis	I	E	Onsite computer	Double	E 120 vs Nap 1000	91	97	70	71
MK 024	w83	Rheumatoid arthritis	I	B	Unknown	Double	E 90 vs Nap 1000	323	170	63	30
MK 024	w178	Rheumatoid arthritis	I	E	Other	Double	E 90 vs Nap 1000	128	144	172	182
MK 024	w178	Rheumatoid arthritis	I	E	Other	Double	E 90 vs Nap 1000	149	152	187	180
MK 025	w84	Rheumatoid arthritis	I	B	Other	Double	E 90 vs Nap 1000	353	181	75	39
MK 025	w84	Rheumatoid arthritis	I	E	Unknown	Double	E 90 vs Nap 1000	161	155	260	231
MK 025	w84	Rheumatoid arthritis	I	E	Unknown	Double	E 90 vs Nap 1000	163	169	266	263
MK 032	w81	Ankylosing spondylitis	I	B	Onsite computer	Double	E 90 vs Nap 1000	103	99	11	10
MK 032	w81	Ankylosing spondylitis	I	E	Onsite computer	Double	E 90 vs Nap 1000	26	28	22	23
MK 032	w81	Ankylosing spondylitis	I	E	Onsite computer	Double	E 90 vs Nap 1000	100	97	80	71
MK 018	w89	Osteoarthritis	I	B	Other	Double	E 60 vs Nap 1000	222	218	49	48
MK 018	w89	Osteoarthritis	I	E	Other	Double	E 60 vs Nap 1000	21	17	32	19
MK 018	w89	Osteoarthritis	I	E	Other	Double	E 60 vs Nap 1000	185	183	241	239
MK 019	w90	Osteoarthritis	I	B	Other	Double	E 60 vs Nap 1000	224	221	51	48
MK 019	w90	Osteoarthritis	I	E	Other	Double	E 60 vs Nap 1000	24	20	42	27
MK 019	w90	Osteoarthritis	I	E	Other	Double	E 60 vs Nap 1000	204	184	322	286
<i>Etoricoxib vs diclofenac</i>											
MK 061 (EDGE)	w179	Osteoarthritis	I	P	Pharmacy	Double	E 90 vs Dic 150	3593	3518	4126	4044

Webtable 2 - Details of trials involving a randomised comparison of a coxib (X) versus a tNSAID (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
								X	Y	X	Y
MK 066 (MEDAL)	w180	OA/RA	I	P	Telephone	Double	E 90 vs Dic 150	5013	11717	14302	31457
MK 072 (EDGE II)	w181	Rheumatoid arthritis	I	P	Pharmacy	Double	E 90 vs Dic 150	2032	2054	4355	4373
MK 086	-	Rheumatoid arthritis	I	E	Unknown	Double	E 90 vs Dic 150	36	48	6	8
MK 086	-	Rheumatoid arthritis	I	E	Unknown	Double	E 90 vs Dic 150	38	34	6	5
MK 086	-	Rheumatoid arthritis	I	E	Unknown	Double	E 90 vs Dic 150	28	37	4	5
MK 086	-	Rheumatoid arthritis	I	E	Unknown	Double	E 90 vs Dic 150	33	30	5	4
Ghosh 2007	w88	Osteoarthritis	T	P	Unknown	Double	E 90 vs Dic 75	195	195	15	15
MK 010	w78	Rheumatoid arthritis	I	E	Unknown	Double	E 60 vs Dic 150	28	79	57	170
MK 010	w78	Rheumatoid arthritis	I	E	Unknown	Double	E 60 vs Dic 150	16	51	37	108
MK 066 (MEDAL)	w180	OA/RA	I	P	Telephone	Double	E 60 vs Dic 150	6774	11717	17393	31457
MK 805	w182	Osteoarthritis	I	P	Other	Double	E 60 vs Dic 150	256	260	38	39
MK 806	w183	Back pain	I	P	Unknown	Double	E 60 vs Dic 150	224	222	25	25
MK 080	w184	Osteoarthritis	U	P	Unknown	Double	E 60 vs Dic 150	90	90	7	7
MK 007	w82	Osteoarthritis	I	E	Pharmacy	Double	E 30 vs Dic 150	76	29	123	31
MK 007	w82	Osteoarthritis	I	E	Pharmacy	Double	E 30 vs Dic 150	74	23	121	33
<i>Etoricoxib vs ibuprofen</i>											
MK 027	w79	Healthy volunteer	I	P	Pharmacy	Double	E 120 vs Ibu 2400	23	18	3	2
MK 029 Etor	w80	Osteoarthritis	I	P	Unknown	Double	E 120 vs Ibu 2400	221	226	54	53
MK 065	w18	Osteoarthritis	I	P	Other	Double	E 90 vs Ibu 2400	108	107	26	25
MK 071	w92	Osteoarthritis	I	P	Pharmacy	Double	E 30 vs Ibu 2400	214	210	54	50
MK 073	w93	Osteoarthritis	I	P	Other	Double	E 30 vs Ibu 2400	224	213	55	51
<i>Lumiracoxib vs naproxen</i>											
Novartis 2312	w185	Rheumatoid arthritis	I	P	Unknown	Unknown	L 1200 vs Nap 1000	41	41	4	4
Novartis 2312	w185	Rheumatoid arthritis	I	P	Unknown	Unknown	L 800 vs Nap 1000	38	41	4	4
Novartis 111	w96	Rheumatoid arthritis	I	P	Unknown	Double	L 400 vs Nap 1000	281	279	109	112
Novartis 117 (TARGET)	w186	Osteoarthritis	I	P	IVRS	Double	L 400 vs Nap 1000	4741	4730	4111	4007
Novartis 111	w96	Rheumatoid arthritis	I	P	Unknown	Double	L 200 vs Nap 1000	280	279	111	112
Novartis 335E	w99	Rheumatoid arthritis	I	B	Unknown	Double	L 200 vs Nap 1000	458	228	103	52
Novartis 335E	w99	Rheumatoid arthritis	I	E	Unknown	Double	L 200 vs Nap 1000	123	118	69	78
Novartis 335E	w99	Rheumatoid arthritis	I	E	Unknown	Double	L 200 vs Nap 1000	272	148	161	88
<i>Lumiracoxib vs diclofenac</i>											
Novartis 104	w94	Osteoarthritis	I	P	Unknown	Double	L 400 vs Dic 150	198	94	15	7
Novartis 105	w95	Rheumatoid arthritis	I	P	Unknown	Double	L 400 vs Dic 150	181	91	13	6
Novartis 104	w94	Osteoarthritis	I	P	Unknown	Double	L 200 vs Dic 150	96	94	7	7
Novartis 105	w95	Rheumatoid arthritis	I	P	Unknown	Double	L 200 vs Dic 150	97	91	7	6
Novartis 104	w94	Osteoarthritis	I	P	Unknown	Double	L 100 vs Dic 150	98	94	7	7
Novartis 105	w95	Rheumatoid arthritis	I	P	Unknown	Double	L 100 vs Dic 150	102	91	7	6
<i>Lumiracoxib vs ibuprofen</i>											
Novartis 110	w173	Rheumatoid arthritis	I	P	Unknown	Double	L 800 vs Ibu 2400	227	216	49	44
Novartis 110	w173	Rheumatoid arthritis	I	P	Unknown	Double	L 400 vs Ibu 2400	227	216	50	44
Novartis 126	w174	Osteoarthritis	I	P	Sealed envelopes	Double	L 400 vs Ibu 2400	260	260	60	56
Novartis 2332 (TARGET)	w186	Osteoarthritis	I	P	IVRS	Double	L 400 vs Ibu 2400	4376	4397	3678	3539
Novartis 126	w174	Osteoarthritis	I	P	Sealed envelopes	Double	L 200 vs Ibu 2400	264	260	60	56
Novartis 2428	w187	Osteoarthritis	I	P	Other	Double	L 100 vs Ibu 1800	394	393	29	29
Novartis A2475	-	Osteoarthritis	U	P	Unknown	Double	L 100 vs Ibu 1800	-	-	-	-
<i>Rofecoxib vs naproxen</i>											
MK 905	w19	Healthy volunteer	I	P	Unknown	Double	R 100 vs Nap 1000	17	17	2	2
MK 068	w107	Rheumatoid arthritis	I	E	Other	Double	R 50 vs Nap 1000	47	40	77	64
MK 068	w107	Rheumatoid arthritis	I	E	Other	Double	R 50 vs Nap 1000	41	46	61	70
MK 088/089 (VIGOR)	w188	Rheumatoid arthritis	I	P	Other	Double	R 50 vs Nap 1000	4047	4029	3282	3238
MK 096	w121	Rheumatoid arthritis	I	E	Unknown	Double	R 50 vs Nap 1000	110	117	135	146
MK 097	w108	Rheumatoid arthritis	I	B	Other	Double	R 50 vs Nap 1000	297	147	63	30
MK 097	w108	Rheumatoid arthritis	I	E	Other	Double	R 50 vs Nap 1000	379	121	494	164
MK 098	w109	Rheumatoid arthritis	I	P	Other	Double	R 50 vs Nap 1000	45	48	11	11
MK 103	w109	Rheumatoid arthritis	I	P	Unknown	Double	R 50 vs Nap 1000	174	172	43	40
MK 068	w107	Rheumatoid arthritis	I	E	Other	Double	R 25 vs Nap 1000	44	40	90	64
MK 068	w107	Rheumatoid arthritis	I	E	Other	Double	R 25 vs Nap 1000	47	46	75	70
MK 096	w121	Rheumatoid arthritis	I	B	Unknown	Double	R 25 vs Nap 1000	311	149	64	32
MK 096	w121	Rheumatoid arthritis	I	E	Unknown	Double	R 25 vs Nap 1000	92	101	99	125
MK 096	w121	Rheumatoid arthritis	I	E	Unknown	Double	R 25 vs Nap 1000	232	117	264	146
MK 097	w108	Rheumatoid arthritis	I	B	Other	Double	R 25 vs Nap 1000	315	147	68	30
MK 097	w108	Rheumatoid arthritis	I	E	Other	Double	R 25 vs Nap 1000	110	118	150	150
MK 097	w108	Rheumatoid arthritis	I	E	Other	Double	R 25 vs Nap 1000	134	121	179	164
MK 102/903 (ADVANTAGE)	w189	Osteoarthritis	I	P	Other	Double	R 25 vs Nap 1000	2785	2772	561	554
Pfizer 635-IFL-0508-002	w161	Osteoarthritis	I	P	Onsite computer	Double	R 25 vs Nap 1000	138	130	27	26
MK 231-0	w190	Rheumatoid arthritis	T	P	Unknown	Double	R 25 vs Nap 1000	77	75	12	11
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	R 25 vs Nap 1000	104	121	12	14
van Kooij 2005	w191	Macular oedema	U	P	Unknown	Open	R 25 vs Nap 500	38	28	12	9
Aisen 2003	w114	Alzheimer's disease	I	P	Other	Double	R 25 vs Nap 440	122	118	129	125
MK 096	w121	Rheumatoid arthritis	I	B	Unknown	Double	R 12.5 vs Nap 1000	148	149	29	32
MK 901	w192	Osteoarthritis	I	P	Onsite computer	Double	R 12.5 vs Nap 1000	470	473	69	70
<i>Rofecoxib vs diclofenac</i>											
MK 029 Rof	w193	Osteoarthritis	I	E	Unknown	Double	R 25 vs Dic 150	20	48	24	72
MK 029 Rof	w193	Osteoarthritis	I	E	Unknown	Double	R 25 vs Dic 150	27	44	35	64
MK 034	w115	Osteoarthritis	I	P	Other	Double	R 25 vs Dic 150	232	230	325	309
MK 035	w194	Osteoarthritis	I	P	Onsite computer	Double	R 25 vs Dic 150	257	268	305	314
MK 029 Rof	w193	Osteoarthritis	I	E	Unknown	Double	R 12.5 vs Dic 150	23	48	30	72
MK 029 Rof	w193	Osteoarthritis	I	E	Unknown	Double	R 12.5 vs Dic 150	31	44	42	64
MK 034	w115	Osteoarthritis	I	P	Other	Double	R 12.5 vs Dic 150	231	230	311	309
MK 035	w194	Osteoarthritis	I	P	Onsite computer	Double	R 12.5 vs Dic 150	259	268	339	314
<i>Rofecoxib vs ibuprofen</i>											
MK 017	-	Rheumatoid arthritis	I	E	Unknown	Unknown	R 125 vs Ibu 2400	35	2	9	1
MK 017	-	Rheumatoid arthritis	I	E	Unknown	Unknown	R 125 vs Ibu 2400	18	6	8	2
MK 017	-	Rheumatoid arthritis	I	E	Unknown	Unknown	R 125 vs Ibu 2400	7	5	2	1
MK 044	w104	Osteoarthritis	I	P	Sealed envelopes	Double	R 50 vs Ibu 2400	186	184	74	59
MK 045	w105	Osteoarthritis	I	P	Unknown	Double	R 50 vs Ibu 2400	193	193	76	63
MK 050	w106	Healthy volunteer	I	P	Other	Double	R 50 vs Ibu 2400	19	13	2	1
MK 033	w115	Osteoarthritis	I	P	Other	Double	R 25 vs Ibu 2400	227	221	33	32
MK 040	w116	Osteoarthritis	I	P	Other	Double	R 25 vs Ibu 2400	242	249	35	36
MK 044	w104	Osteoarthritis	I	P	Sealed envelopes	Double	R 25 vs Ibu 2400	195	184	79	59
MK 045	w105	Osteoarthritis	I	P	Unknown	Double	R 25 vs Ibu 2400	195	193	80	63
MK 050	w106	Healthy volunteer	I	P	Other	Double	R 25 vs Ibu 2400	18	13	2	1
MK 083	w119	Osteoarthritis	I	B	Unknown	Double	R 25 vs Ibu 2400	98	107	21	23

Webtable 2 - Details of trials involving a randomised comparison of a coxib (X) versus a tNSAID (Y)

Trial name	Ref.	Indication for treatment	Data type		Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
			Design					X	Y	X	Y
MK 083	w119	Osteoarthritis	I	E	Unknown	Double	R 25 vs Ibu 2400	38	41	30	33
MK 083	w119	Osteoarthritis	I	E	Unknown	Double	R 25 vs Ibu 2400	82	85	70	70
MK 033	w115	Osteoarthritis	I	P	Other	Double	R 12.5 vs Ibu 2400	219	221	32	32
MK 040	w116	Osteoarthritis	I	P	Other	Double	R 12.5 vs Ibu 2400	244	249	36	36
<i>Rofecoxib vs other tNSAID</i>											
MK 054	-	Hypertension	T	P	Unknown	Unknown	R 25 vs Indomethacin 75	38	39	3	3
MK 058	w117	Osteoarthritis	I	B	Other	Double	R 25 vs Nabumetone 1500	56	115	7	14
MK 058	w117	Osteoarthritis	I	E	Other	Double	R 25 vs Nabumetone 1500	12	13	8	10
MK 058	w117	Osteoarthritis	I	E	Other	Double	R 25 vs Nabumetone 1500	37	79	29	54
Karlsson 2009	w133	OA/RA	T	P	Other	Double	R 25 vs Naproxinod/AZD3582 2250	115	124	13	14
Karlsson 2009	w133	OA/RA	T	P	Other	Double	R 25 vs Naproxinod/AZD3582 1500	115	116	13	13
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	R 25 vs Naproxinod/AZD3582 1500	104	118	12	14
Karlsson 2009	w133	OA/RA	T	P	Other	Double	R 25 vs Naproxinod/AZD3582 750	115	108	13	12
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	R 25 vs Naproxinod/AZD3582 750	104	111	12	13
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	R 25 vs Naproxinod/AZD3582 250	104	111	12	13
MK 058	w117	Osteoarthritis	I	B	Other	Double	R 12.5 vs Nabumetone 1500	118	115	14	14
MK 058	w117	Osteoarthritis	I	E	Other	Double	R 12.5 vs Nabumetone 1500	13	13	8	10
MK 058	w117	Osteoarthritis	I	E	Other	Double	R 12.5 vs Nabumetone 1500	82	79	64	54
MK 085	w141	Osteoarthritis	I	P	Other	Double	R 12.5 vs Nabumetone 1000	424	410	60	57
MK 090	w142	Osteoarthritis	I	P	Other	Double	R 12.5 vs Nabumetone 1000	390	392	55	56
<i>Valdecoxib vs naproxen</i>											
Pfizer N91-99-02-047	w195	OA/RA	T	P	Unknown	Double	V 40 vs Nap 1000	404	415	201	207
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	V 40 vs Nap 1000	221	226	51	52
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	V 40 vs Nap 1000	209	219	48	50
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 20 vs Nap 1000	82	87	9	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 20 vs Nap 1000	79	75	9	9
Pfizer N91-99-02-047	w195	OA/RA	T	P	Unknown	Double	V 20 vs Nap 1000	399	415	199	207
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 20 vs Nap 1000	202	205	46	47
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	V 20 vs Nap 1000	212	226	49	52
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	V 20 vs Nap 1000	219	219	50	50
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 10 vs Nap 1000	166	87	19	10
Pfizer A3471018	w157	Rheumatoid arthritis	T	P	Unknown	Double	V 10 vs Nap 1000	170	167	39	38
Pfizer A3471045	w196	Osteoarthritis	T	P	Unknown	Double	V 10 vs Nap 1000	132	133	15	15
Pfizer A3471101	w197	Osteoarthritis	T	P	Unknown	Double	V 10 vs Nap 1000	70	74	8	9
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 10 vs Nap 1000	165	75	19	9
Pfizer N91-99-02-049	w158	Osteoarthritis	T	P	Unknown	Double	V 10 vs Nap 1000	111	118	26	27
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 10 vs Nap 1000	206	205	47	47
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	V 10 vs Nap 1000	209	226	48	52
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	V 10 vs Nap 1000	226	219	52	50
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 5 vs Nap 1000	83	87	10	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 5 vs Nap 1000	83	75	10	9
Pfizer N91-99-02-049	w158	Osteoarthritis	T	P	Unknown	Double	V 5 vs Nap 1000	120	118	28	27
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 5 vs Nap 1000	201	205	46	47
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 2.5 vs Nap 1000	84	87	10	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 2.5 vs Nap 1000	81	75	9	9
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 1 vs Nap 1000	89	87	10	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 1 vs Nap 1000	77	75	9	9
<i>Valdecoxib vs diclofenac</i>											
Pfizer N91-00-02-079	w145	Cancer pain	T	P	Unknown	Double	V 40 vs Dic 150	60	62	7	7
Pfizer N91-99-02-062	w198	Rheumatoid arthritis	T	P	Other	Double	V 40 vs Dic 150	237	239	118	119
Pfizer I91-99-02-063	w199	Osteoarthritis	T	P	Unknown	Double	V 20 vs Dic 150	261	264	260	263
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	V 20 vs Dic 150	219	212	50	49
Pfizer N91-99-02-062	w198	Rheumatoid arthritis	T	P	Other	Double	V 20 vs Dic 150	246	239	123	119
Pfizer I91-99-02-063	w199	Osteoarthritis	T	P	Unknown	Double	V 10 vs Dic 150	259	264	258	263
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	V 10 vs Dic 150	204	212	47	49
<i>Valdecoxib vs ibuprofen</i>											
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	V 20 vs Ibu 2400	219	207	50	48
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	V 10 vs Ibu 2400	204	207	47	48

OA/RA=Osteoarthritis or rheumatoid arthritis.

Data type (I=Individual patient data; T=Tabular data; U=Unavailable in either tabular or IPD form).

Design (B='Base' phase of a trial with more than one randomisation; C=Cross-over trial (first treatment period only); E='Extension' phase of a trial with a second randomisation (note: a single trial can have several extension phases, each contributing to a different randomised comparison); F=Factorial design; P=Parallel trial with a single randomisation).

Allocation concealment (IVRS = Interactive Voice Response System; Telephone = Telephone central office; Pharmacy = Pharmacy coded containers administered sequentially; Onsite computer = Onsite computer accessible only after entering patients details; Sealed envelopes = Sealed envelopes, sequentially numbered and opaque; Closed list = Closed list of random numbers; Other = Other acceptable method).

Webtable 3 - Details of trials involving a randomised comparison of a tNSAID (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years	
								X	Y	X	Y
<i>Naproxen versus placebo</i>											
Cohick 1994	w200	Rheumatoid arthritis	U	P	Unknown	Double	Nap 1500	93	86	29	26
BRL-14777/267	w201	Healthy volunteer	T	P	Unknown	Double	Nap 1100	72	75	6	6
Bellavance 1990	w202	Migraine	T	P	Other	Double	Nap 1100	60	57	15	14
Fleischmann 1997	w203	Osteoarthritis	T	P	Pharmacy	Double	Nap 1000	92	94	7	7
MK 018	w89	Osteoarthritis	I	B	Other	Double	Nap 1000	218	56	48	11
MK 019	w90	Osteoarthritis	I	B	Other	Double	Nap 1000	221	56	48	12
MK 024	w83	Rheumatoid arthritis	I	B	Unknown	Double	Nap 1000	170	323	30	45
MK 025	w84	Rheumatoid arthritis	I	B	Other	Double	Nap 1000	181	357	39	66
MK 026	w79	OA/RA	I	P	Pharmacy	Double	Nap 1000	244	247	55	60
MK 032	w81	Ankylosing spondylitis	I	B	Onsite computer	Double	Nap 1000	99	93	10	8
MK 096	w121	Rheumatoid arthritis	I	B	Unknown	Double	Nap 1000	149	301	32	56
MK 097	w108	Rheumatoid arthritis	I	B	Other	Double	Nap 1000	147	299	30	59
MK 098	w109	Rheumatoid arthritis	I	P	Other	Double	Nap 1000	48	48	11	12
MK 103	w109	Rheumatoid arthritis	I	P	Unknown	Double	Nap 1000	172	173	40	44
MK 905	w19	Healthy volunteer	I	P	Unknown	Double	Nap 1000	17	16	2	2
Novartis 111	w96	Rheumatoid arthritis	I	P	Unknown	Double	Nap 1000	279	284	112	96
Novartis 335E	w99	Rheumatoid arthritis	I	B	Unknown	Double	Nap 1000	228	465	52	80
Pfizer A3191051	w55	Osteoarthritis	I	P	Unknown	Double	Nap 1000	126	67	13	6
Pfizer A3191052	-	Osteoarthritis	I	P	Unknown	Double	Nap 1000	144	76	13	8
Pfizer A3191053	w56	Osteoarthritis	I	P	Unknown	Double	Nap 1000	129	62	12	6
Pfizer N49-01-02-193	w22	Ankylosing spondylitis	I	P	Unknown	Double	Nap 1000	157	156	30	21
Pfizer N49-96-02-020	w24	Osteoarthritis	I	P	Other	Double	Nap 1000	216	220	37	30
Pfizer N49-96-02-021	w25	Osteoarthritis	I	P	Unknown	Double	Nap 1000	233	247	42	36
Pfizer N49-96-02-022	w8	Rheumatoid arthritis	I	P	Other	Double	Nap 1000	225	231	38	31
Pfizer N49-96-02-023	-	Rheumatoid arthritis	I	P	Unknown	Double	Nap 1000	218	221	37	25
Pfizer N49-96-02-054	w26	Osteoarthritis	I	P	Other	Double	Nap 1000	207	218	33	26
Lohmander 2005	w204	Osteoarthritis	T	P	Unknown	Double	Nap 1000	417	116	48	13
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	Nap 1000	87	87	10	10
Adegbefunbe 2008	w33	Osteoarthritis	T	P	Onsite computer	Double	Nap 1000	21	21	2	2
Bias 2004	w205	Healthy volunteer	T	P	Other	Double	Nap 1000	30	31	2	2
Dore 1995	w206	Osteoarthritis	T	P	Unknown	Double	Nap 1000	82	86	6	7
Jeffcoat 1991	w207	Peritonitis	T	P	Unknown	Double	Nap 1000	7	8	2	2
Johnson 1990	w208	Gingivitis	T	P	Other	Double	Nap 1000	54	57	4	4
Laine 1995	w209	Healthy volunteer	T	P	Pharmacy	Double	Nap 1000	18	17	1	1
Nicox 301	w210	Osteoarthritis	T	P	IVRS	Double	Nap 1000	227	221	57	55
Petri 1987	w211	Shoulder pain	T	F	Closed list	Double	Nap 1000	50	50	4	4
Pfizer A3471018	w157	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000	167	171	38	39
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	Nap 1000	75	82	9	9
Pfizer N91-99-02-049	w158	Osteoarthritis	T	P	Unknown	Double	Nap 1000	118	118	27	27
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	Nap 1000	205	205	47	47
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000	226	222	52	51
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	Nap 1000	219	220	50	51
Schmitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	Nap 1000	121	107	14	12
Ta 2004	w74	Temporomandibular joint pain	T	P	Pharmacy	Double	Nap 1000	22	22	3	3
Averbuch 2004	w212	Osteoarthritis	U	P	Unknown	Double	Nap 1000	98	108	23	25
Goldenberg 1986	w213	Fibromyalgia	U	F	Unknown	Double	Nap 1000	31	31	4	4
Nicox 302	-	Osteoarthritis	U	C	Unknown	Double	Nap 1000	-	-	-	-
Nicox 303	-	Osteoarthritis	U	P	Unknown	Double	Nap 1000	-	-	-	-
Blechman 1978	w214	Osteoarthritis	T	C	Unknown	Double	Nap 750	45	44	3	3
Gebuhr 1991	w215	Hip arthroplasty	T	P	Unknown	Double	Nap 750	35	35	3	3
Mehta 1992	w216	Rheumatoid arthritis	T	P	Sealed envelopes	Double	Nap 750	30	30	5	5
Vielpeau 1999	w217	Osteoarthritis	T	P	Unknown	Double	Nap 750	28	28	3	3
Caruso 1987	w218	Osteoarthritis	U	P	Other	Double	Nap 750	245	241	19	18
Klassen 1995	w219	Hypertension	U	P	Unknown	Double	Nap 750	50	50	4	4
Soffer 1994	w220	Lung cancer	U	P	Unknown	Double	Nap 750	5	5	0.5	0.5
Blom 1995	w221	Incontinence	T	C	Unknown	Single	Nap 500	8	8	1	1
Lopez Sanchez 1983	w222	Degenerative joint disease	T	P	Unknown	Double	Nap 500	10	10	1	1
Lindgaard 1980	w223	Migraine	U	C	Unknown	Double	Nap 500	15	13	2	1
ADAPT	w14	Alzheimer's disease	I	P	Onsite computer	Double	Nap 440	719	1083	2074	3099
Aisen 2003	w114	Alzheimer's disease	I	P	Other	Double	Nap 440	118	111	125	118
<i>Diclofenac versus placebo</i>											
Novartis 104	w94	Osteoarthritis	I	P	Unknown	Double	Dic 150	94	97	7	7
Novartis 105	w95	Rheumatoid arthritis	I	P	Unknown	Double	Dic 150	91	99	6	7
Pfizer N49-98-02-118	w64	Osteoarthritis	I	P	Unknown	Double	Dic 150	199	200	20	17
Wahlstrom 1991	w224	Hip arthroplasty	T	P	Pharmacy	Double	Dic 150	46	47	5	5
Bakshi 1991	w225	Osteoarthritis	T	P	Unknown	Double	Dic 150	208	106	16	8
Bocanegra 1998	w226	Osteoarthritis	T	C	Unknown	Double	Dic 150	154	91	18	10
Furst 2002	w227	Rheumatoid arthritis	T	P	Other	Double	Dic 150	181	177	42	41
Germain 1985	w228	Osteoarthritis	T	P	Unknown	Double	Dic 150	97	94	11	11
Labelle 1997	w229	Frozen shoulder or tennis elbow	T	P	Pharmacy	Double	Dic 150	64	64	5	5
Pfizer N91-00-02-079	w145	Cancer pain	T	P	Unknown	Double	Dic 150	62	61	7	7
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	Dic 150	212	210	49	48
Reis 1992	w230	Osteoarthritis	T	P	Unknown	Double	Dic 150	89	69	10	8
Schmitt 1999	w231	Osteoarthritis	T	P	Unknown	Double	Dic 150	223	56	51	13
Weisman 1986	w232	Rheumatoid arthritis	T	P	Unknown	Double	Dic 150	89	93	10	11
Case 2003	w233	Osteoarthritis	U	P	Unknown	Double	Dic 150	25	28	6	6
Bierger 2004	w234	Osteoarthritis	T	P	Other	Double	Dic 100	43	41	5	5
Buckland-Wright 1995	w235	Osteoarthritis	T	P	Unknown	Double	Dic 100	22	23	33	34
Esselincx 1990	w236	Osteoarthritis	T	P	Pharmacy	Double	Dic 100	87	89	7	7
Laurent 1987	w237	Glomerulonephritis	T	P	Unknown	Double	Dic 100	15	14	2	2
Sandelin 1997	w238	Osteoarthritis	T	P	Other	Double	Dic 100	82	82	6	6
Yocum 2000	w239	Osteoarthritis	T	P	Unknown	Double	Dic 100	153	157	35	36
Dieppe 1993	w240	Osteoarthritis	U	P	Unknown	Double	Dic 100	45	44	90	88
Kirchheiner 1976	w241	Rheumatoid arthritis	T	P	Sealed envelopes	Double	Dic 75	62	57	5	4
Ghosh 2007	w88	Osteoarthritis	T	P	Unknown	Double	Dic 75	195	195	15	15
Schmitt 1999	w231	Osteoarthritis	T	P	Unknown	Double	Dic 75	114	56	26	13
Sangdee 2002	w242	Osteoarthritis	U	F	Unknown	Single	Dic 75	98	95	8	7
<i>Ibuprofen versus placebo</i>											
MK 027	w79	Healthy volunteer	I	P	Pharmacy	Double	Ib 2400	18	21	2	2
MK 029 Etor	w80	Osteoarthritis	I	P	Unknown	Double	Ib 2400	226	233	53	58
MK 033	w115	Osteoarthritis	I	P	Other	Double	Ib 2400	221	69	32	9
MK 040	w116	Osteoarthritis	I	P	Other	Double	Ib 2400	249	74	36	10
MK 044	w104	Osteoarthritis	I	P	Sealed envelopes	Double	Ib 2400	184	177	59	52
MK 045	w105	Osteoarthritis	I	P	Unknown	Double	Ib 2400	193	194	63	61
MK 050	w106	Healthy volunteer	I	P	Other	Double	Ib 2400	13	17	1	2
MK 065	w18	Osteoarthritis	I	P	Other	Double	Ib 2400	107	111	25	25
MK 071	w92	Osteoarthritis	I	P	Pharmacy	Double	Ib 2400	210	104	50	21

Webtable 3 - Details of trials involving a randomised comparison of a tNSAID (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years	
								X	Y	X	Y
MK 073	w93	Osteoarthritis	I	P	Other	Double	Ib 2400	213	111	51	25
MK 083	w119	Osteoarthritis	I	B	Unknown	Double	Ib 2400	107	100	23	21
MK 136 (no ASA)	w125	Osteoarthritis	I	P	Other	Double	Ib 2400	400	410	93	99
Pfizer A3191062	w57	Osteoarthritis	I	P	Unknown	Double	Ib 2400	156	79	15	7
Pfizer A3191063	-	Osteoarthritis	I	P	Unknown	Double	Ib 2400	154	73	16	7
Palmer 2003	w32	Hypertension	T	P	Unknown	Double	Ib 2400	100	96	8	7
Kravitz 1994	w243	Fibromyalgia	T	F	Unknown	Double	Ib 2400	32	29	3	3
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	Ib 2400	207	210	48	48
Wong 1984	w244	Acne	T	F	Closed list	Double	Ib 2400	32	33	5	5
Davies 1999	w245	Osteoarthritis	U	P	Unknown	Double	Ib 2400	54	50	4	4
Singer 1997	w246	Orofacial pain	U	F	Unknown	Double	Ib 2400	-	-	-	-
Giانسracusa 1977	w247	Osteoarthritis	T	C	Unknown	Double	Ib 1800	106	221	8	17
Gurwitz 1996	w248	Hypertension	U	C	Other	Double	Ib 1800	11	11	1	1
Novartis A2475	-	Osteoarthritis	U	P	Unknown	Double	Ib 1800	-	-	-	-
Marks 1996	w249	Obesity	U	P	Other	Double	Ib 1600	15	16	3	4
Haghighi 2005	w250	Osteoarthritis	T	P	Pharmacy	Open	Ib 1200	40	40	3	3
McMillan 1999	w251	Metastatic cancer	T	P	Unknown	Double	Ib 1200	35	38	8	9
Chow 2000	w252	Colorectal polyps	T	P	Unknown	Double	Ib 600	9	9	1	1
Chow 2000	w252	Colorectal polyps	T	P	Unknown	Double	Ib 300	9	9	1	1
<i>Other tNSAID versus placebo</i>											
Hunter 1996	w253	Rheumatoid arthritis	T	P	Other	Double	Aceclofenac 200	38	35	3	3
Haslock 1975	w254	Rheumatoid arthritis	T	P	Unknown	Double	Alclofenac 3000	5	6	1	1
Kraghale 1983	w255	Psoriatic arthritis	T	P	Unknown	Double	Benoxaprofen 600	20	20	3	3
Williams 1983	w256	Osteoarthritis	T	C	Unknown	Double	Benoxaprofen 600	7	8	1	1
Ridolfo 1982	w257	Rheumatoid arthritis	U	C	Unknown	Double	Benoxaprofen 600	-	-	-	-
Lee 1985	w258	Osteoarthritis	U	P	Unknown	Double	Diflunisal 1000	140	143	16	16
Lee 1985	w258	Osteoarthritis	U	P	Unknown	Double	Diflunisal 750	139	143	16	16
Dore 1995	w206	Osteoarthritis	T	P	Unknown	Double	Etodolac 800	86	86	7	7
Laine 1995	w209	Healthy volunteer	T	P	Pharmacy	Double	Etodolac 800	17	17	1	1
Schnitzer 1995	w259	OA/RA	T	P	Unknown	Double	Etodolac 800	91	90	7	7
Vetter 1982	w260	Rheumatoid arthritis	T	P	Unknown	Double	Etodolac 600	8	8	1	1
Williams 1989	w261	Osteoarthritis	T	P	Unknown	Double	Etodolac 600	104	106	8	8
Andelman 1983	w262	Osteoarthritis	T	P	Unknown	Double	Etodolac 400	10	10	2	2
Edwards 1983	w263	Rheumatoid arthritis	T	P	Unknown	Double	Etodolac 400	6	6	1	1
Vetter 1982	w260	Rheumatoid arthritis	T	P	Unknown	Double	Etodolac 200	8	8	1	1
Jacob 1986	w264	Rheumatoid arthritis	U	P	Pharmacy	Double	Etodolac 200	50	51	6	6
Del Toro 1983	w265	Rheumatoid arthritis	T	P	Unknown	Double	Etodolac 100	7	7	2	2
Jacob 1986	w264	Rheumatoid arthritis	U	P	Pharmacy	Double	Etodolac 100	55	51	6	6
Jacob 1986	w264	Rheumatoid arthritis	U	P	Pharmacy	Double	Etodolac 50	56	51	6	6
Diamond 1987	w266	Migraine	T	P	Unknown	Double	Fenoprofen 1800	39	36	9	8
Duff 1976	w267	Rheumatoid arthritis	T	C	Unknown	Double	Fenoprofen 1800	15	15	2	2
Diamond 1987	w266	Migraine	T	P	Unknown	Double	Fenoprofen 600	35	36	8	8
Blechman 1976	w268	Rheumatoid arthritis	U	C	Unknown	Double	Fenoprofen 200	14	13	2	2
Mainland 1967	w269	Rheumatoid arthritis	T	P	Pharmacy	Double	Indomethacin 200	71	65	16	15
Allan 1977	w270	Osteoarthritis	U	P	Unknown	Double	Indomethacin 150	75	70	6	5
Jajic 1982	w271	Ankylosing spondylitis	T	P	Other	Double	Indomethacin 125	34	35	4	4
Rogers 1993	w272	Alzheimer's disease	T	P	Unknown	Double	Indomethacin 100	14	14	7	7
Secchi 1990	w273	Type 1 diabetes	T	P	Unknown	Single	Indomethacin 100	5	10	3	7
Warrington 1990	w274	Healthy volunteer	T	P	Unknown	Double	Indomethacin 100	15	15	1	1
de Jong 2008	w275	Alzheimer's disease	T	P	Unknown	Double	Indomethacin 100	26	25	26	25
Lundholm 1994	w276	Metastatic cancer	U	P	Other	Single	Indomethacin 100	45	45	47	47
Kirchheiner 1976	w241	Rheumatoid arthritis	T	P	Sealed envelopes	Double	Indomethacin 75	63	57	5	4
MK 054	-	Hypertension	U	P	Unknown	Unknown	Indomethacin 75	39	38	3	3
Bahrami 2005	w277	Hepatitis B	T	P	Closed list	Double	Indomethacin 75	56	56	28	28
Buchmann 1966	w278	Osteoarthritis	T	P	Pharmacy	Double	Indomethacin 75	18	16	1	1
Karunakar 2006	w279	Acetabular fracture	T	P	Other	Double	Indomethacin 75	64	63	7	7
Miller 1989	w280	Melanoma	U	P	Sealed envelopes	Open	Indomethacin 75	27	26	4	4
Puddey 1985	w281	Hypertension	T	P	Unknown	Double	Indomethacin 75	9	8	1	1
Scott 2000	w282	Osteoarthritis	T	P	Unknown	Single	Indomethacin 75	202	303	1007	1510
Vielpeau 1999	w217	Osteoarthritis	T	P	Unknown	Double	Indomethacin 75	28	28	3	3
Williams 1983	w256	Osteoarthritis	T	C	Unknown	Double	Indomethacin 70	15	8	1	1
Wright 1969 X1	w283	Rheumatoid arthritis	T	B	Pharmacy	Double	Indomethacin 50	8	8	1	1
Reese 1985 Study 1	w284	Rheumatoid arthritis	U	P	Unknown	Unknown	Isoxicam 300	239	116	27	13
Posner 1985	w285	Osteoarthritis	U	P	Unknown	Double	Isoxicam 200	88	88	10	10
Reese 1985 Study 3	w284	Rheumatoid arthritis	U	P	Unknown	Double	Isoxicam 200	95	96	11	11
Pfizer F49-98-02-137	w61	Ankylosing spondylitis	I	P	Unknown	Double	Ketoprofen 200	90	76	9	6
Hoe-Hansen 1999	w286	Subacromial decompression	U	C	Unknown	Double	Ketoprofen 200	21	20	2	2
Stensrud 1974	w287	Migraine	T	C	Unknown	Double	Ketoprofen 150	14	13	2	1
Bias 2004	w205	Healthy volunteer	T	P	Other	Double	Licofelone 800	30	31	2	2
Bias 2004	w205	Healthy volunteer	T	P	Other	Double	Licofelone 400	30	31	2	2
Berry 1992	w288	Osteoarthritis	T	P	Unknown	Double	Lornoxicam 12	44	42	3	3
Berry 1992	w288	Osteoarthritis	T	P	Unknown	Double	Lornoxicam 8	42	42	3	3
Warrington 1990	w274	Healthy volunteer	T	P	Unknown	Double	Lornoxicam 8	15	15	1	1
Berry 1992	w288	Osteoarthritis	T	P	Unknown	Double	Lornoxicam 6	42	42	3	3
Pfizer A3191174	w20	Back pain	I	P	Unknown	Double	Loxoprofen 180	411	412	54	54
Pfizer J49-01-02-216	-	Osteoarthritis	I	P	Unknown	Double	Loxoprofen 180	385	192	27	14
Lopez Sanchez 1983	w222	Degenerative joint disease	T	P	Unknown	Double	Meclofenamate 300	10	10	1	1
Mahafzah 1989	w289	Neoplastic disease/ Radiotherapy	T	C	Unknown	Double	Meclofenamate 300	17	8	4	2
Petrick 1983 OA (hip)	w290	Osteoarthritis	T	P	Unknown	Double	Meclofenamate 300	91	89	7	7
Petrick 1983 OA (knee)	w290	Osteoarthritis	T	P	Unknown	Double	Meclofenamate 300	122	115	9	9
Petrick 1983 RA (6w)	w291	Rheumatoid arthritis	T	P	Unknown	Double	Meclofenamate 300	81	84	9	10
Petrick 1983 RA (8w)	w291	Rheumatoid arthritis	T	P	Unknown	Double	Meclofenamate 300	105	107	16	16
Willkens 1981	w292	Rheumatoid arthritis	T	P	Unknown	Double	Meclofenamate 300	105	107	16	16
Ellis 1986	w293	Psoriatic arthritis	U	P	Unknown	Double	Meclofenamate 300	47	56	4	4
Petrick 1983 RA (6w)	w291	Rheumatoid arthritis	T	P	Unknown	Double	Meclofenamate 200	84	84	10	10
Buchmann 1966	w278	Osteoarthritis	T	P	Pharmacy	Double	Mefenamic acid 1500	21	16	2	1
Dougados 1999	w294	Ankylosing spondylitis	T	P	Unknown	Double	Meloxicam 22.5	124	121	124	121
Furst 2002	w227	Rheumatoid arthritis	T	P	Other	Double	Meloxicam 22.5	177	177	41	41
Altman 2002	w295	Acute coronary syndrome	T	P	Sealed envelopes	Single	Meloxicam 15	60	60	6	6
Dougados 1999	w294	Ankylosing spondylitis	T	P	Unknown	Double	Meloxicam 15	120	121	120	121
Furst 2002	w227	Rheumatoid arthritis	T	P	Other	Double	Meloxicam 15	184	177	42	41
Lipscomb 1998	w296	Healthy volunteer	T	P	Unknown	Double	Meloxicam 15	15	15	1	1
Yocum 2000	w239	Osteoarthritis	T	P	Unknown	Double	Meloxicam 15	156	157	36	36
Santucci 1995	w297	Healthy volunteer	U	P	Unknown	Double	Meloxicam 15	13	13	1	1
Furst 2002	w227	Rheumatoid arthritis	T	P	Other	Double	Meloxicam 7.5	175	177	40	41
Yocum 2000	w239	Osteoarthritis	T	P	Unknown	Double	Meloxicam 7.5	154	157	35	36
Santucci 1995	w297	Healthy volunteer	U	P	Unknown	Double	Meloxicam 7.5	13	13	1	1
Yocum 2000	w239	Osteoarthritis	T	P	Unknown	Double	Meloxicam 3.75	154	157	35	36
Palmer 2003	w32	Hypertension	T	P	Unknown	Double	Nabumetone 2000	96	96	7	7

Webtable 3 - Details of trials involving a randomised comparison of a tNSAID (X) versus placebo (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day	No. of patients		Person years	
								X	Y	X	Y
BRL-14777/267	w201	Healthy volunteer	T	P	Unknown	Double	Nabumetone 2000	73	75	6	6
Schnitzer 1998	w298	Osteoarthritis	T	P	Pharmacy	Double	Nabumetone 2000	58	53	6	5
MK 058	w117	Osteoarthritis	I	B	Other	Double	Nabumetone 1500	115	52	14	6
Agrawal 1999	w299	Osteoarthritis	T	P	Unknown	Double	Nabumetone 1500	426	382	49	44
Fleischmann 1997	w203	Osteoarthritis	T	P	Pharmacy	Double	Nabumetone 1500	93	94	7	7
Makarowski 1996	w300	Osteoarthritis	T	P	Unknown	Double	Nabumetone 1500	115	116	13	13
Schnitzer 1995	w259	OA/RA	T	P	Unknown	Double	Nabumetone 1500	89	90	7	7
MK 085	w141	Osteoarthritis	I	P	Other	Double	Nabumetone 1000	410	208	57	27
MK 090	w142	Osteoarthritis	I	P	Other	Double	Nabumetone 1000	392	196	56	26
Pando 1999	w301	Osteoarthritis	T	P	Unknown	Double	Nabumetone 1000	27	29	2	2
Weaver 1995	w302	Osteoarthritis	T	P	Unknown	Double	Nabumetone 1000	110	109	13	13
Blechman 1987	w303	Osteoarthritis	U	P	Unknown	Double	Nabumetone 1000	53	53	6	6
Karlsson 2009	w133	OA/RA	T	P	Other	Double	Naproxcinod/AZD3582 2250	124	80	14	9
Lohmander 2005	w204	Osteoarthritis	T	P	Unknown	Double	Naproxcinod/AZD3582 1500	437	116	50	13
Karlsson 2009	w133	OA/RA	T	P	Other	Double	Naproxcinod/AZD3582 1500	116	80	13	9
Nicox 301	w210	Osteoarthritis	T	P	IVRS	Double	Naproxcinod/AZD3582 1500	230	221	57	55
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	Naproxcinod/AZD3582 1500	118	107	14	12
Nicox 302	-	Osteoarthritis	U	C	Unknown	Double	Naproxcinod/AZD3582 1500	-	-	-	-
Nicox 303	-	Osteoarthritis	U	P	Unknown	Double	Naproxcinod/AZD3582 1500	-	-	-	-
Karlsson 2009	w133	OA/RA	T	P	Other	Double	Naproxcinod/AZD3582 750	108	80	12	9
Nicox 301	w210	Osteoarthritis	T	P	IVRS	Double	Naproxcinod/AZD3582 750	240	221	60	55
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	Naproxcinod/AZD3582 750	111	107	13	12
Nicox 302	-	Osteoarthritis	U	C	Unknown	Double	Naproxcinod/AZD3582 750	-	-	-	-
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	Naproxcinod/AZD3582 250	111	107	13	12
Sarzi-Puttini 2001	w304	Psoriatic arthritis	U	P	Unknown	Double	Nimesulide 400	20	20	2	2
Aisen 2002	w305	Alzheimer's disease	T	P	Pharmacy	Double	Nimesulide 200	21	19	5	4
Sarzi-Puttini 2001	w304	Psoriatic arthritis	U	P	Unknown	Double	Nimesulide 200	20	20	2	2
Sarzi-Puttini 2001	w304	Psoriatic arthritis	U	P	Unknown	Double	Nimesulide 100	20	20	2	2
Makarowski 1996	w300	Osteoarthritis	T	P	Unknown	Double	Oxyprozin/oxaprozin 1200	116	116	13	13
Weaver 1995	w302	Osteoarthritis	T	P	Unknown	Double	Oxyprozin/oxaprozin 1200	109	109	13	13
Lopez Sanchez 1983	w222	Degenerative joint disease	T	P	Unknown	Double	Phenylbutazone 300	10	10	1	1
Wright 1969 X1	w283	Rheumatoid arthritis	T	B	Pharmacy	Double	Phenylbutazone 100	8	8	1	1
Astrom 1992	w306	Achilles tendinopathy	T	P	Unknown	Double	Piroxicam 20	35	35	3	3
Dougados 1999	w294	Ankylosing spondylitis	T	P	Unknown	Double	Piroxicam 20	108	121	108	121
Fox 1993	w307	Sjogrens syndrome	T	P	Pharmacy	Double	Piroxicam 20	6	8	3	4
Lipscomb 1998	w296	Healthy volunteer	T	P	Unknown	Double	Piroxicam 20	14	15	1	1
Manna 1998	w308	Migraine	T	C	Unknown	Double	Piroxicam 20	25	25	2	2
Van den Berghe 1986	w309	Temporomandibular joint pain	T	P	Unknown	Unknown	Piroxicam 20	14	12	2	2
Baez 1987	w310	Hypertension	U	P	Unknown	Double	Piroxicam 20	-	-	-	-
Santucci 1995	w297	Healthy volunteer	U	P	Unknown	Double	Piroxicam 20	12	13	1	1
Sigidin 1987	w311	Rheumatoid arthritis	U	P	Unknown	Double	Piroxicam 20	-	-	-	-
Calaluze 2000	w312	Familial adenomatous polyposis	T	P	Unknown	Unknown	Piroxicam 7.5	55	54	110	108
Jajic 1982	w271	Ankylosing spondylitis	T	P	Other	Double	Pirprofen 1000	35	35	4	4
Sigidin 1987	w311	Rheumatoid arthritis	U	P	Unknown	Double	Pirprofen 800	-	-	-	-
Allan 1977	w270	Osteoarthritis	U	P	Unknown	Double	Proquazone 900	71	70	5	5
Puddey 1985	w281	Hypertension	T	P	Unknown	Double	Sulindac 400	9	8	1	1
Baez 1987	w310	Hypertension	U	P	Unknown	Double	Sulindac 400	-	-	-	-
Giardiello 1993	w313	Familial adenomatous polyposis	T	P	Unknown	Double	Sulindac 300	11	11	8	8
Ladenheim 1995	w314	Colorectal polyps	T	P	Unknown	Double	Sulindac 300	22	22	7	7
Rijcken 2007	w315	Colorectal cancer	T	C	Unknown	Double	Sulindac 300	11	11	1	1
Keller 1999	w316	Familial adenomatous polyposis	U	P	Unknown	Double	Sulindac 300	10	11	2	3
Labayle 1991	w317	Familial adenomatous polyposis	U	C	Unknown	Double	Sulindac 300	5	5	2	2
Hattori 2007	w318	Diabetic kidney disease	T	P	Unknown	Single	Sulindac 200	16	24	48	72
Giardiello 2002	w319	Familial adenomatous polyposis	T	P	Unknown	Double	Sulindac 150	21	20	84	80
Esselinckx 1990	w236	Osteoarthritis	T	P	Pharmacy	Double	Tenoxicam 40	86	89	7	7
Bursens 1995	w320	Osteoarthritis	T	P	Unknown	Double	Tenoxicam 20	30	30	3	3
Esselinckx 1990	w236	Osteoarthritis	T	P	Pharmacy	Double	Tenoxicam 20	85	89	7	7
Quijada-Carrera 1996	w321	Fibromyalgia	T	F	Unknown	Double	Tenoxicam 20	82	82	13	13
Zarski 1998	w322	Hepatitis C	T	P	Unknown	Double	Tenoxicam 20	73	76	36	38
Bursens 1995	w320	Osteoarthritis	T	P	Unknown	Double	Tenoxicam 10	30	30	3	3
Scott 2000	w282	Osteoarthritis	T	P	Unknown	Single	Tiaprofenic acid 600	307	303	1530	1510
Smith 1985	w323	Osteoarthritis	U	C	Unknown	Double	Tiaprofenic acid 600	6	6	0.5	0.5
Mikkelsen 1982	w324	Migraine	T	C	Unknown	Double	Tolfenamic acid 300	19	19	4	4
Mikkelsen 1986	w325	Migraine	T	C	Unknown	Double	Tolfenamic acid 300	13	13	3	3

OA/RA=Osteoarthritis or rheumatoid arthritis.

Data type (I=Individual patient data; T=Tabular data; U=Unavailable in either tabular or IPD form).

Design (B='Base' phase of a trial with more than one randomisation; C=Cross-over trial (first treatment period only); E='Extension' phase of a trial with a second randomisation (note: a single trial can have several extension phases, each contributing to a different randomised comparison); F=Factorial design; P=Parallel trial with a single randomisation).

Allocation concealment (IVRS = Interactive Voice Response System; Telephone = Telephone central office; Pharmacy = Pharmacy coded containers administered sequentially; Onsite computer = Onsite computer accessible only after entering patients details; Sealed envelopes = Sealed envelopes, sequentially numbered and opaque; Closed list = Closed list of random numbers; Other = Other acceptable method).

Regimens: Nap=Naproxen; Dic=Diclofenac; Ibu=Ibuprofen.

Webtable 4 - Details of trials involving a randomised comparison of naproxen, ibuprofen or diclofenac (X) versus: a) each other; or b) another tNSAID regimen (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
								X	Y	X	Y
<i>Naproxen versus diclofenac</i>											
Kolodny 1988	w326	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Dic 150	112	111	26	26
Roth 1995	w327	OA/RA	U	P	Unknown	Double	Nap 1000 vs Dic 150	115	112	26	26
Vetter 1985	w328	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Dic 150	30	30	7	7
Scharf 1982	w329	Osteoarthritis	T	C	Unknown	Double	Nap 750 vs Dic 150	24	26	6	6
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Nap 500 vs Dic 100	279	296	64	68
Tannenbaum 1984	w331	Rheumatoid arthritis	T	P	Unknown	Double	Nap 500 vs Dic 100	28	28	6	6
Siegmeth 1978	w332	Osteoarthritis	T	P	Unknown	Open	Nap 500 vs Dic 75	20	20	10	10
Tsavaris 1990	w333	Metastatic cancer	T	C	Unknown	Unknown	Nap 500 vs Dic 75	16	16	2	2
<i>Naproxen versus ibuprofen</i>											
Frizziero 1986	w334	Rheumatoid arthritis	T	P	Unknown	Open	Nap 1000 vs Ib 1800	11	11	2	2
Leuschen Group 1	w335	Multiple sclerosis	T	P	Other	Open	Nap 800 vs Ib 1800	11	8	5	4
Leuschen Group 2	w335	Multiple sclerosis	T	P	Other	Open	Nap 800 vs Ib 1800	12	9	1	1
Klassen 1993	w336	Hypertension	U	P	Unknown	Double	Nap 750 vs Ib 2400	49	48	4	4
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Nap 500 vs Ib 1200	279	235	64	54
<i>Naproxen versus other tNSAID</i>											
Dungal 1991	w337	Osteoarthritis	T	P	Unknown	Double	Nap 1500 vs Tenoxicam 20	91	90	21	21
BRL-14777/267	w201	Healthy volunteer	T	P	Unknown	Double	Nap 1100 vs Nabumetone 2000	72	73	6	6
Kornasoff 1997	w338	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Aceclofenac 200	184	190	42	44
Pasero 1994	w339	Ankylosing spondylitis	T	P	Unknown	Double	Nap 1000 vs Aceclofenac 200	67	63	17	16
Ondal 1983	w340	Osteoarthritis	T	P	Closed list	Double	Nap 1000 vs Diflunisal 1000	40	41	18	19
Dore 1995	w206	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Etodolac 800	82	86	6	7
Jennings 1997	w341	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Etodolac 800	31	29	3	3
Laine 1995	w209	Healthy volunteer	T	P	Pharmacy	Double	Nap 1000 vs Etodolac 800	18	17	1	1
Palferman 1991	w342	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Etodolac 600	27	29	3	3
Pena 1991	w343	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Etodolac 600	31	31	5	5
Taha 1989	w344	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Etodolac 600	15	15	1	1
Platt 1989 Naproxen	w345	Osteoarthritis	U	P	Unknown	Double	Nap 1000 vs Etodolac 600	19	18	2	2
Bianchi Porro RA 1991	w346	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Etodolac 400	26	22	2	2
Viana de Queiros 1991	w347	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Etodolac 400	19	20	4	5
Walham-Weeks 1987	w348	Rheumatoid arthritis	T	C	Unknown	Double	Nap 1000 vs Etodolac 400	18	21	2	2
Briancon 1989 Study 3	w349	Rheumatoid arthritis	U	P	Unknown	Double	Nap 1000 vs Etodolac 400	17	20	3	4
Frankhof 1988	w350	Osteoarthritis	T	P	Other	Double	Nap 1000 vs Isoxicam 200	50	48	4	4
Cardoe OA 1986	w351	Osteoarthritis	U	P	Unknown	Double	Nap 1000 vs Isoxicam 200	117	113	9	9
Cardoe RA 1986	w351	Rheumatoid arthritis	U	P	Unknown	Double	Nap 1000 vs Isoxicam 200	125	124	10	10
Bias 2004	w205	Healthy volunteer	T	P	Other	Double	Nap 1000 vs Licofelone 800	30	30	2	2
Bias 2003 Study A	w352	OA/RA	U	P	Unknown	Double	Nap 1000 vs Licofelone 800	41	35	5	4
Bias 2003 Study B	w353	OA/RA	U	P	Unknown	Double	Nap 1000 vs Licofelone 800	106	95	53	47
Bias 2004	w205	Healthy volunteer	T	P	Other	Double	Nap 1000 vs Licofelone 400	30	30	2	2
Bias 2003 Abstract 68	w354	OA/RA	U	P	Unknown	Double	Nap 1000 vs Licofelone 400	72	68	17	16
Emery 1992	w355	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Nabumetone 2000	149	149	34	34
Hazleman 1987	w356	Rheumatoid arthritis	T	P	Unknown	Single	Nap 1000 vs Nabumetone 2000	24	23	12	11
Krug 2000	w357	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Nabumetone 2000	173	173	40	40
Fleischmann 1997	w203	Osteoarthritis	T	P	Pharmacy	Double	Nap 1000 vs Nabumetone 1500	92	93	7	7
Bianchi Porro 1995	w358	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Nabumetone 1000	30	30	2	2
Cha 2001	w359	Osteoarthritis	T	P	Unknown	Single	Nap 1000 vs Nabumetone 1000	80	79	6	6
Young 1995	w360	Osteoarthritis	U	P	Unknown	Double	Nap 1000 vs Nabumetone 1000	54	45	12	10
Lohmander 2005	w204	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Naproxinod/AZD3582 1500	417	437	48	50
Nicox 301	w210	Osteoarthritis	T	P	IVRS	Double	Nap 1000 vs Naproxinod/AZD3582 1500	227	230	57	57
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	Nap 1000 vs Naproxinod/AZD3582 1500	121	118	14	14
Nicox 302	-	Osteoarthritis	U	C	Unknown	Double	Nap 1000 vs Naproxinod/AZD3582 1500	-	-	-	-
Nicox 303	-	Osteoarthritis	U	P	Unknown	Double	Nap 1000 vs Naproxinod/AZD3582 1500	-	-	-	-
Nicox 301	w210	Osteoarthritis	T	P	IVRS	Double	Nap 1000 vs Naproxinod/AZD3582 750	227	240	57	60
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	Nap 1000 vs Naproxinod/AZD3582 750	121	111	14	13
Nicox 302	-	Osteoarthritis	U	C	Unknown	Double	Nap 1000 vs Naproxinod/AZD3582 750	-	-	-	-
Schnitzer Hee 2005	w138	Osteoarthritis	T	P	Other	Double	Nap 1000 vs Naproxinod/AZD3582 250	121	111	14	13
Quattrini 1995	w361	Osteoarthritis	T	P	Sealed envelopes	Double	Nap 1000 vs Nimesulide 200	60	60	5	5
Myklebust 1986	w362	RA/Ankylosing spondylitis	T	P	Unknown	Double	Nap 1000 vs Piroxicam 20	54	56	12	13
Consoli 1994	w363	Osteoarthritis	T	P	Unknown	Open	Nap 1000 vs Piroxicam 20	30	31	2	2
Huskisson 1983	w364	Rheumatoid arthritis	T	C	Unknown	Single	Nap 1000 vs Piroxicam 20	30	30	2	2
Jennings 1994	w365	Osteoarthritis	T	P	Unknown	Double	Nap 1000 vs Piroxicam 20	23	22	3	3
Fenton 1988	w366	Rheumatoid arthritis	U	C	Unknown	Double	Nap 1000 vs Piroxicam 20	14	28	1	2
Montrone 1994	w367	Rheumatoid arthritis	T	P	Unknown	Double	Nap 1000 vs Piroxicam 1200	20	20	2	2
Boussina 1987	w368	Osteoarthritis	T	P	Pharmacy	Double	Nap 1000 vs Piroxicam 800	30	30	2	2
McMahon 1989	w369	Hypertension	T	C	Other	Double	Nap 1000 vs Sulindac 400	12	12	1	1
Duke 1981	w370	Frozen shoulder	T	P	Unknown	Double	Nap 825 vs Indomethacin 100	30	29	2	2
Atkinson 1980	w371	Rheumatoid arthritis	U	C	Other	Double	Nap 750 vs Benoxaprofen 600	21	21	2	2
Baumgartner 1982	w372	Rheumatoid arthritis	T	P	Pharmacy	Double	Nap 750 vs Diflunisal 1000	15	15	2	2
Osborn 1989	w373	Rheumatoid arthritis	T	P	Unknown	Open	Nap 750 vs Diflunisal 1000	15	18	3	4
Khan 1983	w374	Rheumatoid arthritis	T	P	Other	Double	Nap 750 vs Fenbufen 900	15	15	7	7
Crone 1981	w375	OA/RA	T	P	Unknown	Double	Nap 750 vs Feprazone 600	15	15	1	1
Rhind 1982	w376	Osteoarthritis	T	P	Unknown	Double	Nap 750 vs Indomethacin 100	20	21	2	2
Martinez-Lavin 1980	w377	Osteoarthritis	U	C	Unknown	Double	Nap 750 vs Indomethacin 100	25	29	2	2
Vielpeau 1999	w217	Osteoarthritis	T	P	Unknown	Double	Nap 750 vs Indomethacin 75	28	28	3	3
Brighton 1985	w378	Rheumatoid arthritis	T	P	Unknown	Double	Nap 750 vs Isoxicam 200	20	20	2	2
Schom 1985	w379	Rheumatoid arthritis	T	P	Unknown	Double	Nap 750 vs Isoxicam 200	15	15	1	1
Wojtulewski 1996	w380	Rheumatoid arthritis	U	P	Unknown	Double	Nap 750 vs Meloxicam 7.5	180	199	90	99
Greb 1987	w381	Rheumatoid arthritis	T	P	Unknown	Open	Nap 750 vs Nabumetone 1000	24	24	6	6
Richards 1983	w382	Rheumatoid arthritis	U	C	Unknown	Double	Nap 750 vs Nabumetone 1000	12	12	1	1
Kreigel 2001	w383	Osteoarthritis	T	P	Unknown	Double	Nap 750 vs Nimesulide 200	187	183	186	182
Ginsberg 1984	w384	Osteoarthritis	T	P	Unknown	Double	Nap 750 vs Oxyprozin/oxaprozin 1200	12	12	2	2
Ansell 1978	w385	Ankylosing spondylitis	T	C	Unknown	Double	Nap 750 vs Phenylbutazone 300	12	13	1	1
Alho 1988	w386	Osteoarthritis	T	P	Other	Double	Nap 750 vs Piroxicam 20	126	126	39	39
Husby 1986	w387	Osteoarthritis	T	P	Unknown	Double	Nap 750 vs Piroxicam 20	1014	1021	233	235
Melo Gomes 1993	w388	Osteoarthritis	T	P	Unknown	Double	Nap 750 vs Piroxicam 20	210	217	16	17
Liyanae 1981	w389	Osteoarthritis	T	C	Unknown	Double	Nap 750 vs Sulindac 400	15	15	1	1
Ardia 1994	w390	Rheumatoid arthritis	T	P	Unknown	Double	Nap 750 vs Tolfenamic acid 300	90	90	7	7
Blechman 1980	w391	Osteoarthritis	T	C	Unknown	Double	Nap 500 vs Benoxaprofen 600	15	15	2	2

Webtable 4 - Details of trials involving a randomised comparison of naproxen, ibuprofen or diclofenac (X) versus: a) each other; or b) another tNSAID regimen (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
								X	Y	X	Y
Borjke 1982	w392	Rheumatoid arthritis	T	P	Closed list	Double	Nap 500 vs Diflunisal 500	36	35	6	5
Brooks 1982	w393	Osteoarthritis	T	C	Unknown	Double	Nap 500 vs Diflunisal 500	31	31	4	4
Grayson 1978	w394	Osteoarthritis	T	P	Unknown	Double	Nap 500 vs Diflunisal 500	10	10	2	2
Schorn 1981	w395	Rheumatoid arthritis	T	P	Unknown	Double	Nap 500 vs Diflunisal 500	10	10	2	2
Wojulewski 1978	w396	Osteoarthritis	U	P	Unknown	Double	Nap 500 vs Diflunisal 500	10	10	2	2
D'Omézon 1973	w397	Rheumatoid arthritis	U	C	Unknown	Double	Nap 500 vs Indomethacin 150	44	43	3	3
Kogstad 1973	w398	Rheumatoid arthritis	U	C	Unknown	Double	Nap 500 vs Indomethacin 150	15	15	1	1
Castles 1978	w399	Rheumatoid arthritis	T	C	Unknown	Double	Nap 500 vs Indomethacin 100	69	38	5	3
Cochrane 1973	w400	Osteoarthritis	T	C	Unknown	Double	Nap 500 vs Indomethacin 100	18	17	1	1
Davis 1987	w401	OA/RA/AS	T	P	Unknown	Double	Nap 500 vs Indomethacin 100	76	21	9	2
Tsavaris 1990	w333	Metastatic cancer	T	C	Unknown	Unknown	Nap 500 vs Indomethacin 75	16	16	2	2
Grace 1983	w402	Rheumatoid arthritis	T	P	Unknown	Single	Nap 500 vs Meclonamate 300	20	20	5	5
Lopez Sanchez 1983	w222	Degenerative joint disease	T	P	Unknown	Double	Nap 500 vs Meclonamate 300	10	10	1	1
Brobyn 1987	w403	Rheumatoid arthritis	T	P	Unknown	Double	Nap 500 vs Nabumetone 1000	50	50	25	25
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Nap 500 vs Nabumetone 1000	279	3315	64	762
Pisko 1987 A	w404	Osteoarthritis	T	P	Unknown	Double	Nap 500 vs Nabumetone 1000	244	245	122	122
Pisko 1987 B	w405	OA/RA	T	P	Unknown	Double	Nap 500 vs Nabumetone 1000	20	20	10	10
Pooley 1987	w406	Osteoarthritis	T	P	Unknown	Double	Nap 500 vs Nabumetone 1000	19	18	9	9
Roth 1987	w407	OA/RA	T	P	Unknown	Double	Nap 500 vs Nabumetone 1000	20	20	5	5
Vasey 1987	w408	Rheumatoid arthritis	T	P	Other	Double	Nap 500 vs Nabumetone 1000	181	186	35	36
Fossalluzza 1989	w409	Osteoarthritis	T	P	Unknown	Unknown	Nap 500 vs Nimesulide 200	20	20	2	2
Million 1977	w410	Rheumatoid arthritis	T	C	Unknown	Double	Nap 500 vs Phenylbutazone 400	24	24	2	2
Lopez Sanchez 1983	w222	Degenerative joint disease	T	P	Unknown	Double	Nap 500 vs Phenylbutazone 300	10	10	1	1
Van Gerwen 1978	w411	Ankylosing spondylitis	T	C	Pharmacy	Double	Nap 500 vs Phenylbutazone 200	10	10	1	1
Sekker 1985	w412	Osteoarthritis	T	P	Unknown	Double	Nap 500 vs Piroxicam 800	25	26	2	2
Hybbinette 1981	w413	Osteoarthritis	T	C	Unknown	Double	Nap 500 vs Piroxicam 20	30	30	3	3
Mbuyi-Muamba 1983	w414	Rheumatoid arthritis	T	P	Unknown	Double	Nap 500 vs Piroxicam 20	20	25	5	6
Fenton 1988	w366	Rheumatoid arthritis	U	C	Unknown	Double	Nap 500 vs Piroxicam 20	15	28	1	2
Kogstad 1981	w415	Osteoarthritis	U	C	Unknown	Double	Nap 500 vs Piroxicam 20	71	78	5	6
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Nap 500 vs Piroxicam 10	279	286	64	66
Bragstad 1978	w416	Rheumatoid arthritis	T	P	Unknown	Double	Nap 500 vs Proquazone 900	18	18	9	9
Vainio 1978	w417	Osteoarthritis	T	P	Unknown	Double	Nap 500 vs Proquazone 900	21	19	5	5
Janke 1984	w418	Osteoarthritis	T	P	Other	Open	Nap 500 vs Sulindac 400	48	47	11	11
Pathy 1982 Group II	w419	Osteoarthritis	T	P	Unknown	Open	Nap 500 vs Sulindac 400	42	45	10	10
Nived 1994	w420	Rheumatoid arthritis	T	P	Unknown	Double	Nap 500 vs Tenoxicam 20	155	152	77	76
Davis 1987	w401	OA/RA/AS	T	P	Unknown	Double	Nap 500 vs Tiaprofenic acid 600	76	181	9	21
Telhaq 1981	w421	Osteoarthritis	T	P	Unknown	Double	Nap 500 vs Tolmetin 800	36	34	8	8
Raynauld 2009	w422	Osteoarthritis	T	P	Sealed envelopes	Double	Nap 400 vs Licofelone 1000	177	178	353	355
<i>Diclofenac versus ibuprofen</i>											
Pfizer N49-97-02-071	-	OA/RA	I	P	Unknown	Double	Dic 150 vs Ib 2400	387	346	73	61
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	Dic 150 vs Ib 2400	212	207	49	48
Crook 1981	w423	Osteoarthritis	T	C	Unknown	Double	Dic 100 vs Ib 1600	22	25	2	2
Kiff 1994	w424	OA/RA	T	P	Closed list	Single	Dic 100 vs Ib 1200	263	253	81	78
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Dic 100 vs Ib 1200	296	235	68	54
Koopmans 1987	w425	Hypertension	T	P	Unknown	Open	Dic 75 vs Ib 1200	3	3	0.2	0.2
Prabhu 2008	w426	Osteoarthritis	U	P	Unknown	Open	Dic 50 vs Ib 400	12	12	3	3
<i>Diclofenac versus other tNSAID</i>											
Diaz 1988	w427	Osteoarthritis	T	P	Other	Double	Dic 150 vs Aceclofenac 200	30	29	2	2
Pareek 2006	w428	Osteoarthritis	T	P	Sealed envelopes	Double	Dic 150 vs Aceclofenac 200	122	125	19	19
Pasero 1995	w429	Rheumatoid arthritis	T	P	Unknown	Double	Dic 150 vs Aceclofenac 200	173	170	86	85
Ward 1995	w430	Osteoarthritis	T	P	Unknown	Double	Dic 150 vs Aceclofenac 200	197	200	45	46
Ximenes 1997	w431	Osteoarthritis	U	P	Unknown	Open	Dic 150 vs Aceclofenac 200	53	53	4	4
Tavella 1997	w432	Osteoarthritis	T	P	Unknown	Open	Dic 150 vs Amtolmetin 600	25	25	2	2
Corts Giner 1991	w433	Osteoarthritis	T	P	Unknown	Double	Dic 150 vs Droxicam 150	40	40	5	5
Grisanti 1992	w434	Osteoarthritis	T	P	Unknown	Double	Dic 150 vs Etodolac 600	87	85	13	13
Eisenkolb 1993	w435	Osteoarthritis	U	P	Unknown	Double	Dic 150 vs Etodolac 600	69	66	8	8
Platt 1989 Dic	w345	Osteoarthritis	U	P	Unknown	Double	Dic 150 vs Etodolac 600	47	38	7	6
Lonauer 1993	w436	Rheumatoid arthritis	T	P	Unknown	Double	Dic 150 vs Etodolac 400	55	53	13	12
Briancon 1989 Study 2	w349	Rheumatoid arthritis	U	P	Unknown	Double	Dic 150 vs Etodolac 400	41	45	8	9
Burdeiny 1981	w437	Bechterew's disease	T	P	Unknown	Double	Dic 150 vs Indomethacin 150	14	14	1	1
Kennedy 1994	w438	Osteoarthritis	T	P	Unknown	Double	Dic 150 vs Ketoprofen 200	121	118	39	38
Kidd 1996 X1	w439	Osteoarthritis	T	C	Unknown	Double	Dic 150 vs Lornoxicam 16	45	44	10	10
Kidd 1996 X1	w439	Osteoarthritis	T	C	Unknown	Double	Dic 150 vs Lornoxicam 12	45	46	10	11
Lederman 2001	w440	Osteoarthritis	T	P	Other	Double	Dic 150 vs Loxoprofen 180	30	30	2	2
Furst 2002	w227	Rheumatoid arthritis	T	P	Other	Double	Dic 150 vs Meloxicam 22.5	181	177	42	41
Furst 2002	w227	Rheumatoid arthritis	T	P	Other	Double	Dic 150 vs Meloxicam 15	181	184	42	42
Furst 2002	w227	Rheumatoid arthritis	T	P	Other	Double	Dic 150 vs Meloxicam 7.5	181	175	42	40
Huskisson 1999	w441	Osteoarthritis	T	P	Unknown	Double	Dic 150 vs Nimesulide 200	144	135	66	62
Porto 1994	w442	Osteoarthritis	T	P	Other	Double	Dic 150 vs Nimesulide 200	45	44	3	3
Porto 1998	w443	Osteoarthritis	T	P	Other	Double	Dic 150 vs Nimesulide 200	45	44	3	3
Zgradie 1999	w444	Osteoarthritis	T	P	Unknown	Unknown	Dic 150 vs Nimesulide 200	90	90	7	7
Karbowski 1998 RA	w445	Rheumatoid arthritis	T	P	Unknown	Double	Dic 150 vs Oxyprozin/oxaprozin 1200	29	26	14	13
Große-Kielisch 1983	w446	Rheumatism	T	P	Unknown	Double	Dic 150 vs Proglumetacin 450	20	20	2	2
Nahir 1980	w447	Ankylosing spondylitis	T	P	Unknown	Double	Dic 150 vs Sulindac 600	31	31	2	2
Baumgartner 1979	w448	Osteoarthritis	T	P	Pharmacy	Single	Dic 150 vs Sulindac 400	12	12	2	2
Bellamy 1993	w449	Osteoarthritis	T	P	Other	Double	Dic 150 vs Tenoxicam 20	50	48	11	11
Khan 1987	w450	Ankylosing spondylitis	T	P	Other	Double	Dic 125 vs Indomethacin 125	132	130	33	32
Brasseur 1991	w451	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Etodolac 600	29	32	3	4
Khan 1992	w452	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Etodolac 600	32	32	2	2
Porzio 1993	w453	Rheumatoid arthritis	T	P	Unknown	Double	Dic 100 vs Etodolac 600	41	50	3	4
Liang 2003	w454	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Etodolac 400	32	32	2	2
Sasdeli 1980	w455	Glomerulonephritis	T	P	Unknown	Unknown	Dic 100 vs Indomethacin 100	5	5	1	1
Gostick 1990	w456	Osteoarthritis	T	C	Unknown	Double	Dic 100 vs Indomethacin 75	42	42	3	3
Crowley 1990	w457	Rheumatoid arthritis	U	P	Unknown	Double	Dic 100 vs Indomethacin 75	39	45	3	3
Janssen 1988	w458	Rheumatoid arthritis	T	P	Unknown	Double	Dic 100 vs Lonazolac 600	15	15	1	1
Stewart 1988	w459	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Mefenamic acid 1500	46	48	7	7
Patel 2000	w460	OA/RA	T	P	Unknown	Unknown	Dic 100 vs Meloxicam 75	66	61	5	5
Goel The 1997	w461	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Meloxicam 15	130	128	15	15
Yocum 2000	w239	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Meloxicam 15	153	156	35	36
MELISSA Hawkey 1998	w462	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Meloxicam 7.5	5051	5000	387	383
Chopra 2004 OA	w463	Osteoarthritis	T	P	Other	Double	Dic 100 vs Meloxicam 7.5	68	65	5	5
Hosie 1996	w464	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Meloxicam 7.5	167	169	83	84
Yocum 2000	w239	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Meloxicam 7.5	153	154	35	35
Yocum 2000	w239	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Meloxicam 3.75	153	154	35	35
Bevcar 1999	w465	Osteoarthritis	T	P	Unknown	Open	Dic 100 vs Nabumetone 1500	193	202	44	46

Webtable 4 - Details of trials involving a randomised comparison of naproxen, ibuprofen or diclofenac (X) versus: a) each other; or b) another tNSAID regimen (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
								X	Y	X	Y
Filipowicz-Sosnowska 1997	w466	Osteoarthritis	T	P	Unknown	Unknown	Dic 100 vs Nabumetone 1500	59	59	14	14
Scott 2000 Study I	w467	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Nabumetone 1500	199	200	92	92
Alballa 1992	w468	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Nabumetone 1000	32	35	2	3
Bellamy 1995	w469	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Nabumetone 1000	189	191	94	95
Havranek 1998	w470	Osteoarthritis	T	P	Unknown	Single	Dic 100 vs Nabumetone 1000	13	16	3	4
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Dic 100 vs Nabumetone 1000	296	3315	68	762
Rees 1990	w471	Osteoarthritis	T	P	Onsite computer	Double	Dic 100 vs Nabumetone 1000	121	122	14	14
Laws 1990	w472	Osteoarthritis	U	P	Unknown	Double	Dic 100 vs Nabumetone 1000	121	122	14	14
Estevez 1993	w473	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Nimesulide 200	10	10	2	2
Famaey 1998	w474	Back pain	T	P	Unknown	Open	Dic 100 vs Nimesulide 200	101	95	8	7
Omololu 2005	w475	Osteoarthritis	T	P	Other	Double	Dic 100 vs Nimesulide 200	32	35	4	4
Karbowski 1998 OA	w476	Osteoarthritis	T	P	Unknown	Unknown	Dic 100 vs Oxyprozin/oxaprozin 600	40	40	5	5
GOAL 1998	w477	Osteoarthritis	T	P	Unknown	Unknown	Dic 100 vs Piroxicam 20	55	52	27	26
Gudiño Quiroz 1988	w478	Osteoarthritis	T	P	Closed list	Double	Dic 100 vs Piroxicam 20	18	19	3	3
Sauaya 1996	w479	Rheumatoid arthritis	T	P	Unknown	Double	Dic 100 vs Piroxicam 20	30	30	3	3
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Dic 100 vs Piroxicam 10	296	286	68	66
Shichikawa 1984 supro	w480	Rheumatoid arthritis	T	P	Unknown	Double	Dic 100 vs Suprofen 400	93	96	11	11
Esselincx 1990	w236	Osteoarthritis	T	P	Pharmacy	Double	Dic 100 vs Tenoxicam 40	87	86	7	7
Al-Quorain 1993	w481	OA/RA	T	P	Sealed envelopes	Double	Dic 100 vs Tenoxicam 20	20	20	2	2
Esselincx 1990	w236	Osteoarthritis	T	P	Pharmacy	Double	Dic 100 vs Tenoxicam 20	87	85	7	7
Fellet 1989	w482	Rheumatoid arthritis	T	P	Unknown	Double	Dic 100 vs Tenoxicam 20	15	15	3	3
Schwazer 1990	w483	Ankylosing spondylitis	T	P	Unknown	Unknown	Dic 100 vs Tenoxicam 20	12	12	3	3
Winterer 1994	w484	Osteoarthritis	T	P	Unknown	Double	Dic 100 vs Tenoxicam 20	51	50	8	8
Moser 1989 IB	w485	Osteoarthritis	U	P	Unknown	Double	Dic 100 vs Tenoxicam 20	264	254	20	19
Moser 1989 IIB	w485	Extra-articular rheumatism	U	P	Unknown	Double	Dic 100 vs Tenoxicam 20	209	206	16	16
Genney 1982	w486	Osteoarthritis	T	C	Unknown	Open	Dic 75 vs Benoxaprofen 600	181	700	14	54
Kirchheiner 1976	w241	Rheumatoid arthritis	T	P	Sealed envelopes	Double	Dic 75 vs Indomethacin 75	62	63	5	5
Alegre Marcet 1977	w487	Rheumatoid arthritis	T	P	Unknown	Double	Dic 75 vs Indomethacin 75	41	44	10	11
Bijlsma 1978	w488	Rheumatoid arthritis	T	P	Unknown	Double	Dic 75 vs Indomethacin 75	18	18	8	8
Calabro 1986	w489	Ankylosing spondylitis	T	P	Unknown	Double	Dic 75 vs Indomethacin 75	118	106	27	24
Genney 1982	w486	Osteoarthritis	T	C	Unknown	Open	Dic 75 vs Indomethacin 75	181	200	14	15
Tsavaris 1990	w333	Metastatic cancer	T	C	Unknown	Unknown	Dic 75 vs Indomethacin 75	16	16	2	2
Behrens 1985	w490	Osteoarthritis	T	P	Unknown	Double	Dic 75 vs Isoxicam 300	120	120	28	28
Boey 1988	w491	Rheumatoid arthritis	T	P	Unknown	Open	Dic 75 vs Ketoprofen 100	9	9	2	2
Bellamy 1992 Meclo	w492	Osteoarthritis	T	P	Other	Double	Dic 75 vs Meclonamide 300	31	30	4	3
Aylward 1985	w493	Osteoarthritis	T	P	Unknown	Double	Dic 75 vs Mefenamic acid 1500	19	20	4	5
Li 2001	w494	Rheumatoid arthritis	T	P	Unknown	Open	Dic 75 vs Nabumetone 1000	61	64	14	15
Tan Hong-Chang 2005	w495	Osteoarthritis	T	P	Unknown	Unknown	Dic 75 vs Nabumetone 100	75	81	6	6
Shiokawa 1984	w496	Rheumatoid arthritis	U	P	Unknown	Double	Dic 75 vs Oxyprozin/oxaprozin 400	85	88	10	10
Genney 1982	w486	Osteoarthritis	T	C	Unknown	Open	Dic 75 vs Piroxicam 20	181	166	14	13
Gerecz-Simon 1990	w497	Osteoarthritis	T	P	Other	Double	Dic 75 vs Piroxicam 20	40	40	9	9
Rohde 1980	w498	Rheumatoid arthritis	T	P	Unknown	Open	Dic 75 vs Piroxicam 20	20	20	2	2
Koopmans 1987	w425	Hypertension	T	P	Unknown	Open	Dic 75 vs Sulindac 400	3	3	0.2	0.2
Pathy 1982 Group III	w419	Osteoarthritis	T	P	Unknown	Open	Dic 75 vs Sulindac 400	29	31	7	7
Vandenburg 1984	w499	Osteoarthritis	T	P	Other	Open	Dic 75 vs Sulindac 400	29	33	7	8
Prabhu 2008	w426	Osteoarthritis	U	P	Unknown	Open	Dic 50 vs Nimesulide 100	12	12	3	3
<i>Ibuprofen versus other tNSAID</i>											
Neustadt 1997	w500	Rheumatoid arthritis	T	P	Unknown	Double	Ib 2400 vs Etodolac 1000	417	409	831	815
Neustadt 1997	w500	Rheumatoid arthritis	T	P	Unknown	Double	Ib 2400 vs Etodolac 300	417	620	831	1236
Paulus 2000	w501	Rheumatoid arthritis	T	P	Unknown	Double	Ib 2400 vs Etodolac 300	414	614	1238	1836
Paulus 2000	w501	Rheumatoid arthritis	T	P	Unknown	Double	Ib 2400 vs Etodolac 156	414	405	1238	1211
Levinson 1983	w502	Osteoarthritis	U	C	Unknown	Double	Ib 2400 vs Fenoprofen 2400	23	24	2	2
Palmer 2003	w32	Hypertension	T	P	Unknown	Double	Ib 2400 vs Nabumetone 2000	100	96	8	7
Roth 1993	w503	Osteoarthritis	T	P	Unknown	Unknown	Ib 2400 vs Nabumetone 1000	53	58	12	13
McLaughlin 1985	w504	Rheumatoid arthritis	T	P	Unknown	Double	Ib 2400 vs Piroxicam 20	10	11	3	3
Bird 1984	w505	Rheumatoid arthritis	T	P	Unknown	Double	Ib 2400 vs Tenoxicam 40	10	10	1	1
Bird 1984	w505	Rheumatoid arthritis	T	P	Unknown	Double	Ib 2400 vs Tenoxicam 20	10	10	1	1
Alarcon-Segovia 1980	w506	Osteoarthritis	U	P	Other	Double	Ib 2000 vs Benoxaprofen 600	72	71	39	38
Jennings 1996	w507	Osteoarthritis	T	P	Other	Double	Ib 1800 vs Piroxicam 20	19	20	3	3
Gum 1980	w508	Rheumatoid arthritis	T	P	Unknown	Double	Ib 1600 vs Benoxaprofen 400	84	139	45	75
Bennett 1986	w509	Rheumatoid arthritis	T	P	Unknown	Double	Ib 1600 vs Diflunisal 500	105	105	24	24
McArthur 1979	w510	Rheumatoid arthritis	T	C	Unknown	Double	Ib 1600 vs Indomethacin 100	10	10	1	1
Shadforth 1984	w511	Osteoarthritis	T	P	Unknown	Double	Ib 1600 vs Nabumetone 1000	23	22	4	3
Earl 1996	w512	Osteoarthritis	T	P	Unknown	Double	Ib 1600 vs Piroxicam 20	38	21	3	2
Tyson 1980	w513	Osteoarthritis	T	P	Other	Double	Ib 1200 vs Benoxaprofen 600	60	60	18	18
Klein 1982	w514	Osteoarthritis	T	P	Other	Double	Ib 1200 vs Carprofen 300	10	10	2	2
Bresnahan 1978	w515	Osteoarthritis	T	P	Unknown	Double	Ib 1200 vs Diflunisal 500	19	18	3	3
Keet 1979	w516	Osteoarthritis	T	P	Unknown	Double	Ib 1200 vs Diflunisal 400	18	17	3	3
Brodie 1980	w517	Osteoarthritis	T	P	Unknown	Single	Ib 1200 vs Fenclorfenac 900	29	27	7	6
Bain 1977	w518	Osteoarthritis	T	C	Unknown	Double	Ib 1200 vs Feprazone 600	11	10	1	1
Calin 1977	w519	Rheumatoid arthritis	T	P	Unknown	Double	Ib 1200 vs Ketoprofen 150	50	52	11	12
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Ib 1200 vs Nabumetone 1000	235	3315	54	762
Shah 1984	w520	Type 2 diabetes	T	P	Unknown	Unknown	Ib 1200 vs Phenylbutazone 300	11	11	1	1
Alan 1983	w521	Rheumatoid arthritis	T	P	Unknown	Unknown	Ib 1200 vs Piroxicam 20	15	16	2	2
Lister 1993	w330	OA/RA	T	P	Unknown	Open	Ib 1200 vs Piroxicam 10	235	286	54	66
Ruotsi 1978	w522	Rheumatoid arthritis	T	P	Other	Double	Ib 1200 vs Proquazone 900	23	21	11	10
Admani 1983	w523	Osteoarthritis	T	P	Unknown	Unknown	Ib 1200 vs Sulindac 400	15	15	3	3
Currie 1984	w524	Osteoarthritis	T	P	Other	Open	Ib 1200 vs Sulindac 400	55	54	13	12
Ghosh 1982	w525	Osteoarthritis	T	P	Other	Open	Ib 1200 vs Sulindac 400	16	16	4	4
Koopmans 1987	w425	Hypertension	T	P	Unknown	Open	Ib 1200 vs Sulindac 400	3	3	0.2	0.2
Pathy 1982 Group I	w419	Osteoarthritis	T	P	Unknown	Open	Ib 1200 vs Sulindac 400	47	45	11	10
Vetter 1977	w526	Rheumatoid arthritis	T	P	Unknown	Double	Ib 1200 vs Sulindac 400	16	16	1	1
Royer 1975 OA	w527	Osteoarthritis	T	P	Unknown	Double	Ib 900 vs Indomethacin 75	117	115	54	53
Royer 1975 RA	w528	Rheumatoid arthritis	T	P	Unknown	Double	Ib 900 vs Indomethacin 75	104	114	48	52
Cardoe 1969	w529	Rheumatoid arthritis	T	C	Unknown	Double	Ib 600 vs Phenylbutazone 300	15	15	1	1
Dieppe 1976	w530	Osteoarthritis	T	P	Unknown	Double	Ib 600 vs Sulindac 200	20	20	3	3
Prabhu 2008	w426	Osteoarthritis	U	P	Unknown	Open	Ib 400 vs Nimesulide 100	12	12	3	3
Oyemade 1979	w531	Osteoarthritis	T	P	Unknown	Unknown	Ib 400 vs Sulindac 400	8	20	1	3
Oyemade 1979	w531	Osteoarthritis	T	P	Unknown	Unknown	Ib 400 vs Sulindac 200	8	12	1	2

OA/RA=Osteoarthritis or rheumatoid arthritis. AS=Ankylosing spondylitis.

Data type (I=Individual patient data; T=Tabular data; U=Unavailable in either tabular or IPD form).

Design (B='Base' phase of a trial with more than one randomisation; C=Cross-over trial (first treatment period only); E='Extension' phase of a trial with a second randomisation (note: a single trial can have several extension phases, each contributing to a different randomised comparison); F=Factorial design; P=Parallel trial with a single randomisation).

Webtable 4 - Details of trials involving a randomised comparison of naproxen, ibuprofen or diclofenac (X) versus: a) each other; or b) another tNSAID regimen (Y)

Allocation concealment (IVRS = Interactive Voice Response System; Telephone = Telephone central office; Pharmacy = Pharmacy coded containers administered sequentially; Onsite computer = Onsite computer accessible only after entering patients details; Sealed envelopes = Sealed envelopes, sequentially numbered and opaque; Closed list = Closed list of random numbers; Other = Other acceptable method).

Regimens: Nap=Naproxen; Dic=Diclofenac; Ibu=Ibuprofen.

Webtable 5 - Details of trials involving a randomised comparison of one coxib regimen (X) versus another coxib regimen (Y)

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
								X	Y	X	Y
<i>Celecoxib 400mg daily versus Etoricoxib</i>											
MK 065	w18	Osteoarthritis	I	P	Other	Double	C 400 vs E 90	107	108	25	26
<i>Celecoxib 200mg daily versus Etoricoxib</i>											
MK 076	w45	Osteoarthritis	I	B	Unknown	Double	C 200 vs E 30	241	231	50	50
MK 076	w45	Osteoarthritis	I	E	Unknown	Double	C 200 vs E 30	44	41	12	12
MK 076	w45	Osteoarthritis	I	E	Unknown	Double	C 200 vs E 30	192	191	55	55
MK 077	w45	Osteoarthritis	I	B	Other	Double	C 200 vs E 30	247	244	53	53
MK 077	w45	Osteoarthritis	I	E	Other	Double	C 200 vs E 30	30	30	9	9
MK 077	w45	Osteoarthritis	I	E	Other	Double	C 200 vs E 30	202	212	57	60
<i>Celecoxib 400mg daily versus Lumiracoxib</i>											
Novartis 110	w173	Rheumatoid arthritis	I	P	Unknown	Double	C 400 vs L 800	223	227	51	49
Novartis 110	w173	Rheumatoid arthritis	I	P	Unknown	Double	C 400 vs L 400	223	227	51	50
Novartis 114	-	Rheumatoid arthritis	I	P	Unknown	Unknown	C 400 vs L 400	302	313	64	63
Novartis 114	-	Rheumatoid arthritis	I	P	Unknown	Unknown	C 400 vs L 200	302	315	64	63
<i>Celecoxib 200mg daily versus Lumiracoxib</i>											
Novartis 109	w49	Osteoarthritis	I	P	Unknown	Double	C 200 vs L 400	444	463	96	101
Novartis 112E	w50	Osteoarthritis	I	B	Unknown	Double	C 200 vs L 400	481	491	122	125
Novartis 112E	-	Osteoarthritis	I	E	Unknown	Double	C 200 vs L 400	56	59	36	40
Novartis 112E	-	Osteoarthritis	I	E	Unknown	Double	C 200 vs L 400	343	352	220	224
Novartis 126	w174	Osteoarthritis	I	P	Sealed envelopes	Double	C 200 vs L 400	258	260	59	60
Novartis 109	w49	Osteoarthritis	I	P	Unknown	Double	C 200 vs L 200	444	462	96	100
Novartis 112E	w50	Osteoarthritis	I	B	Unknown	Double	C 200 vs L 200	481	487	122	125
Novartis 112E	-	Osteoarthritis	I	E	Unknown	Double	C 200 vs L 200	56	56	36	37
Novartis 112E	-	Osteoarthritis	I	E	Unknown	Double	C 200 vs L 200	343	348	220	212
Novartis 126	w174	Osteoarthritis	I	P	Sealed envelopes	Double	C 200 vs L 200	258	264	59	60
Novartis 2364	w532	Osteoarthritis	I	P	Unknown	Double	C 200 vs L 200	351	352	39	39
Novartis 2369	w533	Osteoarthritis	I	P	IVRS	Double	C 200 vs L 200	758	1519	747	1499
Novartis 2367	w51	Osteoarthritis	I	P	Other	Double	C 200 vs L 100	419	427	127	129
Novartis 2369	w533	Osteoarthritis	I	P	IVRS	Double	C 200 vs L 100	758	755	747	745
Novartis 360E	w52	Osteoarthritis	I	B	Other	Double	C 200 vs L 100	393	776	86	185
Novartis 361E	w53	Osteoarthritis	I	B	Other	Double	C 200 vs L 100	420	840	111	227
Novartis 361E	-	Osteoarthritis	I	E	Other	Double	C 200 vs L 100	130	176	83	115
Novartis 361E	-	Osteoarthritis	I	E	Other	Double	C 200 vs L 100	323	667	199	395
<i>Celecoxib 800mg daily versus Rofecoxib</i>											
Kvale 2006	w1	HIV	T	P	Unknown	Open	C 800 vs R 50	13	12	3	3
<i>Celecoxib 400mg daily versus Rofecoxib</i>											
MK 905	w19	Healthy volunteer	I	P	Unknown	Double	C 400 vs R 100	17	17	2	2
Aw 2006	w534	Osteoarthritis	T	P	Unknown	Open	C 400 vs R 50	5	6	1	1
<i>Celecoxib 200mg daily versus Rofecoxib</i>											
MK 2007_636	-	OA/RA	U	P	Unknown	Double	C 200 vs R 42	-	-	-	-
MK 106 (VACT-1)	w535	Osteoarthritis	I	P	Other	Double	C 200 vs R 25	97	95	12	12
MK 112	w46	Osteoarthritis	I	P	Unknown	Double	C 200 vs R 25	456	459	64	66
MK 116	w46	Osteoarthritis	I	P	Unknown	Double	C 200 vs R 25	460	471	66	68
MK 150 (VACT-2)	w536	Osteoarthritis	I	P	Other	Double	C 200 vs R 25	523	527	55	55
Pfizer 635-IFL-0508-002	w161	Osteoarthritis	I	P	Onsite computer	Double	C 200 vs R 25	136	138	28	27
Pfizer 635-IFL-0508-003	w54	Osteoarthritis	I	P	Other	Double	C 200 vs R 25	189	190	19	20
Pfizer N49-00-02-181 (SUCCESS-VII)	w537	Osteoarthritis	I	P	Other	Double	C 200 vs R 25	549	546	59	57
Pfizer N49-99-02-149	w538	Osteoarthritis	I	P	Other	Double	C 200 vs R 25	412	399	42	41
Pfizer N49-99-02-152	w65	Osteoarthritis	I	P	Other	Double	C 200 vs R 25	63	59	6	6
MK 2007_636	-	OA/RA	U	P	Unknown	Double	C 200 vs R 21	-	-	-	-
MK 106 (VACT-1)	w535	Osteoarthritis	I	P	Other	Double	C 200 vs R 12.5	97	96	12	11
MK 112	w46	Osteoarthritis	I	P	Unknown	Double	C 200 vs R 12.5	456	456	64	65
MK 150 (VACT-2)	w536	Osteoarthritis	I	P	Other	Double	C 200 vs R 12.5	523	529	55	27
MK 219	w47	Osteoarthritis	I	P	Other	Double	C 200 vs R 12.5	157	160	17	17
MK 220	w48	Osteoarthritis	I	P	Unknown	Double	C 200 vs R 12.5	169	159	24	23
<i>Celecoxib 400mg daily versus GW403681</i>											
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	C 400 vs G 50	132	137	16	17
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	C 400 vs G 50	379	379	84	81
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	C 400 vs G 35	132	139	16	17
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	C 400 vs G 25	379	380	84	83
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	C 400 vs G 10	132	133	16	16
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	C 400 vs G 10	379	379	84	85
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	C 400 vs G 5	379	379	84	85
<i>Celecoxib 200mg daily versus GW403681</i>											
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	C 200 vs G 50	111	109	14	14
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	C 200 vs G 50	190	190	43	43
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	C 200 vs G 35	111	110	14	14
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	C 200 vs G 25	190	190	43	43
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	C 200 vs G 20	111	105	14	13
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	C 200 vs G 10	111	107	14	13
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	C 200 vs G 10	190	192	43	42
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	C 200 vs G 5	190	191	43	41
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	C 200 vs G 1	190	189	43	42
<i>Etoricoxib 90mg daily versus Rofecoxib</i>											
MK 036	w85	Haemophilic arthropathy	I	E	Other	Double	E 90 vs R 25	25	16	12	9
<i>Lumiracoxib 400mg daily versus Rofecoxib</i>											
Novartis 128	w97	Osteoarthritis	I	P	Unknown	Double	L 400 vs R 25	205	102	45	23
Novartis 2307	w539	Osteoarthritis	I	P	Unknown	Double	L 400 vs R 25	154	155	17	17
<i>Rofecoxib 25mg daily versus Valdecoxib</i>											
Pfizer 872-IFL-0513-004	w137	OA/RA	T	P	Unknown	Double	R 25 vs V 20	225	228	26	26

OA/RA=Osteoarthritis or rheumatoid arthritis.

Data type (I=Individual patient data; T=Tabular data; U=Unavailable in either tabular or IPD form).

Webtable 5 - Details of trials involving a randomised comparison of one coxib regimen (X) versus another coxib regimen (Y)

Design (B='Base' phase of a trial with more than one randomisation; C=Cross-over trial (first treatment period only); E='Extension' phase of a trial with a second randomisation (note: a single trial can have several extension phases, each contributing to a different randomised comparison); F=Factorial design; P=Parallel trial with a single randomisation).

Allocation concealment (IVRS = Interactive Voice Response System; Telephone = Telephone central office; Pharmacy = Pharmacy coded containers administered sequentially; Onsite computer = Onsite computer accessible only after entering patients details; Sealed envelopes = Sealed envelopes, sequentially numbered and opaque; Closed list = Closed list of random numbers; Other = Other acceptable method).

Regimens: C=Celecoxib; E=Etoricoxib; L=Lumiracoxib; R=Rofecoxib; V=Valdecoxib; G=GW403681.

Webtable 6 - Details of trials involving a randomised comparison of two doses of the same coxib (high [X] vs low [Y])

Trial name	Ref.	Indication for treatment	Data type	Design	Allocation concealment	Method of blinding of investigators and patients	Regimen, mg per day (X vs Y)	No. of patients		Person years	
								X	Y	X	Y
MK 301-0 X1	w135	Osteoarthritis	T	B	Unknown	Double	R 25 vs R 12.5	97	90	11	10
MK 304-0	w541	Back pain	T	P	Unknown	Double	R 25 vs R 12.5	17	20	1	2
Schnitzer Tesser 2009	w542	Osteoarthritis	T	P	Unknown	Double	R 25 vs R 12.5	129	138	10	11
MK 029 Rof	w103	Osteoarthritis	I	B	Unknown	Double	R 12.5 vs R 5	144	149	17	17
<i>Valdecoxib versus valdecoxib</i>											
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 20 vs V 10	82	166	9	19
Pfizer A3471090	w152	Osteoarthritis	T	P	Unknown	Double	V 20 vs V 10	106	101	12	12
Pfizer I91-99-02-063	w199	Osteoarthritis	T	P	Unknown	Double	V 20 vs V 10	261	259	260	258
Pfizer N91-01-02-133	w153	Back pain	T	P	Unknown	Double	V 20 vs V 10	158	164	36	38
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 20 vs V 10	79	165	9	19
Pfizer N91-98-02-048	w155	Osteoarthritis	T	P	Unknown	Double	V 20 vs V 10	219	204	50	47
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 20 vs V 10	202	206	46	47
Pfizer N91-99-02-060	w149	Rheumatoid arthritis	T	P	Unknown	Double	V 20 vs V 10	212	209	49	48
Pfizer N91-99-02-061	w150	Rheumatoid arthritis	T	P	Other	Double	V 20 vs V 10	219	226	50	52
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 10 vs V 5	166	83	19	10
Pfizer A3471090	w152	Osteoarthritis	T	P	Unknown	Double	V 10 vs V 5	101	105	12	12
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 10 vs V 5	165	83	19	10
Pfizer N91-99-02-049	w158	Osteoarthritis	T	P	Unknown	Double	V 10 vs V 5	111	120	26	28
Pfizer N91-99-02-053	w156	Osteoarthritis	T	P	Pharmacy	Double	V 10 vs V 5	206	201	47	46
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 5 vs V 2.5	83	84	10	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 5 vs V 2.5	83	81	10	9
Pfizer N91-97-02-016	w151	OA/RA	T	P	Other	Double	V 2.5 vs V 1	84	89	10	10
Pfizer N91-97-02-015	w154	OA/RA	T	P	Unknown	Double	V 2.5 vs V 1	81	77	9	9
<i>GW403681 versus GW403681</i>											
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	G 50 vs G 35	109	110	14	14
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	G 50 vs G 35	137	139	17	17
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 50 vs G 25	190	190	43	43
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	G 50 vs G 25	379	380	81	83
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	G 35 vs G 20	110	105	14	13
GSK CXA20006	-	Rheumatoid arthritis	I	P	Other	Double	G 35 vs G 10	139	133	17	16
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 25 vs G 10	190	192	43	42
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	G 25 vs G 10	380	379	83	85
GSK CXA20005	w43	Osteoarthritis	I	P	Other	Double	G 20 vs G 10	105	107	13	13
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 10 vs G 5	192	191	42	41
GSK CXA30009	-	Rheumatoid arthritis	I	P	Onsite computer	Double	G 10 vs G 5	379	379	85	85
GSK CXA30007	w43	Osteoarthritis	I	P	IVRS	Double	G 5 vs G 1	191	189	41	42

OA/RA=Osteoarthritis or rheumatoid arthritis.

Data type (I=Individual patient data; T=Tabular data; U=Unavailable in either tabular or IPD form).

Design (B='Base' phase of a trial with more than one randomisation; C=Cross-over trial (first treatment period only); E='Extension' phase of a trial with a second randomisation (note: a single trial can have several extension phases, each contributing to a different randomised comparison); F=Factorial design; P=Parallel trial with a single randomisation).

Allocation concealment (IVRS = Interactive Voice Response System; Telephone = Telephone central office; Pharmacy = Pharmacy coded containers administered sequentially; Onsite computer = Onsite computer accessible only after entering patients details; Sealed envelopes = Sealed envelopes, sequentially numbered and opaque; Closed list = Closed list of random numbers; Other = Other acceptable method).

Regimens: C=Celecoxib; E=Etoricoxib; L=Lumiracoxib; R=Rofecoxib; V=Valdecoxib; G=GW403681.

Trials shown in supplementary tables 1-6

- w1 Kvale D et al. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. *AIDS* 2006;20:813-20
- w2 Dirix LY et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. *J Clin Oncol* 2008;26:1253-9
- w3 Bertagnoli M et al. APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. *New Engl J Med* 2006;355:873-84
- w4 Cudkovic ME et al. Trial of celecoxib in amyotrophic lateral sclerosis. *Ann Neurol* 2006;60:22-31
- w5 Falandry C et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. *Breast Cancer Res Tr* 2009;116:501-8
- w6 Steinbach G et al. The effect of celecoxib, a cyclooxygenase inhibitor, in familial adenomatous polyposis. *New Engl J Med* 2000;342:1946-52
- w7 Hubbard RC et al. Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis [abstract]. *Arthritis Rheum* 1997;40:S51
- w8 Simon LS et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. *JAMA* 1999;282:1921-8
- w9 Antonarakis ES et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. *J Clin Oncol* 2009;27:4986-93
- w10 Kim ES et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. *Cancer Prev Res* 2010;3:148-59
- w11 Smith MR et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy. *J Clin Oncol* 2006;24:2723-8
- w12 Jhee SS et al. A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer's disease. *Clin Res Regul Aff* 2004;21:49-66
- w13 De Ruyscher D et al. Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial. *Radiother Oncol* 2007;84:23-5
- w14 ADAPT Research Group. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). *Arch Neurol* 2008;65:896-905
- w15 Bresee J et al. The effects of celecoxib augmentation on cytokine levels in schizophrenia. *Int J Neuropsychopharmacol* 2006;9:343-8
- w16 Solomon SD et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. *Circulation* 2008;117:2104-13
- w17 Koo B-K et al. Effect of celecoxib on restenosis after coronary angioplasty with Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. *Lancet* 2007;370:567-73
- w18 Di Battiste PM et al. Etoricoxib has no adverse effects on biomarkers of cardiovascular risk in patients with osteoarthritis. *J Am Coll Cardiol* 2004;43:11A
- w19 Schwartz J et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal salt-diet. *Clin Pharmacol Ther* 2002;72:50-61
- w20 Pfizer Inc. A randomized, double-blind multicenter, active and placebo-controlled parallel group study to evaluate the efficacy and safety of celecoxib (YM177) 200 mg BID compared to Loxoprofen-Na 60 mg TID in patients with low back pain [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w21 Soininen H et al. Long-term efficacy and safety of celecoxib in Alzheimer's disease. *Dement Geriatr Cogn* 2007;23:8-21
- w22 Barkhuizen A et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. *J Rheumatol* 2006;33:1805-12
- w23 Kivitz AJ et al. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. *Semin Arthritis Rheum* 2007;37:164-73
- w24 Bensen WG et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. *Mayo Clin Proc* 1999;74:1095-105
- w25 Moskowitz RW et al. American Pain Society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies. *Am J Therap* 2003;10:12-20
- w26 Kivitz AJ et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. *J Int Med Res* 2001;29:467-79
- w27 Arber N et al. Celecoxib for the prevention of colorectal adenomatous polyps. *New Engl J Med* 2006;355:885-95
- w28 Farley JH et al. A randomised double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor celecoxib in the treatment of cervical dysplasia. *Gynecol Oncol* 2006;103:429-30
- w29 Muller N et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. *Am J Psychiatr* 2002;159:1029-34
- w30 Muller N et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: result of a double blind, randomised, placebo controlled, add-on pilot study to reboxetine. *Mol Psychiatr* 2006;11:680-4
- w31 Limburg PJ et al. Randomized, placebo-controlled, limboing squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. *Gastroenterology* 2005;129:863-73
- w32 Palmer R et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. *Am J Hypertens* 2003;16:135-9
- w33 Adegbehingbe OO et al. Clinical effects of Garcinia kola in knee osteoarthritis. *J Orthop Sur Res* 2008;3:34
- w34 Akhondzadeh S et al. Celecoxib as adjunctive therapy in schizophrenia; a double-blind randomized and placebo-controlled trial. *Schizophr Res* 2007;90:179-85
- w35 Feng G-S et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. *World J Gastroenterol* 2008;14:4535-9
- w36 Nery FG et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. *Hum Psychopharmacol Clin Exp* 2008;23:87-94
- w37 Pfizer Inc. A double-blind, placebo-controlled, randomized study of the efficacy of celecoxib as add-on therapy to risperidone versus risperidone alone in patients with schizophrenia [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w38 Pfizer Inc. A multicenter, randomized, double-blind, placebo-controlled, multiple dose assessment of the bone resorption activity of celecoxib 400 mg QD, estradiol 0.5 mg QD, estradiol 0.5 mg and celecoxib 400 mg QD, and placebo in women with osteopenia [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w39 Papadimitrakopoulou VA et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. *Clin Cancer Res* 2008;14:2095-101
- w40 Heath EI et al. Secondary chemoprotection of Barrett's Esophagus with celecoxib: results of a randomised trial. *J Natl Cancer Inst* 2007;99:545-57
- w41 White W et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. *Hypertension* 2002;39:929-34
- w42 Reid MS et al. A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence. *Addiction* 2005;100(Suppl. 1):32-42
- w43 Boswell DJ et al. Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. *Medscape J Med* 2008;10:259
- w44 Kohne CH et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. *Ann Oncol* 2008;19:920-6
- w45 Bingham CO et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. *Rheumatology* 2007;46:496-507
- w46 Smugar SS et al. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results from two similarly designed studies. *Curr Med Res Opin* 2006;22:1353-67
- w47 Birbara CA et al. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. *Curr Med Res Opin* 2006;22:199-210
- w48 Ruoff G et al. Treatment of osteoarthritis patients with rofecoxib 12.5 mg and celecoxib 200 mg: a randomized, placebo-controlled trial. *Osteoarth Res Soc Int* 2004;Abstract P215:118
- w49 Fleischmann R et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomised 13-week study versus placebo and celecoxib. *Clin Rheumatol* 2005;25:42-53
- w50 Tannenbaum H et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee; a 13 week, randomised, double blind study versus placebo and celecoxib. *Ann Rheum Dis* 2004;63:1419-26
- w51 Schnitzer TJ et al. Lumiracoxib improves pain and functional status in patients with primary hip osteoarthritis: a 13-week, multicenter, randomized, placebo-controlled, active comparator trial. *Osteoarth Cartilage* 2007;15 (Suppl. C):141
- w52 Sheldon E et al. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee; a 13-week, randomized, double-blind comparison with celecoxib and placebo. *Clin Ther* 2005;27:64-77
- w53 Lehmann R et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs placebo and celecoxib. *Curr Med Res Opin* 2005;21:517-26
- w54 Gibofsky A et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis. *Arthritis Rheum* 2003;48:3102-11
- w55 Katz P et al. Depression and patients' ratings of the effectiveness of pain medications for knee osteoarthritis. *Arthritis Rheum* 2003;48(Suppl.608): (Abstract 1579)
- w56 Espinoza L et al. Celecoxib in hispanic-americans: efficacy, safety, and tolerability compared to naproxen or placebo in the treatment of osteoarthritis of the knee. *Ann Rheum Dis* 2003;48(Suppl.1):FR10278
- w57 Pfizer Inc. A study of the efficacy and tolerability of once daily Celebrex (celecoxib) and three times daily ibuprofen vs placebo in the treatment of subjects with osteoarthritis of the knee [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w58 Pfizer Inc. A3191069. A double-blind, placebo-controlled study of the efficacy and tolerability of once daily celebrex (celecoxib) vs placebo in the treatment of subjects with osteoarthritis of the knee non-responsive to naproxen and ibuprofen [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w59 Pincus T et al. Patient preference for placebo, acetaminophen or celecoxib efficacy studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. *Ann Rheum Dis* 2004;63:931-9
- w60 Pfizer Inc: A3191082. A double-blind, placebo controlled study of the efficacy and tolerability of once daily celebrex (celecoxib) vs placebo in the treatment of subjects with osteoarthritis of the knee non-responsive to naproxen and ibuprofen [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w61 Dougados M et al. Efficacy of celecoxib, a cyclooxygenase 2 specific inhibitor, in the treatment of ankylosing spondylitis. *Arthritis Rheum* 2001;44:180-5
- w62 Williams GW et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. *J Clin Rheumatol* 2000;6:65-74
- w63 Williams GW et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. *Clin Ther* 2001;23:213-27
- w64 McKenna F et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. *Scand J Rheumatol* 2001;30:11-8
- w65 McKenna F et al. COX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled, randomized, double-blind study. *Clin Rheumatol* 2001;7:151-9
- w66 Clegg DO et al. Glucosamine, chondroitin sulfate, and the two combinations for painful knee osteoarthritis. *New Engl J Med* 2006;354:795-808
- w67 Gonzalez-Ortiz M et al. Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects. *Metabolic Syndrome and Related Disorders* 2005;3:95-101
- w68 Yen CA et al. The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. *J Periodontol* 2008;79:104-13
- w69 Donley BG et al. The efficacy of oral nonsteroidal anti-inflammatory medication (NSAID) in the treatment of plantar fasciitis: a randomised, prospective, placebo controlled study. *Foot Ankle Int* 2007;28:20-3
- w70 Lionberger DR et al. Celecoxib does not affect osteointegration of cementless total hip stems. *J Arthroplasty* 2005;20:115-22 (Suppl.)
- w71 Pfizer Inc. A double-blind, placebo-controlled, randomized 24-month study, assessing the effect of celecoxib long term treatment on hip osteoarthritis (OA) progression [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]

Trials shown in supplementary tables 1-6

- w72 Pfizer Inc. Multicenter, double-blind, randomized, placebo-controlled trial of the efficacy and safety of usual care plus celecoxib compared to placebo for perioperative and rehabilitation pain control and return to function in osteoarthritis patients undergoing total knee arthroplasty [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w73 Small GW et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. *Am J Geriatr Psychiat* 2008; 16:999-9
- w74 Ta LE et al. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. *Pain* 2004;111:13-21
- w75 Sinsakul M et al. A randomized trial of a 6 week course of celecoxib on proteinuria in diabetic kidney disease. *Am J Kidney* 2007;50:946-51
- w76 Falahatkar S et al. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. *Urology* 2008;72:813-6
- w77 Rother M et al. Efficacy and safety of epicutaneous ketoprofen in transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: a multicentre randomised controlled trial. *Ann Rheum Dis* 2007;66:1178-83
- w78 Curtis SP et al. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients. *Arthritis Rheum* 2003;48:124-5(Suppl.)
- w79 Hunt RH et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. *Aliment Pharm Therap* 2003;17:201-10
- w80 Hunt RH et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. *Am J Gastroenterol* 2003;98:1725-33
- w81 Van der Heijde D et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. *Arthritis Rheum* 2005;52:1205-15
- w82 Gottesdiener K et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. *Rheumatology* 2002;41:1052-61
- w83 Matsumoto AK et al. A randomised, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. *J Rheumatol* 2002;29:1623-30
- w84 Collantes E et al. A multinational randomised, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. *BMC Family Practice* 2002;3:10
- w85 Tsoukas C et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. *Blood* 2006;107:1785-90
- w86 Pallay RM et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. *Scand J Rheumatol* 2004;33:257-66
- w87 Birbara CA et al. Treatment of chronic back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor. Improvement in pain and disability - A randomised, placebo controlled, 3-month trial. *J Pain* 2005;4:307-15
- w88 Ghosh S et al. A study on the effect of diclofenac sodium and etoricoxib in the treatment of osteoarthritis. *J Ind Med Ass* 2007;105:260-2
- w89 Reginster JY et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138 week randomised studies of patients with osteoarthritis. *Ann Rheum Dis* 2007;66:945-51
- w90 Leung AT et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active comparator controlled 12 week efficacy trial. *Curr Med Res Opin* 2002;18:49-58
- w91 El Miedany Y et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. *Am J Gastroenterol* 2006;101:311-7
- w92 Wiesenhutter CW et al. Protocol 071 Study Group. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc* 2005;80:470-9
- w93 Puopolo A et al. A randomised placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. *Osteoarth Cart* 2007;15:1348-56
- w94 Schnitzer TJ et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, 4-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;51:549-57
- w95 Schnitzer TJ et al. Lumiracoxib in the treatment of osteoarthritis and acute postoperative dental pain: results of three dose-response studies. *Curr Med Res Opin* 2005;21:151-61
- w96 Geusens P et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. *Int J Clin Pract* 2004;58:1033-41
- w97 Berenbaum F et al. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. *J Int Med Res* 2005;33:21-41
- w98 Grifka JK et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. *Clin Exp Rheumatol* 2004;22:589-96
- w99 Pavelka K et al. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: a 13-week, randomized, double-blind study. *Ann Rheum Dis* 2004;63:280 (Abstract FR10107)
- w100 Benevolenskaya L et al. Lumiracoxib is effective in relieving symptoms of osteoarthritis of the hip or knee after 4 weeks of treatment: results from a randomised placebo-controlled trial (study 2316). *EULAR* 2003; (Abstract FR10246)
- w101 Ehrlich EW et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib. *J Rheumatol* 1999;26:2438-47
- w102 Treiber G et al. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2006;132:699-708
- w103 Ehrlich EW et al. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. *Am J Manag C* 2001;7:609-16
- w104 Laine L et al. A randomised trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. *Gastroenterology* 1999;117:776-83
- w105 Hawkey C et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. *Arthritis Rheum* 2000;43:370-7
- w106 Hunt RH et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. *Am J Med* 2000;109:201-6
- w107 Schnitzer TJ et al. The safety profile, tolerability and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. *Clinic Therap* 1999;21:1688-702
- w108 Geusens PP et al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. *Scand J Rheumatol* 2002;31:230-8
- w109 Hawkey CJ et al. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. *Gut* 2003;52:820-6
- w110 Nickel JC et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. *J Urology* 2003;169:1401-5
- w111 Katz N et al. Efficacy and safety of rofecoxib in patients with chronic low back pain. *Spine* 2003;28:851-9
- w112 Tikiz C et al. Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary heart disease. *Acta Med Okayama* 2005;59:11-7
- w113 Di Silverio F et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). *Eur Urol* 2005;47:72-9
- w114 Aisen PS et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. *JAMA* 2003;289:2819-26
- w115 Saag K et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. *Arch Fam Med* 2000;9:1124-34
- w116 Day R et al. A randomised trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. *Arch Intern Med* 2000;160:1781-7
- w117 Truitt KE et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. *Aging (Milano)* 2001;13:112-21
- w118 Thal LJ et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. *Neuropsychopharmacol* 2005;30:1204-15
- w119 Murphy G et al. Effects of rofecoxib and ibuprofen on bone mineral density (BMD) and biochemical indices of bone turnover in patients with osteoarthritis. *Ann Rheum Dis* 2003;62(Suppl. 1):Abstract FR10226
- w120 Reines SA et al. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. *Neurology* 2004;62:66-71
- w121 van Adelsburg J et al. One-year results from an active comparator-controlled trial of rofecoxib in patients with rheumatoid arthritis. *Arthritis Rev* 2002;49:336-7(Suppl.)
- w122 Bresalier RS et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *New Engl J Med* 2005;352:1092-102
- w123 Brandes JL et al. Montelukast for migraine prophylaxis: a randomized, double-blind placebo-controlled study. *Headache* 2004;44:581-6
- w124 Reicin A et al. Cardiovascular safety profile of rofecoxib in elderly patients with Alzheimer's disease or cognitive impairment: an updated pooled analysis. *Ann Rheum Dis* 2003;62(Suppl. 1):407
- w125 Laine L et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double blind trial. *Gastroenterology* 2004;127:395-402
- w126 van Adelsburg J et al. The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. *Curr Med Res Opin* 2007; 23:2063-70
- w127 Kerr DJ et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. *New Engl J Med* 2007;357:360-9
- w128 Banovac K et al. Prevention of heterotropic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). *Spinal Cord* 2004;42:707-10
- w129 Bogaty P et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomised placebo-controlled study. *Circulation* 2004;110:9300-39
- w130 Cobelli L et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. *Eur J Obstet Gyn R B* 2004;116:100-2
- w131 Heffler LA et al. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III. A phase II trial. *Eur J Obstet Gyn R B* 2006;125:251-4
- w132 Higuchi T et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. *Clin Canc Res* 2003;9:4756-60
- w133 Karlsson et al. Efficacy, safety and tolerability of the cyclooxygenase-inhibiting nitric oxide donor naproxenol in treating osteoarthritis of the hip or knee. *J Rheumatol* 2009;36:1290-7
- w134 Leung WK et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. *Clin Cancer Res* 2006;12:4766-72
- w135 Merck & Co. Inc. MK-0966 Phase III study - osteoarthritis - (study ID: RC966A301) [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w136 Monakier D et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. *Chest* 2004;125:1610-5
- w137 Pfizer Inc. Double-blind, placebo-controlled, randomized six week comparison study of the efficacy of valdecoxib 20 mg QD and rofecoxib 25 mg QD in relieving the signs and symptoms of osteoarthritis of the knee [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w138 Schnitzer TJ et al. Comparison of the COX-inhibiting nitric oxide donor AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. *Arthritis Rheum* 2005;53:827-37
- w139 Title LM et al. Effect of cyclooxygenase-2 inhibitor with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. *J Am Coll Cardiol* 2003;42:1747-53
- w140 Kuklinska AM et al. Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes. *Rocz Akad Med Białymst* 2005;50:339-42
- w141 Kivitz AJ et al. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1000 mg in patients with osteoarthritis of the knee: A randomized controlled trial. *J Am Geriatr Soc* 2004;52:666-74

Trials shown in supplementary tables 1-6

- w142 Weaver AL et al. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. *J Clin Rheumatol* 2006;12:17-25
- w143 Iwama T et al. Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? *Int J Clin Oncol* 2006;11:133-9
- w144 Pfizer Inc. A randomized, double-blind, placebo-controlled comparison of the analgesic activity of valdecoxib (SC-65872) 40 mg BID as add-on therapy to opioid medication in patients with chronic cancer pain [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w145 Pfizer Inc. A randomized, double-blind, placebo-controlled, parallel group comparison of the analgesic activity of valdecoxib (SC-65872) 20 mg BID versus diclofenac 75 mg BID in patients with chronic cancer pain [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w146 Coats TL et al. Analgesic efficacy of valdecoxib 40 mg QD in the treatment of chronic low back pain. *J Am Osteopath Assoc* 2002;102:445(Abstract C10)
- w147 Coats TL et al. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomised, placebo-controlled trial. *Clin Ther* 2004;26:1249-60
- w148 Pfizer Inc. A 12 week randomized, double-blind, placebo controlled multicenter study of the analgesic efficacy of valdecoxib 20 mg QD and 40 mg QD compared to placebo in patients with chronic low back pain [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w149 Bensen W et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomised, controlled comparison with placebo and naproxen. *Rheumatology* 2002;41:1008-16
- w150 Williams GW et al. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. *Clin Ther* 2006;28:204-21
- w151 Pfizer Inc. Double-blind, placebo-controlled, randomized, dose ranging and pilot efficacy study of SC-65872 (valdecoxib) in treating the signs and symptoms of rheumatoid arthritis [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w152 Pfizer Inc. A dose-ranging study of valdecoxib 5 mg, 10 mg and 20 mg once daily versus placebo in patients with osteoarthritis of the knee (Japan). Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w153 Pfizer Inc. A 12 week randomized, double-blind, placebo controlled multicenter study of the analgesic efficacy of valdecoxib 10 mg QD and 20 mg QD compared to placebo in patients with chronic low back pain [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w154 Fiechter JJ et al. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee. *Ann Rheum Dis* 2001;60(Suppl.1):OP0048
- w155 Sikes DH et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. *Eur J Gastroenterol Hepatol* 2002;14:1101-11
- w156 Kivitz A et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. *J Fam Practice* 2002;51:530-7
- w157 Gibofsky A et al. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12 week, multicenter, randomized, double-blind placebo-controlled study. *Clin Ther* 2007;29:1071-85
- w158 Makarowski W et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomised, double blind, placebo-controlled comparison with naproxen. *Osteoarthr & Cartil* 2002;10:290-6
- w159 Singh G et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 Study. *Am J Med* 2006;119:255-66
- w160 Goldstein JL et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. *Am J Gastroenterol* 2001;96:1019-27
- w161 Sowers JR et al. The effects of cyclooxygenase-2 inhibitors and non-steroidal anti-inflammatory therapy on 24 hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes mellitus. *Arch Intern Med* 2005;165:161-8
- w162 Pfizer Inc. A randomized, multi-center, double-blind, double-dummy study comparing the efficacy and tolerability of once daily Celebrex (celecoxib) and naproxen 500 mg twice daily in the 6-month treatment of subjects with osteoarthritis of the knee [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w163 Silverstein FE et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. *JAMA* 2000;284(10):1247-55
- w164 Sieper J et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. *Ann Rheum Dis* 2008;67:323-9
- w165 Pfizer Inc. A 12-week, randomized, double-blind, parallel-group study of 2 doses of celecoxib compared to diclofenac in patients with ankylosing spondylitis [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w166 Emery P et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. *Lancet* 1999;354:2106-11
- w167 Emery P et al. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery. *Clin Ther* 2008;30:70-83
- w168 Izhaz M et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. *Hypertension* 2004;43:573-7
- w169 Dahlberg LE et al. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. *Scand J Rheumatol* 2009;38:133-43
- w170 Pfizer Inc. A one year, double-blind, parallel group study to compare tolerability of celecoxib 200 mg daily versus diclofenac 50 mg twice daily in elderly patients with osteoarthritis of the hip or knees. [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w171 McKenna F et al. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. *Clin Exp Rheumatol* 2002;20:35-43
- w172 Tascioglu F et al. [Comparison of the efficacy of celecoxib and diclofenac sodium in the treatment of knee osteoarthritis][Turkish]. *Turkiye Fiziksel Tip Ve Rehabilitasyon Dergisi* 2004;50:7-12
- w173 Kivitz AJ et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. *Aliment Pharmacol Ther* 2004;19:1189-98
- w174 Hawkey C et al. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. *J Rheumatol* 2004;31:1804-10
- w175 Jajic Z et al. Gastrointestinal safety of amlotmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2005;23:809-18
- w176 Pfizer Inc. A phase 4, 4 week, multi-center, parallel group, randomized, comparative, open clinical trial to compare anti-arthritis effect and safety of celecoxib 200 mg QD and aceclofenac 100 mg BID for the patients with osteoarthritis of the knee [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w177 Ozgocmen S et al. In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. *Ann Clin Lab Sci* 2005;35:137-43
- w178 Matsumoto A et al. Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. *Curr Med Res Opin* 2007;23:2259-68
- w179 Baraf HS et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. *J Rheumatol* 2007;34:408-20
- w180 Combe B et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomised controlled clinical trial (The MEDAL study). *Rheumatology* 2009;48:425-32
- w181 Krueger K et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). *Ann Rheum Dis* 2008;67:315-22
- w182 Zacher J et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. *Curr Med Res Opin* 2003;19:725-36
- w183 Zerhini C et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in patients with chronic low back pain: results of a 4 week, multinational, randomised, double blind study. *Curr Med Res Opin* 2005;21:2037-49
- w184 Merck & Co. Inc. A multicenter, randomized, parallel-group, 4 week, double-blind and active comparator-controlled study to assess the efficacy, safety and tolerability of MK-0663 tablet 60 mg once daily versus diclofenac sodium 75 mg two times daily in the treatment of Chinese patients with osteoarthritis of the knee or hip (PN 080; NCT00140972) [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w185 Scott G et al. Multiple-dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis. *Proc 6th Congress Eur Assoc Clin Pharmacol & Ther* 2003;124:(Abstract P-197)
- w186 Farkouh ME et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. *Lancet* 2004;364:675-84
- w187 MacDonald TM et al. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. *J Hypertens* 2008;26:1695-702
- w188 Bombardier C et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *New Engl J Med* 2000;343:1520-8
- w189 Lisse JR et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis. *Ann Intern Med* 2003;139:539-46
- w190 Merck & Co. Inc. A multicenter, randomized, parallel-group, 8 week, double-blind and active comparator-controlled study to assess the efficacy, safety and tolerability of rofecoxib tablet 25 mg once daily versus naproxen tablet 500 mg twice daily in the treatment of Chinese patients with rheumatoid arthritis (Protocol number 231) [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w191 van Kooij B et al. The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edema. *Am J Ophthalmol* 2005;140:563-4
- w192 Myllykangas-Luosujärvi R et al. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. *Scand J Rheumatol* 2002;31:337-44
- w193 Ehrlich EW et al. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. *Am J Manag C* 2001;7: 609-16
- w194 Cannon GW et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. *Arthritis Rheum* 2000;43:978-87
- w195 Agrawal N. Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoid arthritis patients. *Arthritis Rheum* 2001; 44(Suppl. 9): 372
- w196 Pfizer Inc. Double-blind, double dummy, randomized comparison study to evaluate the efficacy and safety of valdecoxib 10 mg once daily and naproxen 500 mg twice daily in treating the signs and symptoms of osteoarthritis of the knee [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w197 Pfizer Inc. A double-blind, double dummy, randomized comparison study of the efficacy and safety of valdecoxib 10 mg QD and naproxen 500 mg BID in treating the signs and symptoms of osteoarthritis of the knee or hip in Taiwan [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w198 Pavelka K et al. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. *Rheumatology* 2003;42:1207-15

Trials shown in supplementary tables 1-6

- w199 Pfizer Inc. A multicenter, double-blind, randomized, parallel group comparison study of the efficacy over 6 months of therapy and joint radiographic changes and safety over 12 months of therapy with valdecoxib 10 mg or 20 mg once daily or diclofenac 75 mg SR twice daily in treating the signs and symptoms of osteoarthritis of the knee and/or hip [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w200 Cohick CB. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein. *J Lab Clin Med* 1994;123:721-7
- w201 GSK. A randomized, double-blind, placebo-controlled, endoscopic study to assess the gastroduodenal effects of an investigational formulation of nabumetone, relafen, naproxen sodium, and placebo administered to healthy subjects [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w202 Bellavance AJ et al. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. *Headache* 1990; 30:710-5
- w203 Fleischmann R et al. A double-masked comparison of Naprelan and nabumetone in osteoarthritis of the knee. *Clin Ther* 1997;19:642-55
- w204 Lohmander LS et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. *Ann Rheum Dis* 2005;64:449-56
- w205 Bias P et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licoferone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomised, controlled trial. *Am J Gastro* 2004;99:611-8
- w206 Dore R et al. Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study. *Clin Ther* 1995;17:656-66
- w207 Jeffcoat MK et al. Use of digital radiography to demonstrate the potential of naproxen as an adjunct in the treatment of rapidly progressive periodontitis. *J Periodont Res* 1991;26:415-21
- w208 Johnson RH et al. Assessment of the efficacy of a nonsteroidal anti-inflammatory drug, Naprosyn, in the treatment of gingivitis. *J Periodont Res* 1990; 25:230-5
- w209 Laine L et al. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. *Gastrointest Endosc* 1995;42:428-33
- w210 White W et al. Effects of cyclooxygenase inhibiting nitric oxide donor naproxen versus naproxen on systemic blood pressure in patients with osteoarthritis. *Am J Cardiol* 2009;104:840-5
- w211 Petri M et al. Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder. *Arthritis Rheum* 1987;30:1040-5
- w212 Averbuch M et al. Assessment of visual analog versus categorical scale for measurement of osteoarthritis pain. *J Clin Pharmacol* 2004;44:368-72
- w213 Goldenberg DL et al. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. *Arthritis Rheum* 1986;29:1371-7
- w214 Blechman W et al. Naproxen in osteoarthritis. Double-blind crossover trial. *Ann Rheum Dis* 1978;37:80-4
- w215 Gebuhr P et al. Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients. *Acta Orthop Scand* 1991;62:226-9
- w216 Mehta S et al. A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis. *Am J Gastroenterol* 1992;87:996-1000
- w217 Vielpeau C et al. Naproxen in the prevention of heterotopic ossification after total hip replacement. *Clin Orthop Related Res* 1999;369:279-88
- w218 Caruso I et al. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. *Am J Med* 1987;83(5A):66-71
- w219 Klassen DK et al. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. *Am J Hypertens* 1995;8:146-53
- w220 Soffer EE et al. Morphology and pathology of radiation-induced esophagitis. Double-blind study of naproxen vs placebo for prevention of radiation injury. *Dig Dis Sci* 1994;39:655-9
- w221 Blom MW et al. The effects of an estradiol transdermal therapeutic system, alone and in combination with naproxen, on urge incontinence in elderly women: a pilot study. *Curr Ther Res Clin E* 1995;56:1100-4
- w222 Lopez Sanchez J & Yanez Marchena G. Meclofenamate sodium, phenylbutazone, and naproxen in the treatment of degenerative joint disease. Report of a placebo-controlled double-blind clinical comparison. *Arzneimittel-Forschung* 1983;33(4A):653-6
- w223 Lindegaard KF et al. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. *Headache* 1980;20:96-8
- w224 Wahlstrom O et al. Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties. *Acta Orthop Scand* 1991;62:419-21
- w225 Bakshi R et al. Efficacy and tolerability of diclofenac dispersible in elderly patients with osteoarthritis. *Curr Med Res Opin* 1991; 12:459-65
- w226 Bocanegra T et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. *Arthrosc Osteoarthritis Study Group. J Rheumatol* 1998;25:1602-11
- w227 Furst DE et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis. *J Rheumatol* 2002;29:436-46
- w228 Germain BF. A placebo-controlled study of diclofenac sodium for the treatment of osteoarthritis of the hip and knee. *Curr Ther Res Clin E* 1985;37:259
- w229 Labelle H et al. Efficacy of diclofenac in lateral epicondylitis of the elbow also treated with immobilization. The University of Montreal Orthopaedic Research Group. *Arch Fam Med* 1997; 6:257-62
- w230 Reis HJ et al. The suppression of heterotopic ossification after total hip arthroplasty. *Int Orthop* 1992;16:140-5
- w231 Schmitt W et al. Clinical trial on the efficacy and safety of different diclofenac formulations: Multiple-unit formulations compared to enteric coated tablets in patients with activated osteoarthritis. *Inflammopharmacology* 1999; 7:363-75
- w232 Weisman MH. Double-blind randomized trial of diclofenac sodium versus placebo in patients with rheumatoid arthritis. *Clin Ther* 1986;8:427-38
- w233 Case JP et al. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. *Arch Intern Med* 2003;163:169-78
- w234 Biegert C et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. *J Rheumatol* 2004; 31: 2121-4.
- w235 Buckland-Wright JC et al. Quantitative microfocus radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy. *J Rheumatol* 1995;22:937-43
- w236 Esselincx W et al. Double-blind comparative study of tenoxicam in arthrosis of the knee and hip. *Curr Ther Res Clin E* 1990;48:206
- w237 Laurent J et al. Diclofenac, a non-steroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study. *Am J Nephrol* 1987;7:198-202
- w238 Sandelin J et al. Local NSAID gel (Eltenc) in the treatment of osteoarthritis of the knee: A double blind study comparing eltenac with oral diclofenac and placebo gel. *Scand J Rheumatol* 1997; 26:287-92
- w239 Yocum D et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. *Arch Intern Med* 2000;160:2947-54
- w240 Dieppe P et al. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. *Brit J Rheumatol* 1993;32:595-600
- w241 Kirchheiner B et al. Diclophenax sodium (Voltaren) in rheumatoid arthritis: a double-blind comparison with indomethacin and placebo. *Int J Clin Pharm Biopharm* 1976;13:292-7
- w242 Sangdee C et al. Electroacupuncture versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. *BMC Compl Alternat Med* 2002; 2:3
- w243 Kravitz HM et al. Alprazolam and ibuprofen in the treatment of fibromyalgia - Report of a double-blind placebo-controlled study. *J Musculoskelet Pain* 1994;2:3-27
- w244 Wong RC et al. Oral ibuprofen and tetracycline for the treatment of acne vulgaris. *J Am Acad Dermatol* 1984;11:1076-81
- w245 Davies GM et al. Comparison of the responsiveness and relative effect size of the western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients. *Arthritis Care Res* 1999;12:172-9
- w246 Singer E et al. A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. *J Orofac Pain* 1997;11:139-46
- w247 Giansiracusa JE et al. Ibuprofen in osteoarthritis. *Southern Med J* 1977;70:49-52
- w248 Gurwitz JH et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. *J Gerontology Series A-Biological Sci Med Sci*;51:M74-9
- w249 Marks JW et al. Effects of ursodiol or ibuprofen on contraction of gallbladder and bile among obese patients during weight loss. *Dig Dis Sci* 1996;41:242-9
- w250 Haghghi M. Comparing the effects of ginger (Zingiber officinale) extract and ibuprofen on patients with osteoarthritis. *Arch Iran Med* 2005;8:267-71
- w251 McMillan DC et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. *Brit J Cancer* 1999;79:495-500
- w252 Chow HHS et al. Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. *Cancer Epidem Biomar* 2000;9:351-6
- w253 Hunter JA et al. Aceclofenac in rheumatoid arthritis: a useful and novel anti-inflammatory. *Clin Rheumatol* 1996;15:329-34
- w254 Haslock I. The effect of alclofenac on clinical and laboratory measures of disease activity in rheumatoid arthritis: preliminary results. *Curr Med Res Opin* 1975;3:298-308
- w255 Kragballe K et al. Benoxaprofen improves psoriasis. A double-blind study. *Arch Dermatol* 1983;119:548-52
- w256 Williams P et al. A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis. *Curr Med Res Opin* 1983;8:90-8(Suppl.)
- w257 Ridolfo AS et al. A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus aspirin in patients with rheumatoid arthritis. *Eur J Rheumatol Infl* 1982;5:239-44
- w258 Lee P et al. The efficacy of diflunisal in osteoarthritis of the knee. A Canadian Multicenter Study. *J Rheumatol* 1985;12:544-8
- w259 Schnitzer TJ et al. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. *Clin Ther* 1995;17:602-12
- w260 Vetter G et al. Comparative efficacy of etodolac and placebo in rheumatoid arthritis patients. *Int J Clin Pharm Ther Toxic* 1982;20:240-5
- w261 Williams PI et al. Etodolac therapy for osteoarthritis: a double-blind, placebo-controlled trial. *Curr Med Res Opin* 1989;11:463-70
- w262 Andelman SY. Etodolac, aspirin, and placebo in patients with degenerative joint disease: a twelve-week study. *Clin Ther* 1983; 5:651-61
- w263 Edwards W. Etodolac, aspirin, and placebo in patients with rheumatoid arthritis: a 12-week study. *Clin Ther* 1983;5:495-503
- w264 Jacob G et al. Minimum effective dose of etodolac for the treatment of rheumatoid arthritis. *J Clin Pharmacol* 1986; 26:195-202
- w265 del Toro RA et al. Twelve-week study of etodolac, aspirin, and placebo in patients with rheumatoid arthritis. *Clin Ther* 1983;5:436-44
- w266 Diamond S et al. Fenoprofen in the prophylaxis of migraine: a double-blind, placebo controlled study. *Headache* 1987;27:246-9
- w267 Duff IF et al. Fenoprofen in patients with rheumatoid arthritis receiving maintenance gold therapy. *J Rheumatol* 1976;3:32-7(Suppl. 2)
- w268 Blechman WJ et al. Fenoprofen calcium in steroid treated rheumatoid arthritis: efficacy, safety, and steroid-sparing effect. *J Rheumatol* 1976;2:38-42
- w269 Mainland D et al. A three-month trial of indomethacin in rheumatoid arthritis, with special reference to analysis and inference. *Clin Pharmacol Therap* 1967;8:11-37
- w270 Allan R et al. Biarsion in the treatment of degenerative joint diseases: comparison with indomethacin and placebo. *J Int Med Res* 1977; 5:253-64
- w271 Jajic I et al. Pirprofene, indometacine et placebo dans la spondylarthrite ankylosante: comparaison en double insu. [French] *Nouvelle Presse Medicale* 1982;11:2491-3

Trials shown in supplementary tables 1-6

- w272 Rogers J et al. Clinical trial of indomethacin in Alzheimer's disease. *Neurology* 1993; 43:1609-11
- w273 Secchi A et al. Prednisone administration in recent onset type I diabetes. *J Autoimmun* 1990;3:593-600
- w274 Warrington SJ et al. Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men. *Postgrad Med J* 1990;66:622-6
- w275 de Jong D et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. *PLoS ONE [Electronic Resource]* 2008;3(1):e1475
- w276 Lundholm K et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. *Cancer Res* 1994;54:5602-6
- w277 Bahrami H et al. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial. *Am J Gastroenterol* 2005; 100:856-61
- w278 Buchmann E. Mefenamic acid compared with indomethacin and placebo in osteoarthritis. *Ann Physic Med* 1966;19-25(Suppl.)
- w279 Karunakar MA et al. Indometacin as prophylaxis for heterotopic ossification after the operative treatment of fractures of the acetabulum. *J Bone Joint Surg Br* 2006; 88:1613-7
- w280 Miller RL et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. *Cancer Res* 1989;49:1871-6
- w281 Puddey IB et al. Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects. *Clin Sci* 1985;69:327-36
- w282 Scott DL et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. *Rheumatology* 2000;9:1095-101
- w283 Wright V et al. Indomethacin in the treatment of rheumatoid arthritis. A controlled trial comparing indomethacin, phenylbutazone, and placebo. *Ann Rheum Dis* 1969;28:157-62
- w284 Reese RW. Long-term studies of isoxicam in the treatment of rheumatoid arthritis. *Am J Med* 1985; 79(4B):12-6
- w285 Posner SL. Six-week, double-blind, placebo-controlled and long-term, open-label multicenter study of isoxicam in treatment of degenerative joint disease. *Am J Med* 1985;79(4B):17-23
- w286 Hoe-Hansen C et al. The clinical effect of ketoprofen after arthroscopic subacromial decompression: a randomized double-blind prospective study. *Arthroscopy* 1999;15:249-52
- w287 Stensrud P et al. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 R.P.) in migraine prophylaxis. *Headache* 1974;14:96-100
- w288 Berry H et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. *Ann Rheum Dis* 1992;51:238-42
- w289 Mahafzah M et al. Radio-protective effect of sodium meclofenamate. A prospective clinical trial. *J Med* 1989;20:261-72
- w290 Petrick TJ et al. Multicenter studies in the United States and Canada of meclofenamate sodium in osteoarthritis of the hip and knee. Double-blind comparison with placebo and long-term experience. *Arzneimittel-Forschung* 1983;33(4A):644-8
- w291 Petrick TJ et al. Double-blind multicenter studies with meclofenamate sodium in the treatment of rheumatoid arthritis in the United States and Canada. *Arzneimittel-Forschung* 1983; 33(4A):631-5
- w292 Willkens RF et al. Sodium meclofenamate (Meclomen) in the treatment of rheumatoid arthritis: a double-blind comparison with aspirin and placebo. *Pharmatherapeutica* 1981;2:587-96
- w293 Ellis CN et al. Effects of oral meclofenamate therapy in psoriasis. *J Am Acad Dermatol* 1986;14:49-52
- w294 Dougados M et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. *Rheumatology* 1999; 38:235-44
- w295 Altman R et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the non-steroidal anti-inflammatory drugs in unstable angina treatment-2(NUT-2) pilot study. *Circulation* 2002;106:191-5
- w296 Lipscomb GR et al. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. *Brit J Clin Pharmacol* 1998;46:133-7
- w297 Santucci L et al. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with *Helicobacter pylori* infection and high levels of serum pepsinogens. *Dig Dis Sci* 1995;40:2074-80
- w298 Schnitzer TJ et al. Effect of nabumetone on hemostasis during arthroscopic knee surgery. *Clin Ther* 1998;20:110-24
- w299 Agrawal NM et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 & nabumetone in osteoarthritis patients at high risk for developing non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers. *Clin Ther* 1999; 21:659-74
- w300 Makarowski W et al. The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. *Clin Ther* 1996;18:114-24
- w301 Pardo A et al. A placebo-controlled study of interaction between nabumetone and acenocoumarol. *Brit J Clin Pharmacol* 1999; 47:441-4
- w302 Weaver A et al. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. *Clin Ther* 1995;17:735-45
- w303 Blechman WJ. Nabumetone therapy of osteoarthritis. A six-week, placebo-controlled study. *Am J Med* 1987;83(4B):70-3
- w304 Sarzi-Puttini P et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. *Clin Exp Rheumatol* 2001;19:20(Suppl.)
- w305 Aisen PS et al. Randomized pilot study of nimesulide treatment in Alzheimer's disease. *Neurology* 2002;58:1050-4
- w306 Astrom M et al. No effect of piroxicam on achilles tendinopathy. A randomized study of 70 patients. *Acta Orthop Scand* 1992;63:631-4
- w307 Fox PC et al. Prednisone and piroxicam for treatment of primary Sjogren's syndrome. *Clin Exp Rheumatol* 1993;11:149-56
- w308 Manna V. Effects of piroxicam-beta-cyclodextrin in the treatment of spontaneous migraine attacks and reserpine-induced headache: Putative serotonergic involvement in antinociceptive drug activity. *Adv Ther* 1998;15:75-84
- w309 van den Bergh LJ et al. Double-blind clinical study of piroxicam as adjuvant in the treatment of the pain and dysfunction of the temporomandibular joints. *Cranio* 1986;4:351-6
- w310 Baez MA et al. Effects of the non-steroidal anti-inflammatory drugs, piroxicam or sulindac, on the anti-hypertensive actions of propranolol and verapamil. *J Hypertens* 1987;5:563-6 (Suppl.)
- w311 Sigidin Y et al. A new non-steroidal anti-inflammatory agent pirofen (regenasil) in the treatment of rheumatoid arthritis and osteoarthritis 1987. *Ter Arkh*;59:73-6
- w312 CALaluce R et al. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial. *Cancer Epidemiol Biomar* 2000;9:1287-92
- w313 Giardiello FM et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *New Engl J Med* 1993;328:1313-6
- w314 Ladenheim J et al. Effect of sulindac on sporadic colonic polyps. *Gastroenterology* 1995;108:1083-7
- w315 Rijken FE et al. Sulindac treatment in hereditary non-polyposis colorectal cancer. *Eur J Cancer* 2007;43:1251-6
- w316 Keller JJ et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. *Gut* 1999;45:822-8
- w317 Labayle D et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. *Gastroenterology* 1991;101:635-9
- w318 Hattori Y et al. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. *Curr Med Res Opin* 2007;23:1913-7
- w319 Giardiello FM et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. *New Engl J Med* 2002;346:1054-9
- w320 Bursens A et al. Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. *Acta Orthopaedica Belgica* 1995;61:205-11
- w321 Quijada-Carrera J et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *Pain* 1996;65:221-5
- w322 Zarski JP et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. *Hepatology* 1998;27:862-7
- w323 Smith MD et al. The effect of tiaprofenic acid on blood pressure control in treated hypertensive patients. *Curr Med Res Opin* 1985;9:388-93
- w324 Mikkelsen BM et al. Prophylactic treatment of migraine with tolfenamic acid. A comparative double-blind crossover study between tolfenamic acid and placebo. *Acta Neurol Scand* 1982;66:105-11
- w325 Mikkelsen B et al. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. *Acta Neurol Scand* 1986;73:423-7
- w326 Kolodny AL. Two double-blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. *J Rheumatol* 1988;15:1205-11
- w327 Roth SH et al. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. *Clin Drug Invest* 1995;9:171-9
- w328 Vetter G. A comparison of naproxen and diclofenac sodium in the treatment of osteoarthritis in elderly patients. *Brit J Clin Pract* 1985;39:276-81
- w329 Scharf Y et al. A comparative study of naproxen with diclofenac sodium in osteoarthritis of the knees. *Rheumatol Rehabil* 1982; 21:167-70
- w330 Lister BJ et al. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. *Am J Med* 1993;95(2A):2-9(Suppl.)
- w331 Tannenbaum H et al. A double-blind, multicenter, controlled study on diclofenac (voltaren) and naproxen in patients with rheumatoid arthritis (RA). *Curr Ther Res* 1984;35:357-62
- w332 Siegmeth W et al. Langzeitvergleichsstudie: diclofenac (Voltaren) und naproxen (Proxen) bei arthrosen. [German] *Schweiz Med Wschr* 1978; 108:349-53
- w333 Tsavaris N et al. A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. *J Int Med* 1990; 228:451-5
- w334 Frizziero L et al. Ibuprofen granulare nell'artrite reumatoide: Confronto di efficacia e tollerabilita con naproxen [Italian]. *Clin Terap* 1986;117:493-7
- w335 Leuschen MP et al. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects. *Mult Scler* 2004; 22:1941-6
- w336 Klassen D et al. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. *J Clin Pharmacol* 1993;33:971-8
- w337 Dungal H et al. Tenoxicam versus naproxen: A randomized double-blind study in osteoarthritis. *Curr Ther Res Clin E* 1991;50:84-92
- w338 Komassoff D et al. Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. *Clin Rheumatol* 1997; 16:32-8
- w339 Pasero G et al. Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: A double-blind, controlled study. *Curr Ther Res Clin E* 1994;55:833-42
- w340 Omdal R. Naprosyn (naproxen) versus Donobid (diflunisal) i behandling av cox-og gonartrose. [Norwegian] *Tidsskrift for Den Norske Laegeforening* 1983;103:1066-9
- w341 Jennings MB et al. A controlled comparison of etodolac and naproxen in osteoarthritis of the foot. *Lower Extremity* 1997;4:43-8
- w342 Palferman TG et al. Double-blind, parallel comparison of etodolac and naproxen in patients with osteoarthritis of the knee. *Acta Therap* 1991;17:19-34
- w343 Pena M et al. Double-blind comparison of etodolac and naproxen in patients with osteoarthritis. *Acta Therap* 1991;17:5-18
- w344 Taha AS et al. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. *Brit J Rheumatol* 1989;28:329-32
- w345 Platt PN. Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee. *Clin Rheumatol* 1989; 8:62(Suppl.)
- w346 Bianchi Porro G et al. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. *J Intern Med* 1991;229:5-8
- w347 de Queiros MF. Double-blind comparison of etodolac and naproxen in the treatment of rheumatoid arthritis. *Clin Ther* 1991;13:38-46

Trials shown in supplementary tables 1-6

- w348 Waltham-Weeks et al. Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. *Curr Med Res Opin* 1987;10:540-7
- w349 Briancon D. International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy. *Clin Rheumatol* 1989;8:72(Suppl.)
- w350 Frankhof W. Controlled-release naproxen compared with isoxicam in patients with osteoarthritis. *Curr Med Res Opin* 1988;11:28-33
- w351 Cardoe N et al. Double-blind multicentre UK hospital studies of isoxicam vs naproxen. *Brit J Clin Pharmacol* 1986;22:167-72(Suppl.)
- w352 Bias P et al. Licofelone - an inhibitor of 5-LOX, COX-1 and COX-2 has superior GI tolerability in OA patients compared with naproxen, regardless of low-dose aspirin co-medication, previous ulcer history or H pylori status. *Arthritis Rheum* 2003;48(9):72(Suppl.)(Abstract 67)
- w353 Bias P et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomised, controlled trial. *Am J Gastroenterol* 2004;99:611-8
- w354 Bias P et al. Licofelone a 5-LOX, COX-1 and COX-2 inhibitor is as effective as naproxen and has improved GI tolerability in patients with osteoarthritis. *Arthritis Rheum* 2003;48(9):72(Suppl.)(Abstract 68)
- w355 Emery P et al. Nabumetone compared with naproxen in the treatment of rheumatoid arthritis: a multicenter, double blind, randomized, parallel group trial in hospital outpatients. *J Rheumatol* 1992;19:41-7(Suppl.)
- w356 Hazleman BL et al. Single-blind comparative study of nabumetone (Relafen) versus naproxen in the treatment of rheumatoid arthritis. *Am J Med* 1987;83(4B):60-4
- w357 Krug H et al. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis. *Clin Ther* 2000;22:40-52
- w358 Bianchi Porro G et al. Gastrointestinal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. *Am J Gastroenterol* 1995;90:1485-8
- w359 Cha HS et al. Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee. *Int J Clin Pharmacol Ther* 2001;39:539-45
- w360 Young D et al. Effects of naproxen and nabumetone on serum cholesterol levels in patients with osteoarthritis. *Clin Ther* 1995;17:231-40
- w361 Quattrini A et al. A double-blind study comparing nimesulide with naproxen in the treatment of osteoarthritis of the hip. *Clin Drug Invest* 1995;10:139-46
- w362 Myklebust G. Naproxen sammenlignet med piroxicam ved reumatoid artritt og bechterews syndrom [Norwegian]. *Tidsskrift for Den Norske Laegeforening* 1986;106:1485-7
- w363 Consofi G et al. Piroxicam compresse sublinguali a rapida dissoluzione versus naprossene nel trattamento dell'osteoartrosi riacutizzata [Italian]. *Minerva Medica* 1994;85:89-96
- w364 Huskisson EC et al. Naproxen and piroxicam. A comparative trial in rheumatoid arthritis. *Eur J Rheumatol Infl* 1983;6:242-6
- w365 Jennings MB. Comparison of piroxicam and naproxen in osteoarthritis of the foot. *J Am Podiat Med Assn* 1994;84:348-54
- w366 Fenton S et al. A double-blind, crossover, multicenter study of piroxicam and naproxen in rheumatoid arthritis. *Curr Ther Res Clin E* 1988;44:1058
- w367 Montrone F et al. A comparison of severe gastric damage as a result of pirofen and naproxen treatment in rheumatoid arthritis: a controlled endoscopic study. *J Int Med* 1994;236:153-9
- w368 Boussina I et al. Efficacy and tolerance of naproxen versus pirofen in the treatment of patients with osteoarthritis. *Pharmatherapeutica* 1987;5:16-20
- w369 McMahon FG et al. Does sulindac attenuate pressure control among hypertensives? *Curr Ther Res Clin E* 1989;45:143-51
- w370 Duke O et al. Anti-inflammatory drugs in periarthritits of the shoulder: a double-blind, between-patient study of naproxen versus indomethacin. *Rheumatol Rehabil* 1981;20:54-9
- w371 Atkinson MH et al. Crossover comparison of benoxaprofen and naproxen in rheumatoid arthritis. *J Rheumatol* 1980;6:109-15 (Suppl.)
- w372 Baumgartner H et al. Diflunisal im vergleich mit naproxen bei chronischer polyarthritits. [German] *Schweizerische Medizinische Wochenschrift* 1982;112:281-5
- w373 Osbom TG et al. Diflunisal versus naproxen in the management of rheumatoid arthritis. *Clin Ther* 1989;11:736-43
- w374 Khan FM. A six-month parallel group comparison of fenbufen and naproxen in the treatment of rheumatoid arthritis. *Clin Ther* 1983;5:483-7
- w375 Crone M et al. Ergebnisse einer einfachen offenen sowie einer kontrollierten vergleichsstudie mit feprazon und naproxen bei polyarthritits und osteoarthrose patienten. [German] *Wiener Medizinische Wochenschrift* 1981;131:597-601
- w376 Rhind V et al. Naproxen and indomethacin in periarthritits of the shoulder. *Rheumatol Rehabil* 1982;21:51-3
- w377 Martinez-Lavin M et al. A comparison of naproxen, indomethacin and aspirin in osteoarthritis. *J Rheumatol* 1980;7:711-6
- w378 Brighton SW et al. Comparison of isoxicam and naproxen in patients with rheumatoid arthritis. A 4-week parallel group, double-blind study. *South Afr Med J* 1985;4:232-4
- w379 Schom D. A comparative study of isoxicam and naproxen in rheumatoid arthritis. *South Afr Med J* 1985;12:452-4
- w380 Wojtulewski JA et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. *Brit J Rheumatol* 1996;35(Suppl.1):22-8
- w381 Greb WH et al. Endoscopic studies of nabumetone in patients with rheumatoid arthritis. A comparative endoscopic and histologic evaluation. *Am J Med* 1987;83(4B):19-24
- w382 Richards AM et al. Nabumetone, a new non-steroidal anti-inflammatory drug: a comparison with naproxen. *New Zeal Med J* 1983;96:1015-6
- w383 Krieger W et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. *Int J Clin Pract* 2001;8:510-4
- w384 Ginsberg F et al. A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis. *Curr Med Res Opin* 1984;8:689-95
- w385 Ansell BM et al. A comparative study of Butacote and Naprosyn in ankylosing spondylitis. *Ann Rheum Dis* 1978;37:436-9
- w386 Alho A et al. Piroxicam and naproxen in patients with osteoarthritis of the hip waiting for total hip replacement. *Clin Rheumatol* 1988;7:208-13
- w387 Husby G et al. A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. *Clin Rheumatol* 1986;5:84-91
- w388 Melo Gomes JA et al. Double-blind comparison of efficacy and gastrointestinal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. *Ann Rheum Dis* 1993;52:881-5
- w389 Lyanage SP et al. Naproxen and sulindac in the treatment of osteoarthritis of the hip and knee. *Rheumatol Rehabil* 1981;20:184-7
- w390 Ardia A et al. Comparative studies with tofenamic acid in rheumatic disorders. *Pharmacol Toxicol* 1994;75:71(Suppl.)
- w391 Blechman WJ et al. Crossover comparison of benoxaprofen and naproxen in osteoarthritis. *J Rheumatol* 1980;6:116-24 (Suppl.)
- w392 Borkje B et al. Diflunisal eller naproxen ved artrose. [Norwegian] *Tidsskrift for Den Norske Laegeforening* 1982;102:1077-9
- w393 Brooks PM et al. Naproxen and diflunisal in osteoarthritis. *Rheum Rehab* 1982;21:95-7
- w394 Grayson MF. Two trials of diflunisal in osteoarthritis. *Curr Med Res Opin* 1978;5:567-71
- w395 Schom D. Diflunisal in rheumatoid arthritis. A controlled trial. *South Afr Med J* 1981;24:936-7
- w396 Wojtulewski JA et al. Diflunisal compared with naproxen in the treatment of osteoarthritis of hip or knee: a double-blind trial. *Curr Med Res Opin* 1978;5:562-6
- w397 D'omezon Y. Etudes des cliniciens francais sur l'action du naproxene dans la PCE [French]. *Scand J Rheumatol* 1973;164-70 (Suppl.2)
- w398 Kogstad O. A double-blind cross-over study of naproxen and indomethacin in patients with rheumatoid arthritis. *Scand J Rheumatol* 1973;63(Suppl.)
- w399 Castles JJ et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. *Arch Intern Med* 1978;138:362-6
- w400 Cochrane GM et al. A double-blind comparison of naproxen with indomethacin in osteoarthritis. *Scand J Rheumatol* 1973(Suppl.12):89-93
- w401 Davis P et al. Multicenter comparative study of tiaprofenic acid in the treatment of patients with rheumatic diseases. *Curr Ther Res Clin E* 1987;42:916
- w402 Grace EM et al. Clinical therapeutic trial of sodium meclofenamate and naproxen in rheumatoid arthritis, with comments on the use of placebos in clinical trials. *Curr Med Res Opin* 1983;8:417-24
- w403 Brobyn R et al. Nabumetone in the treatment of active adult rheumatoid arthritis. *Am J Med* 1987;83(4B):50-4
- w404 Pisko EJ et al. Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis. *Am J Med* 1987;83(4B):86-91
- w405 Pisko et al. A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis. *Pharmatherapeutica* 1987;5:90-98
- w406 Pooley JE. Nabumetone versus naproxen in the treatment of osteoarthritis. A six-month trial. *Am J Med* 1987;83(4B):82-5
- w407 Roth SH. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. *Am J Med* 1987;83(4B):25-30
- w408 Vasey FB et al. Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. Nabumetone versus naproxen double-blind parallel study. *Am J Med* 1989;83(4B):55-9
- w409 Fossaluzza V et al. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. *J Int Med Res* 1989;17:295-303
- w410 Million R. Butacote and naproxen: a comparison of effectiveness in rheumatoid arthritis. *J Int Med Res* 1977;5:Suppl. 80
- w411 Van Gerwen F et al. Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis. *Ann Rheum Dis* 1978;37:85-8
- w412 Sekker W et al. Klinische prufung von pirofen und naproxen bei patienten mit gon-und coxarthrosen [German]. *Fortschritte Der Medizin* 1985;103(Spec:No 7A):182-4
- w413 Hybbinette CH. Piroxicam and naproxen in the treatment of osteoarthritis. *Brit J Clin Pract* 1981;35:30-4
- w414 Mbuyi-Muamba JM et al. Piroxicam versus naproxen in rheumatoid arthritis. *Curr Med Res Opin* 1983;8:612-7
- w415 Kogstad O. Double blind crossover trial of piroxicam and naproxen in the treatment of osteoarthritis of hip and knee. *Brit J Clin Pract* 1981;35:45-50
- w416 Bragstad A et al. A comparative, double-blind trial with proquazone and naproxen in the treatment of rheumatoid arthritis. *Scand J Rheumatol* 1978;21:33-5(Suppl.)
- w417 Vainio JT et al. A long-term comparison of proquazone and naproxen in the treatment of osteoarthritis of the hip. *Scand J Rheumatol* 1978;21:25-7(Suppl.)
- w418 Janke PG et al. A multi-centre study of sulindac versus naproxen in the treatment of elderly osteoarthritic patients. *Pharmatherapeutica* 1984;3:663-7
- w419 Pathy MS. Osteoarthritis and non-steroidal and anti-inflammatory drugs: a multi-centre comparative study. *Curr Med Res Opin* 1982;7(Suppl.1):1-52
- w420 Nived O et al. A comparison of 6 months' compliance of patients with rheumatoid arthritis treated with tenoxicam and naproxen. Use of patient computer data to assess response to treatment. *J Rheumatol* 1994;21:1537-41
- w421 Telhag H et al. A double-blind comparative evaluation of tolmetin versus naproxen in osteoarthritis. *Curr Med Res Opin* 1981;7:392-400
- w422 Raynauld JP et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. *Ann Rheum Dis* 2009;68:938-47
- w423 Crook PR et al. A study of the efficacy and tolerability of diclofenac and ibuprofen in osteoarthritis of the hip. *Brit J Clin Pract* 1981;35:309-12
- w424 Kiff PS et al. Arthrotec, diclofenac and ibuprofen in general practice. *Eur J Rheum Infl* 1994;14:8(Suppl.)
- w425 Koopmans PP et al. The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. *Eur J Clin Pharmacol* 1987;31:553-7
- w426 Prabhu VV. A comparative clinical trial evaluating efficacy and safety of fixed dose combination of nimesulide and racemethionine versus reference drug (nimesulide) and other NSAIDs in treatment of osteoarthritis. *J Ind Med Assoc* 2008;106:402-4
- w427 Diaz C et al. Comparison of aceclofenac and diclofenac in osteoarthritic pain. *Curr Ther Res Clin E* 1988;44:252-6
- w428 Pareek A et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: A randomized double-blind comparative clinical trial versus diclofenac - An Indian experience. *Curr Med Res Opin* 2006;22:977-88

Trials shown in supplementary tables 1-6

- w429 Pasero G et al. A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. *Curr Med Res Opin* 1995;13:305-15
- w430 Ward DE et al. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. *Clin Rheumatol* 1995;14:656-62
- w431 Ximenes AC et al. Estudo comparativo randomizado da eficacia e tolerabilidade de aceclofenaco versus diclofenaco no tratamento da osteoartrite. Trabalho multicentrico no Brasil. [Portuguese] *Revista Brasileira de Medicina* 1997;54:351-7
- w432 Tavella A et al. Studio clinico sull'attivita' antiinfiammatoria e sulla tollerabilita' gastro-enterica di amtolmetineguacil, un nuovo FANS, in confronto a diclofenac su pazienti anziani con patologie osteoarticolari. [Italian] *Clinica Terapeutica* 1997;148:543-8
- w433 Corts G Jr et al. Double-blind, randomized and parallel comparison between droxicam and diclofenac sodium in patients with coxarthrosis and gonarthrosis. *Eur J Rheum Infl* 1991;11:29-34
- w434 Grisanti AM et al. Comparison of etodolac and diclofenac in osteoarthritis of the knee. *Clin Ther* 1992;14:791-800
- w435 Eisenkolb T et al. Double-blind, parallel-group evaluation of the safety and efficacy of etodolac compared with diclofenac in patients with osteoarthritis of the knee. *Acta Ther* 1993;19:137-50
- w436 Lonauer G et al. Double-blind comparison of etodolac and diclofenac in patients with rheumatoid arthritis. *Curr Med Res Opin* 1993;13:70-7
- w437 Burdeiny AP et al. [Double-blind trial of the therapeutic efficacy of voltaren and indomethacin in Bechterew's disease][Russian]. *Terapevticheskii Arkhiv* 1981;53:107-11
- w438 Kennedy AC et al. A double-blind comparison of the efficacy and safety of ketoprofen extended-release (200 mg once daily) and diclofenac (75 mg twice daily) for treatment of osteoarthritis. *Curr Ther Res Clin E* 1994; 55:119-32
- w439 Kidd B et al. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. *J Rheumatol* 1996; 23:1605-11
- w440 Lederman R et al. Eficacia clinica e seguranga do loxoprofeno sodico (Loxonin) no tratamento da gonartrose. [Portuguese] *Revista Brasileira De Medicina* 2001;58:263-71
- w441 Huskisson EC et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: An active controlled equivalence study. *Curr Ther Res Clin E* 1999;60:253-65
- w442 Porto A et al. Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritis patients. *Eur J Rheumatol Infl* 1994;14:33-8
- w443 Porto A et al. Gastrointestinal tolerability of nimesulide and diclofenac in patients with osteoarthritis. *Curr Ther Res Clin E* 1998;59:654-65
- w444 Zgradie I. Comparison of therapeutic efficacy of nimesulide and diclofenac in patients with degenerative joint diseases. *Journal of Indian Medical Association* 1999;97:119-23
- w445 Karbowski A et al. Therapie der rheumatoiden arthritis mit nichtsteroidalen antiphlogistika: oxaprozin versus diclofenac. [German] *Aktuelle Rheumatologie* 1998;23:11-5
- w446 Große-Kielisch C et al. Therapie der chronischen polyarthritis: doppelblindstudie mit proglumetacin im vergleich zu diclofenac. [German] *Munchener Medizinische Wochenschrift* 1983;125:1105-6
- w447 Nahir AM et al. A comparative study of diclofenac and sulindac in ankylosing spondylitis. *Rheumatol Rehabil* 1980;19:189-98
- w448 Baumgartner H. Vergleich von sulindac und diclofenac bei der behandlung von arthrosen. [German] *Schweizerische Rundschau Fur Medizin Praxis* 1979;68:916-22
- w449 Bellamy N et al. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. *J Rheumatol* 1993; 20:999-1004
- w450 Khan MA. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. *J Rheumatol* 1987;14:118-23
- w451 Brasseur JP et al. Double-blind parallel comparison of etodolac and diclofenac S.R. in patients with osteoarthritis of the knee. *Acta Ther* 1991;17:345-54
- w452 Khan FM et al. Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee. *Curr Med Res Opin* 1992;13:1-12
- w453 Porzio F & Schattenkirchner M. Double-blind comparison of etodolac sustained-release tablets and diclofenac sustained-release tablets in patients with rheumatoid arthritis. *Curr Ther Res Clin E* 1993;53:144
- w454 Liang TH et al. Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. *Curr Med Res Opin* 2003;19:336-41
- w455 Sasdelli M et al. Il diclofenac sodico nella terapia delle glomerulonefriti croniche idiopatiche. [Italian] *Clin Terap* 1980; 93: 401-16
- w456 Gostick N et al. Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of osteoarthritis: a comparative controlled clinical trial in general practice. *Curr Med Res Opin* 1990;12:135-42
- w457 Crowley B et al. Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid arthritis: a comparative controlled clinical trial. *Curr Med Res Opin* 1990;12:143-50
- w458 Janssen M et al. A double-blind parallel group comparative study of lonazolac-calcium and diclofenac in patients with rheumatoid arthritis. *Clin Rheumatol* 1988; 7:545-7
- w459 Stewart I et al. Mefenamic acid compared with diclofenac sodium in elderly patients with osteoarthritis. *Brit J Clin Pract* 1988; 42:316-20
- w460 Patel BR. A comparative study of subsyde-CR versus meloxicam in rheumatic disorders. *J Indian Med Assoc* 2000; 98:250-2
- w461 Goei The HS et al. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. *Osteoarthr Cartil* 1997;5:283-8
- w462 Hawkey C et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. *Brit J Rheumatol* 1998;37:937-45
- w463 Chopra A et al. Randomized double-blind clinical drug trials of meloxicam in rheumatoid arthritis and osteoarthritis knees: An Indian experience. *APLAR J Rheumatol* 2004;7:108-16
- w464 Hsieh J et al. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. *Brit J Rheumatol* 1996;35:39-43 (Suppl.1)
- w465 Becvar R et al. Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard. *Clin Rheumatol* 1999;18:273-8
- w466 Filipowicz-Sosnowska A et al. Relifex w leczeniu choroby zwyrodnieniowej stawow biodrowych i kolanowych. [Polish] *Reumatologia* 1997;35:39-50
- w467 Scott DL et al. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. *Aliment Pharmacol Therap* 2000;14:443-52
- w468 Albala SR et al. Randomized, double-blind, short-term trial of nabumetone versus diclofenac in osteoarthritis of the knee. *Curr Ther Res Clin E* 1992; 52:581-6
- w469 Bellamy N et al. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. *J Rheumatol* 1995;22:915-20
- w470 Havranek H et al. Seuridad y eficacia de nabumetona versus diclofenac retard en el tratamiento de la artrosis de rodilla (grado II - III) no complicada y activa. [Spanish] *AINE* 1998;2:37-45
- w471 Rees T et al. A multicentre general practice trial of nabumetone and slow-release diclofenac in osteoarthritis. *Drug Invest* 1990; 2:53-60
- w472 Laws D et al. A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis. *Drugs* 1990;40:29-33(Suppl. 5)
- w473 Estevez F et al. Diclofenac vs nimesulida en artrosis: Niveles plasmaticos y eficacia clinica. [Spanish] *Medicina* 1993;53:307-14
- w474 Famaey JP et al. Open controlled randomized multicenter comparison of nimesulide and diclofenac in the treatment of subacute and chronic low back pain. *J Clin Res* 1998;1:219-38
- w475 Omololu B et al. Double blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthritis of the hip and knee joints. *West Afr J Med* 2005;24:128-33
- w476 Karbowski A et al. Ozaprozin versus diclofenac retard zur behandlung der aktivierten arthrose. [German] *Zeitschrift fur Rheumatologie* 1998; 57:108-13
- w477 La Montagna G et al. Quality of life assessment during six months of NSAID treatment [Gonarthrosis and quality of life (GOAL) study]. *Clin Exp Rheumatol* 1998;16:49-54
- w478 Gudino Quiroz J. Caracterizacion clinica de la eficacia terapeutica y tolerancia de dos farmacos antiinflamatorios no esteroldeos en pacientes con gonartrosis. [Spanish] *Compendio De Investigaciones Clinicas Latinoamericanas* 1988;8:29-37
- w479 Sauaya DR. Eficacia terapeutica e tolerabilidade de dois potentes antiinflamatorios:diclofenaco sodico e piroxicam, no tratamento da artrite reumatoide. Estudo comparativo duplo-cego. [Portuguese] *Folha Medica* 1996; 113:77-85
- w480 Shichikawa K et al. [Clinical evaluation of suprofen in the treatment of rheumatoid arthritis-double-blind comparison with diclofenac sodium][Japanese]. *Ryumachi* 1984; 24:204-14
- w481 al-Quorain AA et al. Non-steroidal anti-inflammatory drug-induced gastropathy: a comparative endoscopic and histopathological evaluation of the effects of tenoxicam and diclofenac. *J Int Med Res* 1993;21:89-97
- w482 Fellet AJ et al. Tenoxicam vs diclofenaco sodico 'retard' no tratamento da artrite reumatoide. Estudo duplo-cego comparativo. [Portuguese] *Folha Medica* 1989;98:337-44
- w483 Schwarzer AC et al. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. *Curr Med Res Opin* 1990;11:648-53
- w484 Winterer W. Comparative gastroduodenal tolerance and efficacy of tenoxicam and diclofenac SR in the treatment of osteoarthritic patients. *Eur J Clin Res* 1994;5:130-4
- w485 Moser U et al. A double-blind randomised multicentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. *Scand J Rheumatol* 1989;71-80(Suppl. 80)
- w486 Gennery BA et al. Multicentre osteoarthritis trial. *Eur J Rheumatol Infl* 1982; 5:270-276
- w487 Alegre MC et al. Ensayo doble-ceigo, multicentrico, comparativo, between-patient, entre diclofenac e indometacina en artrosis tratadas durante 3 meses. [Spanish] *Revista Espanola de Reumatismo* 1977;20:139-57
- w488 Bijlsma A et al. The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. *Scand J Rheumatol* 1978;7:74-80 (Suppl.)
- w489 Calabro JJ et al. Efficacy of diclofenac in ankylosing spondylitis. *Am J Med* 1986;80(4B):58-63
- w490 Behrens U et al. A double-blind multicenter comparison of isoxicam and diclofenac in the treatment of osteoarthritis. *Curr Ther Res* 1985;37:739-46
- w491 Boey ML et al. Comparison of efficacy of and tolerance to ketoprofen and diclofenac sodium in the treatment of rheumatoid arthritis. *Singapore Med J* 1988;29:240-5
- w492 Bellamy N et al. Double-blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index. *J Rheumatol* 1992;19:153-9
- w493 Aylward M et al. Mefenamic acid and diclofenac sodium in osteoarthritis of the weight bearing joints: a double blind comparison. *Brit J Clin Pract* 1985;39:135-9
- w494 Li S et al. [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. (Chinese). *Chung-Hua I Hsueh Tsa Chih (Chinese Medical Journal)* 2001;81(9):557-60
- w495 Tan HC et al. [Comparison between clinical therapeutic effects of nabumetone and diclofenac sodium on recovery of joint function in patients with osteoarthritis][Chinese] *Chin J Clin Rehab* 2005;9:20-1
- w496 Shiokawa Y et al. [Clinical evaluation of oxaprozin on rheumatoid arthritis] [Japanese] *Igaku No Ayumi* 1984;130:386-403
- w497 Gerecz-Simon E et al. A controlled comparison of piroxicam and diclofenac in patients with osteoarthritis. *Clin Rheumatol* 1990;9:229-34
- w498 Rohde J et al. Zur behandlung der chronischen polyarthritis: offene paralleluntersuchung der nichtsteroidalen antirheumatika piroxicam und diclofenac. [German] *Deutsche Medizinische Wochenschrift* 1980;105:1614-7
- w499 VandenBurg MJ et al. Differential effects of two non-steroidal anti-inflammatory drugs on the plasma urea of elderly patients with osteoarthritis. A multicentre study. *Brit J Clin Pract* 1984; 38:403-6
- w500 Neustadt DH et al. Double-blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. *J Rheumatol* 1997;24:17-22 (Suppl.)
- w501 Paulus HE et al. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis.[see comment]. *J Rheumatol* 2000; 27:1632-7
- w502 Levinson DJ et al. Double-blind comparison of fenoprofen calcium and ibuprofen in osteoarthritis of large joints. *Curr Ther Res Clin E* 1983;34:280-4

Trials shown in supplementary tables 1-6

- w503 Roth SH et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. *Arch Int Med* 1993;153:2565-71
- w504 McLaughlin GE. A double-blind comparative study of piroxicam and ibuprofen in the treatment of rheumatoid arthritis. *Sem Arthritis Rheum* 1985;14:Suppl. 3
- w505 Bird HA et al. A double-blind comparison of tenoxicam (Tilcotil, Mobiflex) at two doses against ibuprofen in rheumatoid arthritis. *Eur J Rheum Infl* 1984;7:28-32
- w506 Alarcon-Segovia D et al. Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double-blind comparison with aspirin and ibuprofen. *J Rheumatol* 1980;6:89-99(Suppl.)
- w507 Jennings MB. A comparison study of piroxicam and ibuprofen in osteoarthritis of the foot. *Foot* 1996;6:58-62
- w508 Gum OB. Long-term efficacy and safety of benoxaprofen: comparison with aspirin and ibuprofen in patients with active rheumatoid arthritis. *J Rheumatol* 1980;6:76-88 (Suppl.)
- w509 Bennett RM et al. A 12-week, double-blind, multicenter study comparing diflunisal twice daily and ibuprofen four times daily in the treatment of rheumatoid arthritis. *Clin Ther* 1986;9:36(Suppl.)
- w510 McArthur AW et al. A comparative study of indomethacin and ibuprofen. *Med J Australia* 1979;1:25-7
- w511 Shadforth MF et al. Study comparing nabumetone and ibuprofen in osteoarthritis of the knee. *Royal Society of Medicine International Congress & Symposium* 1984;69:133-8
- w512 Earl RT et al. A double-masked comparison of the efficacy of once-daily sustained-release ibuprofen and once-daily piroxicam for 24-hour control of arthralgia due to osteoarthritis in the elderly. *Curr Ther Res* 1996;57:811-21
- w513 Tyson VC et al. A comparative study of benoxaprofen and ibuprofen in osteoarthritis in general practice. *J Rheumatol Suppl* 1980;6:132-8
- w514 Klein B. Carprofen in osteoarthritis. *Eur J Rheum Infl* 1982;5:507-13
- w515 Bresnihan B et al. Diflunisal in the treatment of osteoarthritis: a double-blind study comparing diflunisal with ibuprofen. *Curr Med Res Opin* 1978;5:556-61
- w516 Keet JG. A comparative clinical trial of diflunisal and ibuprofen in the control of pain in osteoarthritis. *J Int Med Res* 1979;7:272-6
- w517 Brodie NH et al. Fenclofenac and ibuprofen in the treatment of osteoarthritis: a comparative study in general practice. *Brit J Clin Pract* 1980;34:334-6
- w518 Bain LS et al. A double-blind trial of feprazone in osteoarthritis of the hip. *Curr Med Res Opin* 1977;4:665-9
- w519 Calin A et al. Double-blind, multi-centre parallel trial of ketoprofen and ibuprofen in the treatment of rheumatoid arthritis. *J Rheumatol* 1977;4:153-7
- w520 Shah SJ et al. Drug interaction between chlorpropamide and non-steroidal anti-inflammatory drugs, ibuprofen and phenylbutazone. *Int J Clin Pharm Ther Tox* 1984; 22:470-2
- w521 Alan MN et al. Comparative study of piroxicam and ibuprofen in rheumatoid arthritis. *Bangladesh Med Res Council Bull* 1983; 9:54-9
- w522 Ruotsi A et al. A long-term double-blind comparative study on proquazone (Biarison) and ibuprofen in rheumatoid arthritis. *Scand J Rheumatol* 1978; 21:28-32 (Suppl.)
- w523 Admani AK et al. A study of sulindac versus ibuprofen in elderly patients with osteoarthritis. *Curr Med Res Opin* 1983;8:315-20
- w524 Currie WJC et al. Symptomatic osteoarthritis in the elderly: Multicentre comparative study of sulindac and ibuprofen. *Brit J Clin Pract* 1984;38:176-81
- w525 Ghosh AK et al. A randomized comparison between sulindac and ibuprofen in osteoarthritis of the aged. *Curr Med Res Opin* 1981;7:482-7
- w526 Vetter G & Picha B. Die behandlung der chronischen polyarthritis mit sulindac. [German] *Munch med Wschr* 1977;119:1369-70
- w527 Royer GL et al. A six-month double-blind trial of ibuprofen and indomethacin in osteoarthritis. *Curr Therap Res Clin E* 1975;17:234-48
- w528 Royer GL et al. A long-term double-blind clinical trial of ibuprofen and indomethacin in rheumatoid arthritis. *J Int Med Res* 1975; 3:158-71
- w529 Davies EF et al. Ibuprofen: a review of its pharmacological properties and therapeutic efficacy in rheumatic disorders. *Drugs* 1971;2:416-46
- w530 Dieppe PA et al. Sulindac in osteoarthritis of the hip. *Rheumatol Rehabil* 1976;15:112-5
- w531 Oyemade GA et al. A controlled clinical study comparing sulindac with ibuprofen and aspirin in the treatment of musculo-skeletal diseases. *J Int Med Res* 1979;7:556-9
- w532 Bin S-I et al. Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6-week, randomised, double blind, parallel-group study. *APLAR J Rheum* 2007;10:190-7
- w533 Fleischmann R et al. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. *BMC Musculoskeletal Disorders* 2008;9:32-46
- w534 Aw T-J et al. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? *J Hypertens* 2006;24:1979-84
- w535 Geba GP et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. *JAMA* 2002;287:64-71
- w536 Schnitzer TJ et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. *J Rheumatol* 2005;32:1093-105
- w537 Whelton A et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients greater-than or equal to 65 years of age with systemic hypertension and osteoarthritis. *Am J Cardiol* 2002;90:959-63
- w538 Whelton A et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. *Am J Ther* 2001;8:85-95
- w539 Stricker K et al. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. *BMC Musculoskeletal Disorders* 2008;9:118-30
- w540 Zeng X et al. Clinical evaluation of celecoxib in treating type IIIa chronic prostatitis. *Natl J Androl* 2004;10:278-81
- w541 Merck & Co. Inc. MK-0966 Phase III study - Low Back Pain - (study ID: RC966A304) [online]. Available from URL:<http://www.clinicalstudyresults.org> [Accessed 2009 Feb 19]
- w542 Schnitzer TJ et al. A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. *Osteoarthr Cartilage* 2009;17:1-7

Other trials (not already listed) that involved two or more NSAIDs

- 1 Adelword OO et al. Comparative double blind study of the efficacy and safety of tenoxicam vs. piroxicam in osteoarthritis of knee and hip joints. *West African Journal of Medicine* 1998; 17:194-8
- 2 al-Nahdi M et al. Efficacy and tolerability of long-term tenoxicam versus piroxicam in patients with rheumatoid arthritis or osteoarthritis. *Curr Ther Res Clin E* 1992;52:639-45
- 3 Amante C et al. Tenoxicam versus piroxicam in rheumatoid arthritis. *Drug Invest* 1990;2:40-55 (Suppl.)
- 4 Amante CM et al. Randomized comparative study on programmed released ketoprofen vs. piroxicam in the treatment of rheumatoid arthritis. *Philippine J Int Med* 1988; 26:69-73
- 5 Ammitzbohl F et al. Fenbufen and indomethacin in the treatment of rheumatoid arthritis. A comparative double-blind, crossover study. *Scand J Rheumatol* 1979; 13:5-10 (Suppl.)
- 6 Amor et al. Double-blind Randomised Comparison of Two Oxicams (Tenoxicam and Piroxicam) in Rheumatic Practice. *Litera Rheumatologica* 1987;7:7-13
- 7 Andrada SS et al. A double-blind randomised controlled trial of droxicam versus indomethacin in rheumatoid arthritis. *Eur J Rheum Infl* 1991; 11:15-20
- 8 Astorga G et al. Double-blind, parallel clinical trial of tenoxicam (Ro 12-0068) versus piroxicam in patients with ankylosing spondylitis. *Eur Rheum Infl* 1987; 9:70-3
- 9 Astorga PG et al. Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. *Curr Med Res Opin* 1991; 12:401-12
- 10 Atkinson M et al. The efficacy and safety of sulindac (400 mg vs 600 mg daily) in rheumatoid arthritis. A Canadian Multicentre Study. *J Rheumatol* 1988; 15:1001-4
- 11 Aylward M et al. Long-term study of indomethacin and alclufenac in treatment of rheumatoid arthritis. *BMJ* 1975;2(5961):7-9
- 12 Aylward M et al. Treatment of rheumatoid arthritis with tolmetin: a comparison with alclufenac. *Curr Med Res Opin* 1976; 4:695-702
- 13 Bach GL et al. Activated osteoarthritis (osteoarthritis) and its treatment with indomethacin and benoxaprofen: a double-blind crossover study. *Eur J Rheum Infl* 1982; 5:224-9
- 14 Bahous I et al. Double-blind multicentre, between patients comparison of two different doses of indoprofen and one of indomethacin in osteoarthritis. *Eur J Rheum Infl* 1981; 4:118-25
- 15 Batlle-Gualda E et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: A multicenter controlled clinical trial. *Journal of Rheumatology* 1996;23(7):
- 16 Bellamy N et al. Double-blind randomized controlled trial of isoxicam vs piroxicam in elderly patients with osteoarthritis of the hip and knee. *Brit J Clin Pharmacol* 1986; 22:149S-55S
- 17 Bernstein RM et al. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylitis. *Eur J Rheum Infl* 1992;12:6-13
- 18 Bianchi Porro G et al. Endoscopic assessment of tenoxicam- and piroxicam-induced lesions in osteoarthritic patients. *Drug Invest* 1991;3:53-6
- 19 Bird HA et al. A comparative study of benoxaprofen and indomethacin in ankylosing spondylitis. *J Rheumatol* 1980;6:139-42 (Suppl.)
- 20 Bird HA et al. A comparison of faecal blood loss caused by tenoxicam and piroxicam in normal healthy male volunteers. *Curr Med Res Opin* 1985;9:524-8
- 21 Bird HA et al. A double-blind parallel study of tenoxicam and piroxicam in patients with osteoarthritis. *Eur J Rheum Infl* 1985;8:53-9
- 22 Bird HA et al. A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. *Pharmatherapeutica* 1986;4:457-62
- 23 Bonardelli P et al. Efficacy and gastrointestinal tolerability of beta-cyclodextrin-piroxicam and tenoxicam in the treatment of chronic osteoarthritis. *Clin Ther* 1990;12:547-55
- 24 Bradley JD et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. *New Engl J Med* 1991;325:87-91
- 25 Briancon D et al. Double-blind parallel-group evaluation of the safety and efficacy of etodolac capsules compared with piroxicam capsules in patients with rheumatoid arthritis. *Acta Therap* 1991;17:35-47
- 26 Bursens A et al. Double-blind comparison of etodolac SR tablets and tenoxicam capsules in the treatment of osteoarthritis of the knee. *Acta Therap* 1993;19:35-48
- 27 Buxton R et al, Grennan DM, Palmer DG. Fenbufen compared with indomethacin in osteoarthritis. *Curr Med Res Opin* 1978;5:682-7
- 28 Caldwell JR et al. Ketoprofen versus indomethacin in patients with rheumatoid arthritis: a multicenter double blind comparative study. *J Rheumatol* 1979; 15:1476-1479
- 29 Cardoe N et al. Double-blind cross-over study of ketoprofen and phenylbutazone in patients with chronic osteoarthritis of the hip. *Rheumatol Rehabil* 1976;27-33 (Suppl.)
- 30 Carle WK et al, Wade AG, Kill DC, Poland M. Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice. *J Rheumatol* 1992;19:58-62(Suppl. 36)
- 31 Chamberlain MA et al. A double blind trial to assess the value of alclufenac compared with phenylbutazone in the management of rheumatoid arthritis. *Ann Rheum Dis* 1975; 34:186-9
- 32 Chang D-M et al. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. *Clinical Rheumatology* YR?? 20(2):104-113
- 33 Charlot J et al. A comparative study of benoxaprofen and ketoprofen in ankylosing spondylitis. *Eur J Rheumatol Infl* 1982; 5:277-81
- 34 Chivabongs A et al. Controlled-release ketoprofen in rheumatoid arthritis and osteoarthritis: comparison of two doses in Thailand. *Clin Ther* 1988;10: 254-8
- 35 Chodock AL. Crossover comparison of benoxaprofen and indomethacin in rheumatoid arthritis and osteoarthritis. *Eur J Rheumatol Infl* 1982; 5:246-57
- 36 Chopra A et al. Randomized double-blind clinical drug trials of meloxicam in rheumatoid arthritis and osteoarthritis knees: An Indian experience. *APLAR J Rheumatol* 2004;7:108-16
- 37 Chou CT et al. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acetaminacin for the management of osteoarthritis. *Int J Clin Pharma Res* 2002; 22:1-6
- 38 Collins AJ et al. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. *Brit J Rheumatol* 1988; 27:106-9
- 39 Davies J et al. A double blind cross-over comparison of piroxicam and indomethacin in the treatment of rheumatoid arthritis. *Eur J Rheumatol Infl* 1981;4:314-7
- 40 del Campo JB. Double-blind multicentre, between patients comparison of indoprofen and indomethacin in rheumatoid arthritis patients under basic steroid treatment. *Eur J Rheum Infl* 1981;4:135-43
- 41 Deodhar SD et al. A comparative study of fenbufen and indomethacin in patients with rheumatoid arthritis. *Curr Med Res Opin* 1979;6:263-6
- 42 Dequeker J et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (SELECT) trial in osteoarthritis. *Brit J Rheumatol* 1998;37:946-51.
- 43 Desproges-Gotteron R, et al. A double-blind comparison of alclufenac and indomethacin in osteoarthritis of the hip. *Current Therapeutic Research, Clin Exp* 1971; 13:393-7
- 44 Dick WC et al. Double-blind comparison of etodolac and piroxicam in the treatment of rheumatoid arthritis. *Clin Ther* 1993;15:148-59
- 45 Dick WC et al. Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee. *Clin Ther* 1992;14:517-26
- 46 Diverse P, Franchimont P. Clinical trial of pirofen in arthrosis of the knee joint: a double-blind comparison with indomethacin. *J Int Med Res* 1983;11:218-21
- 47 Domljan Z et al. Efficacy of tenoxicam in the treatment of patients with rheumatoid arthritis. *Drug Investigation* 1990; 2:45-47(Suppl.)
- 48 Dreiser RL. A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis. *Rheumatol Int* 1993;13(2):Suppl. 8
- 49 Dunky A et al. European double-blind multicenter study comparing meclofenamate sodium and indomethacin in the treatment of rheumatoid arthritis. *Arzneimittel-Forschung* 1983;33(4A):636-40
- 50 Ebner W et al. Meclofenamate sodium in the treatment of ankylosing spondylitis. Report of a European double-blind controlled multicenter study. *Arzneimittel-Forschung* 1983;33(4A):660-3
- 51 Ejstrup L et al. A randomised double-blind multicentre trial comparing tenoxicam and ketoprofen in osteoarthritis. *Scand J Rheumatol* 1989;80:48-53 (Suppl.)
- 52 Finstad R et al. A double-blind, crossover, multicentre study of piroxicam and indomethacin in the treatment of rheumatoid arthritis. *Brit J Clin Pract* 1981;35:35-9
- 53 Franchimont P et al. A double-blind crossover study of benoxaprofen and indomethacin in outpatients suffering from osteoarthritis of knees. *Eur J Rheum Infl* 1982;5:230-8
- 54 Frank E. & Manz G. Comparison of Fenoprofen and Oxypfenbutazone in Patients with Rheumatoid Arthritis. *Curr Ther Res* 1977;21: 43-49
- 55 Franssen MJ et al. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. *Clin Rheumatol* 1986;5:210-20
- 56 Freitas GG. A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis. *Curr Med Res Opin* 1990;12:255-62
- 57 Gibson T et al. Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross-over study. *Rheumatol Rehabil* 1980;19:189-92
- 58 Gijón Baños J et al. Eficacia y seguridad de la nabumetona en el tratamiento de la gonartrosis: ensayo clínico comparativo con aceclofenaco. *Medicina Clínica (Barc)* 1997;109:130-4
- 59 Godfrey RG et al. Effect of ibuprofen dosage on patient response in rheumatoid arthritis. *Arthritis Rheum* 1975;18:135-7
- 60 Gordin A et al. Comparison of slow-release indomethacin and diflunisal in patients with arthrosis. *Curr Med Res Opin* 1984;9:275-9
- 61 Harkness AJ et al. A trial of feprazone in ankylosing spondylitis. *Rheumatol Rehabil* 1977;16:158-61
- 62 Havranek H. Double-blind study of tenoxicam 20 mg versus piroxicam 20 mg in rheumatoid arthritis. *Eur J Rheum Infl* 1987;9:105-8
- 63 Honorato J et al. Ensayo clínico, paralelo, doble ciego con el tenoxicam de artritis reumatoide. *Revista De Medicina De La Universidad De Navarra* 1984;28:49-53
- 64 Hooper JW et al. Fecal blood loss during isoxicam and piroxicam administration for 28 days. *Clin Pharmacol Ther* 1985;38:533-7
- 65 Hosie J et al. Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee. A six-month double-blind study. *Clin Drug Invest* 1997;13:175-84
- 66 Janke P et al. Sulindac versus piroxicam in the treatment of osteoarthritis. *Curr Med Res Opin* 1983; 8:434-40
- 67 Jessop JD et al. European double-blind multicenter study comparing isoxicam and indomethacin in treatment of degenerative joint disease. *Am J Med* 1985;79(4B):24-7
- 68 Jessop JD. Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. *Rheumatol Rehabil* 1976; 37-42 (Suppl.)
- 69 Jubb RW et al. Double-blind comparison of etodolac sustained-release tablets and piroxicam capsules in patients with rheumatoid arthritis: An interim report. *Curr Ther Res Clin Exp* 1992; 52:769-779

Other trials (not already listed) that involved two or more NSAIDs

- 70 Juvakoski T et al. A double-blind cross-over evaluation of ketoprofen and indomethacin in Reiter's disease. *Scand J Rheumatol* 1982;11:106-8
- 71 Karbowski A. Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. *Curr Med Res Opin* 1991; 12:309-17
- 72 Komassoff D et al. The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. *Rheumatol Int* 1996; 15:225-30
- 73 Kraag G R et al. Piroxicam vs indomethacin: a double blind multicenter comparative study in osteoarthritis. A Canadian Multicenter Study. *J Rheumatol* 1985;12:328-36
- 74 Lalos J et al. Long-term (four year) clinical trial with tenoxicam and basis therapy in patients suffering from rheumatoid arthritis. *Scand J Rheumatol* 1989;18(80):67-70 (Suppl.)
- 75 Lee HK et al. Double-blind evaluation of the safety and efficacy of tenoxicam (Tilcotil) compared with piroxicam in patients with degenerative arthritis. *Drug Invest* 1990; 2(Suppl. 3): 50-1
- 76 Lightfoot R. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. *Etodolac Study 326 Rheumatoid Arthritis Investigators Group. J Rheumatol* 1997;47:10-16(Suppl)
- 77 Linden B et al. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. *Brit J Rheum* 1996;35(Suppl. 1):35-8
- 78 Lucker PW et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac. *Eur J Rheum Infl* 1994;14:29-38
- 79 Lund B et al. A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12-24 month interval. *Eur J Rheum Infl* 1994;14:29-38
- 80 Lund HI et al. A double-blind study comparing sulindac with indomethacin in rheumatoid arthritis. *Scand J Rheumatol* 1981;37:1-6(Suppl.)
- 81 Lussier A et al. Comparative evaluation of carprofen and indomethacin in rheumatoid patients. *Int J Clin Pharm Ther Toxic* 1980;18:482-7
- 82 Marcolongo R et al. Efficacy and tolerability of ketoprofen 200 mg controlled-release cps vs indomethacin 50 mg cps in patients with symptomatic hip osteoarthritis. A multicenter study. *Minerva Medica* 1997; 88(10):39:83-91
- 83 Martin-Mola E et al. Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. *Rheumatol Int* 1995;15:111-6
- 84 Mendelsohn SL. Clinical efficacy and tolerability of naproxen in osteoarthritis patients using twice-daily and once-daily regimens. *Clin Ther* 1991;13(Suppl. A):8-15
- 85 Meurice J. Treatment of osteoarthritis: a 3-month comparison between tiaprofenic acid and indomethacin. *Curr Med Res Opin* 1983;8:295-301
- 86 Molnar JP et al. Ibuprofen (Motrin), a double blind comparison of two dosages, 2400 mg and 3200 mg daily, for treating rheumatoid arthritis. *Curr Ther Res Clin Exp* 1979;26:581
- 87 Montagna G et al. Beta-cyclodextrin-Piroxicam in the Treatment of the Active Phase of Osteoarthritis Pathology. *Eur Rev Med Pharmacol Sci* 1990;XII:265-72
- 88 Muller-Fassbender HH et al. Comparative study of piroxicam and indomethacin retard in osteoarthritis. *Eur J Rheumatol Infl* 1983;6:106-12
- 89 O'Brien K et al. A comparison of the effects of tenoxicam and piroxicam on grip strength in patients with rheumatoid arthritis. *Scand J Rheumatol* 1989; 80:81-5(Suppl.)
- 90 Perez Busquier M et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. *Clin Rheumatol* 1997; 16:154-159
- 91 Perez-Ruiz F et al. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. *Clin Rheumatol* 1996; 15:473-7
- 92 Perpignano G et al. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and knee. *Int J Clin Pharmacol Res* 1994;14:203-16
- 93 Rejholec V et al. A. *Scand J Rheumatol* 1979;(24):13-16 (Suppl.)
- 94 Rejholec V et al. Toffenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. *Scan J Rheumatol* 1980;36:1-7(Suppl.)
- 95 Renier JC et al. Spondylarthritis ankylosante: Essai comparatif de deux anti-inflammatoires non steroïdiens, le piroprofene et le ketoprofene. *Nouvelle Presse Medicale* 1982; 11:2494-6
- 96 Rice DM. Comparison of diflunisal and piroxicam in the management of patients with rheumatoid arthritis. *Clin Ther* 1987;10:92-7
- 97 Rodriguez-de-la-Serna A et al. Comparative double-blind study of droxicam (new NSAID) versus indomethacin in rheumatoid arthritis. *Eur J Rheumatol Inflam* 1991; 11:35-44
- 98 Rogind H et al. Comparison of etodolac and piroxicam in patients with osteoarthritis of the hip or knee: A prospective, randomised, double-blind, controlled multicentre study. *Clin Drug Invest* 1997;13:66-75
- 99 Roth SH. A comparison of benoxaprofen and sulindac in patients with rheumatoid arthritis and osteoarthritis. *Eur J Rheumatol Inflam* 1982; 5:258-69
- 100 Roy V et al. Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chondroprotection: a double blind randomised study. *J Indian Med Assoc* 1999; 97:4
- 101 Rubinstein J et al. Long-term study with tenoxicam (Ro 12-0068) in the treatment of gonarthrosis and coxarthrosis. *Eur J Rheumatol Inflam* 1987; 9:126-2
- 102 Salzman RT et al. Long-term, double-blind, randomized parallel group studies comparing fenbufen with indometacin in patients with osteoarthritis. *Pharmacology* 1982; 25(Suppl. 1): 54-62
- 103 Schattenkirchner M. Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. *Curr Med Res Opin* 1991; 12:497-506
- 104 Schuetz E et al. Therapeutic activity, clinical and gastric tolerance of 20mg daily dose of droxicam in comparison with piroxicam in patients with degenerative joint disease. *Eur Rheum Infl* 1991;11:21-8
- 105 Scott DL et al. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. *Aliment Pharmacol Therap* 2000;14:443-52
- 106 Serry MM. Proquazone ('Biarison') in osteoarthritis of the knee: a double-blind, dose comparison trial. *Pharmatherapeutica* 1980;2:323-9
- 107 Sharma S et al. Comparative efficacy and safety of nimesulide versus piroxicam in osteoarthritis with special reference to chondroprotection. *Am J Therap* 1999; 6:191-7
- 108 Shichikawa K et al. [A controlled clinical trial of TAI-284 acid in rheumatoid arthritis][Japanese]. *Ryumachi* 1977; 17:409-29
- 109 Shichikawa K et al. [A double-blind multi-center clinical trial of benoxaprofen against indomethacin in rheumatoid arthritis][Japanese]. *Ryumachi* 1982; 22:88-102
- 110 Shichikawa K et al. [A multicenter trial of sulindac in rheumatoid arthritis][Japanese]. *Ryumachi* 1979; 19:164-82
- 111 Shichikawa K et al. [Clinical evaluation of feprazone in rheumatoid arthritis][Japanese]. *Ryumachi* 1979; 19:147-163.
- 112 Shichikawa K et al. [Clinical evaluation of piroxicam in rheumatoid arthritis by double blind comparative multi-center studies][Japanese]. *Ryumachi* 1980; 20:220-8
- 113 Shichikawa K et al. [Determination of efficacy of proquazone in chronic rheumatoid arthritis][Japanese]. *Ryumachi* 1982; 22:275-283
- 114 Shichikawa K et al. [Double blind clinical trial of pirofen in patients with rhumatoid arthritis][Japanese]. *Ryumachi* 1984; 24: 407-414.
- 115 Shichikawa K et al. [Effect of indoprofen in patients with rheumatoid arthritis][Japanese]. *Ryumachi* 1984; 24:63-73
- 116 Shichikawa K et al. [Long-term multicentre, open-label comparative study of sulindac and indomethain in rheumatoid arthritis][Japanese]. *Ryumachi* 1981; 22: 168-184
- 117 Shichikawa K. [Results of the test on efficacy of alclofenac in chronic rheumatoid arthritis][Japanese]. *Ryumachi* 1980; 20:305-321.
- 118 Simpson J et al. A large multicentre, parallel group, double-blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. *Brit J Clin Pract* 1989; 43:328-33
- 119 Standel W & Josenhants G. Clinical evaluation of tenoxicam in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. *Eur J Rheumatol Infl* 1985; 8:28-38.
- 120 Thompson et al. Sulindac and Sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase 1 study. *Cancer Prevention Research* 2010; 3: 101-07
- 121 Thune S. Comparison of phenyl- and monophenylbutazone (Mobutazon), especially in respect to the incidence of side effects. A double-blind study. *Acta Rheumatol Scand* 1967;13:63-80
- 122 Vergara-Castro J et al. A comparative clinical trial of fenbufen and indomethacin in patients with rheumatoid arthritis. *J Int Med Res* 1976;4:418-26
- 123 Videman T et al. Double-blind parallel study of piroxicam versus indomethacin in the treatment of low back pain. *Ann Clin Res* 1984;16:156-60
- 124 Villa Alcazar LF et al. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. *J Rheumatol*.1996;23:1194-9
- 125 Waterworth R et al. A Comparison of Tenoxicam and Piroxicam in a Long-term Clinical Study in Patients with Osteoarthritis of Hip or Knee Joints. *Eur J Rheum Infl* 1985; 8:21-27
- 126 Waterworth RF et al. Double-blind comparative study of etodolac and piroxicam in patients with osteoarthritis of the knee. *Adv Ther* 1992;9:240-9
- 127 Wordsworth BP et al. A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. *Rheumatol Rehab* 1980;19:260-3
- 128 Xu JH et al. A double-blind, randomized controlled clinical study of meloxicam and nabumetone in the treatment of rheumatoid arthritis. *Chin Pharma J* 2002;37:310-2
- 129 Young JH et al. 'Osmosin' in general practice: preliminary report of a double-blind study in the treatment of osteoarthritis. *Curr Med Res Opin* 1983;8(Suppl. 2):99-108
- 130 Zuccollo R et al. Oxaprozin and sulindac in rheumatoid arthritis: a double-blind comparative trial. *Curr Med Res Opin* 1983;8:302-9